A serum autoantibody marker of neuromyelitis optica:

Lancet, The

364, 2106-2112

DOI: 10.1016/s0140-6736(04)17551-x

Citation Report

#	Article	IF	Citations
1	CLINICAL SPECTRUM: DEFINITION AND NATURAL PROGRESSION. , 1997, , 1015-1030.		0
2	Multiple sclerosis â€“ novel insights and new therapeutic strategies. Current Opinion in Neurology, 2005, 18, 211-220.	1.8	34
3	Pathogenesis of multiple sclerosis. Current Opinion in Neurology, 2005, 18, 225-230.	1.8	142
4	Is there a rationale for therapeutic immunoadsorption in multiple sclerosis?. European Journal of Clinical Investigation, 2005, 35, 467-468.	1.7	5
5	Immunological mechanisms in multiple sclerosis. Clinical and Applied Immunology Reviews, 2005, 5, 257-269.	0.4	4
6	Recurrent myelitis and optic neuritis in a 29-year-old woman. Lancet Neurology, The, 2005, 4, 510-516.	4.9	13
7	â€œOSMS is NMO, but not MSâ€• confirmed by NMO-IgG?. Lancet Neurology, The, 2005, 4, 594-595.	4.9	18
8	Diagnostic criteria for multiple sclerosis: 2005 revisions to the â€œMcDonald Criteriaâ€• Annals of Neurology, 2005, 58, 840-846.	2.8	4,495
9	Neuromyelitis optica. Current Treatment Options in Neurology, 2005, 7, 173-182.	0.7	90
10	Treatment of pediatric multiple sclerosis. Current Treatment Options in Neurology, 2005, 7, 191-199.	0.7	12
11	Multiple Sclerosis: Looking beyond Autoimmunity. Journal of the Royal Society of Medicine, 2005, 98, 303-306.	1.1	14
12	Western vs optic-spinal MS: Two diseases, one treatment?. Neurology, 2005, 64, 594-595.	1.5	14
13	Report from the Neurology Scientific Integrity Advisor: Year 1. Neurology, 2005, 65, 781-781.	1.5	0
14	Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology, 2005, 65, 782-783.	1.5	42
15	Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology, 2005, 65, 781-782.	1.5	23
16	An open label study of the effects of rituximab in neuromyelitis optica. Neurology, 2005, 64, 1270-1272.	1.5	607
17	Thrombotic cocktail in stroke. Neurology, 2005, 65, 781.	1.5	8
18	Acute transverse myelitis: Is the "idiopathic" form vanishing?. Neurology, 2005, 65, 1857-1858.	1.5	21

#	Article	IF	Citations
19	Treatment of children and adolescents with multiple sclerosis. Expert Review of Neurotherapeutics, 2005, 5, 391-401.	1.4	22
20	IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. Journal of Experimental Medicine, 2005, 202, 473-477.	4.2	1,998
21	Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 367-371.	1.4	73
22	Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain, 2005, 128, 988-1002.	3.7	316
23	Imaging in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, iii11-iii18.	0.9	39
24	Multiple sclerosis: looking beyond autoimmunity. Journal of the Royal Society of Medicine, 2005, 98, 303-306.	1.1	15
25	Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet, The, 2005, 366, 579-582.	6.3	411
27	Unveiling the enigma of the CNS as a B-cell fostering environment. Trends in Immunology, 2005, 26, 254-259.	2.9	87
28	Mechanisms of Action for Treatments in??Multiple Sclerosis. BioDrugs, 2005, 19, 299-308.	2.2	33
30	Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology, 2006, 67, 176-177.	1.5	41
32	Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain, 2006, 129, 1953-1971.	3.7	875
33	The approach to bilateral simultaneous isolated optic neuritis. British Journal of Ophthalmology, 2006, 90, 526-527.	2.1	3
34	Acute demyelinating optic neuritis. Expert Review of Ophthalmology, 2006, 1, 159-170.	0.3	3
36	Neuromyelitis optica. Practical Neurology, 2006, 6, 180-184.	0.5	5
37	Discriminative analysis of relapsing neuromyelitis optica and relapsingâ€“remitting multiple sclerosis based on two-dimensional histogram from diffusion tensor imaging. NeuroImage, 2006, 31, 543-549.	2.1	16
38	Update on Multiple Sclerosis. Magnetic Resonance Imaging Clinics of North America, 2006, 14, 203-224.	0.6	1
41	Characterization of the T cell receptor repertoire in the Japanese neuromyelitis optica: T cell activity is up-regulated compared to multiple sclerosis. Journal of the Neurological Sciences, 2006, 249, 145-152.	0.3	26
42	Revised diagnostic criteria for neuromyelitis optica. Neurology, 2006, 66, 1485-1489.	1.5	2,438

#	Article	IF	Citations
43	Update on Multiple Sclerosis. Radiologic Clinics of North America, 2006, 44, 79-100.	0.9	10
44	The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Multiple Sclerosis Journal, 2006, 12, 121-132.	1.4	119
45	Immunopathogenesis and immunotherapy of multiple sclerosis. Nature Clinical Practice Neurology, 2006, 2, 201-211.	2.7	224
46	Brain abnormalities in neuromyelitis optica. American Journal of Ophthalmology, 2006, 142, 203.	1.7	0
47	The spectrum of multiple sclerosis and treatment decisions. Clinical Neurology and Neurosurgery, 2006, 108, 333-338.	0.6	29
48	Neuromyelitis Optica Immunoglobulin G in a Child. Pediatric Neurology, 2006, 35, 370-372.	1.0	9
49	Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers. Disease Markers, 2006, 22, 213-225.	0.6	18
50	A mighty mouse: building a better model of multiple sclerosis. Journal of Clinical Investigation, 2006, 116, 2313-2316.	3.9	22
52	Preliminary Studies on the Clinical Features of Multiple Sclerosis in Korea. Journal of Clinical		

#	Article	IF	Citations
62	Loss of Aquaporin-4 in Active Perivascular Lesions in Neuromyelitis Optica: A Case Report. Tohoku Journal of Experimental Medicine, 2006, 209, 269-275.	0.5	110
63	Analysis of the C/T?1single nucleotide polymorphism in the CD40 gene in multiple sclerosis. Tissue Antigens, 2006, 68, 335-338.	1.0	25
64	Idiopathic inflammatory demyelinating disorders after acute transverse myelitis. European Journal of Neurology, 2006, 13, 862-868.	1.7	28
65	Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. European Journal of Neurology, 2006, 13, 655-658.	1.7	43
66	SUNCT Associated with Devic's Syndrome. Cephalalgia, 2006, 26, 221-224.	1.8	12
67	Soluble CD26 and CD30 levels in CSF and sera of patients with relapsing neuromyelitis optica. Journal of Neurology, 2006, 253, 111-113.	1.8	8
73	Autoimmune optic neuropathy. Current Neurology and Neuroscience Reports, 2006, 6, 396-402.	2.0	15
74	Neuropsychiatric manifestations ofÂsystemic lupus erythematosus. Joint Bone Spine, 2006, 73, 639-645.	0.8	37
75	Neuromyelitis optica â€" Devic's syndrome, update. Autoimmunity Reviews, 2006, 5, 537-543.	2.5	60
76	OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurology, The, 2006, 5, 110-111.	4.9	71
77	MRI and the diagnosis of multiple sclerosis: expanding the concept of â€œno better explanationâ€• Lancet Neurology, The, 2006, 5, 841-852.	4.9	217
78	Paraneoplastic Syndromes Affecting the Nervous System. Seminars in Oncology, 2006, 33, 270-298.	0.8	153
79	Antibodies as biological markers for pathophysiological processes in MS. Journal of Neuroimmunology, 2006, 180, 50-62.	1.1	69
80	Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Annals of Neurology, 2006, 59, 566-569.	2.8	548
81	B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation. Annals of Neurology, 2006, 59, 880-892.	2.8	283
82	Evidence for humoral autoimmunity in neuromyelitis optica. Neurological Research, 2006, 28, 348-353.	0.6	39
83	Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica?. Neurological Research, 2006, 28, 354-359.	0.6	22
84	MRI of Central Nervous System (CNS) Vasculitis. Current Medical Imaging, 2006, 2, 425-434.	0.4	3

#	Article	IF	Citations
85	Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1073-1075.	0.9	201
86	The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology, 2006, 67, 258-262.	1.5	188
87	Gradual hearing loss with bilateral labyrinthine hemorrhage in chronic myelogenous leukemia. Neurology, 2006, 67, 177-178.	1.5	11
88	Effect of rituximab in refractory SLE: inhibition of Th1?. Rheumatology, 2006, 45, 121-122.	0.9	3
89	Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 325-327.	0.9	41
90	Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression. Archives of Neurology, 2006, 63, 964.	4.9	643
91	Devic's syndrome in systemic lupus erythematosus and probable antiphospholipid syndrome. Rheumatology, 2006, 45, 120-121.	0.9	17
92	Neuromyelitis Optica in Patients With Myasthenia Gravis Who Underwent Thymectomy. Archives of Neurology, 2006, 63, 851.	4.9	93
93	Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic Disease). Archives of Neurology, 2006, 63, 957.	4.9	167
94	Infantile onset myasthenia gravis with MuSK antibodies. Neurology, 2006, 67, 174-174.	1.5	18
95	Brain Abnormalities in Neuromyelitis Optica. Archives of Neurology, 2006, 63, 390.	4.9	637
96	Devic's syndrome in systemic lupus erythematosus and probable antiphospholipid syndrome: reply. Rheumatology, 2006, 45, 121-121.	0.9	7
97	Repetitive transcranial magnetic stimulation of the motor cortex for hemichorea. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1095-1097.	0.9	16
98	Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1001-1002.	0.9	13
99	Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19057-19062.	3.3	213
100	Demyelinating diseases. Journal of Clinical Pathology, 2006, 59, 1151-1159.	1.0	274
101	Passive smoking and Parkinson disease. Neurology, 2006, 67, 179-180.	1.5	41
102	Hypoglossal neuropathy in Lewis-Sumner syndrome masquerading as motor neuron disease. Neurology, 2006, 67, 175-176.	1.5	17

#	Article	IF	Citations
103	The lumping and splitting of inflammatory CNS diseases. Neurology, 2006, 66, 1466-1467.	1.5	9
104	Fulminant Devic disease successfully treated by lymphocytapheresis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1094-1095.	0.9	25
105	Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 324-325.	0.9	39
106	Toward biomarkers in multiple sclerosis: new advances. Expert Review of Neurotherapeutics, 2006, 6, 781-794.	1.4	10
107	Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Multiple Sclerosis Journal, 2007, 13, 968-974.	1.4	152
108	Diagnostic biomarkers in multiple sclerosis. Expert Opinion on Medical Diagnostics, 2007, 1, 225-233.	1.6	4
109	Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology, 2007, 69, 2221-2231.	1.5	442
110	B-cell subsets: cellular interactions and relevance in multiple sclerosis. Expert Review of Clinical Immunology, 2007, 3, 73-83.	1.3	1
111	Subarachnoid hemorrhage is followed by temporomesial volume loss: MRI volumetric study. Neurology, 2007, 68, 1324-1325.	1.5	14
112	Clinical manifestations and treatment of rheumatoid pachymeningitis. Neurology, 2007, 68, 1079-1080.	1.5	70
113	A three-dimensional approach for understanding the spectrum of idiopathic inflammatory demyelinating disorders: importance of the â€˜attack-related severityâ€™ axis. Multiple Sclerosis Journal, 2007, 13, 199-207.	1.4	3
114	Speech and language delay are early manifestations of juvenile-onset Huntington disease. Neurology, 2007, 68, 1325-1325.	1.5	8
115	Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain, 2007, 130, 1206-1223.	3.7	249
116	High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology, 2007, 68, 865-867.	1.5	38
117	The long (-itudinally extensive) and the short of it: Transverse myelitis in children. Neurology, 2007, 68, 1447-1449.	1.5	17
118	Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain, 2007, 130, 1194-1205.	3.7	650
119	NMO-IgG in the diagnosis of neuromyelitis optica. Neurology, 2007, 68, 1076-1077.	1.5	183
120	Survey of training programs' means for promoting neurology and attracting trainees. Neurology, 2007, 68, 1324-1324.	1.5	3

#	Article	IF	Citations
121	Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning. Neurology, 2007, 68, 1325-1326.	1.5	0
122	Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology, 2007, 68, 1326-1327.	1.5	21
123	Clinical and laboratory features of neuromyelitis optica with oligoclonal IgG bands. Multiple Sclerosis Journal, 2007, , .	1.4	0
124	Complexity and heterogeneity in demyelinating disease. Brain, 2007, 130, 1178-1180.	3.7	10
125	Letter To the Editor. Multiple Sclerosis Journal, 2007, 13, 686-686.	1.4	1
126	The spectrum of neuromyelitis optica: a case of NMO with extensive brain stem involvement. Neurological Research, 2007, 29, 32-35.	0.6	9
127	Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain, 2007, 130, 1224-1234.	3.7	547
128	The Accuracy of Prevalence Rates of Multiple Sclerosis: A Critical Review. Neuroepidemiology, 2007, 29, 150-155.	1.1	42
129	Vision Loss in a 22-Year-Old Woman. Laboratory Medicine, 2007, 38, 605-607.	0.8	0
130	Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Multiple Sclerosis Journal, 2007, 13, 256-259.	1.4	190
131	Relapsing Neuromyelitis Optica and Relapsing-Remitting Multiple Sclerosis: Differentiation at Diffusion-Tensor MR Imaging of Corpus Callosum. Radiology, 2007, 244, 249-256.	3.6	36
132	Neuromyelitis Optica: New Findings on Pathogenesis. International Review of Neurobiology, 2007, 79, 665-688.	0.9	38
133	Neuromyelitis optica with brainstem lesion mistaken for brainstem glioma. Journal of Neurosurgery: Pediatrics, 2007, 107, 251-254.	0.8	4
134	Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. Biomarkers in Medicine, 2007, 1, 111-119.	0.6	8
135	Revised criteria for neuromyelitis opticaâ€"a new diagnostic standard?. Nature Clinical Practice Neurology, 2007, 3, 132-133.	2.7	7
136	Clinical features of children and adolescents with multiple sclerosis. Neurology, 2007, 68, S37-S45.	1.5	103
137	More on Multiple Sclerosis and Neuromyelitis Optica. Archives of Neurology, 2007, 64, 1802.	4.9	3
138	Neuromyelitis Optica Is a Variant of Multiple Sclerosis. Archives of Neurology, 2007, 64, 901.	4.9	33

#	Article	IF	Citations
139	More on Multiple Sclerosis and Neuromyelitis Opticaâ€"Reply. Archives of Neurology, 2007, 64, 1802.	4.9	5
140	Clinical and laboratory features of neuromyelitis optica with oligoclonal IgG bands. Multiple Sclerosis Journal, 2007, 13, 332-335.	1.4	25
141	Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 990-992.	0.9	43
142	Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Multiple Sclerosis Journal, 2007, 13, 850-855.	1.4	106
143	Is Sjogren myelopathy Devic disease?. Annals of the Rheumatic Diseases, 2007, 67, 730-731.	0.5	10
144	Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Multiple Sclerosis Journal, 2007, 13, 128-132.	1.4	249
145	Is Neuromyelitis Optica Distinct From Multiple Sclerosis?. Archives of Neurology, 2007, 64, 903.	4.9	19
146	B-cell function in CNS inflammatory demyelinating disease: a complexity of roles and a wealth of possibilities. Expert Review of Clinical Immunology, 2007, 3, 565-578.	1.3	9
148	Multiple Sclerosis in Children: Clinical, Diagnostic, and Therapeutic Aspects. International Review of Neurobiology, 2007, 79, 269-279.	0.9	6
149	Efficacy of propafenone in paramyotonia congenita. Neurology, 2007, 68, 1080-1081.	1.5	28
150	Devic Disease With Abnormal Brain Magnetic Resonance Image Findings: The First Portuguese Case. Archives of Neurology, 2007, 64, 290.	4.9	10
151	Devic Disease With Abnormal Brain Magnetic Resonance Image Findings: The First Portuguese Caseâ€"Reply. Archives of Neurology, 2007, 64, 291.	4.9	0
152	Hyperostosis frontalis interna as a novel finding in Unverricht-Lundborg disease. Neurology, 2007, 68, 1077-1078.	1.5	5
153	Neuromyelitis Optica Is Distinct From Multiple Sclerosis. Archives of Neurology, 2007, 64, 899.	4.9	82
154	New Insights into Adaptive Immunity in Chronic Neuroinflammation. Advances in Immunology, 2007, 96, 1-40.	1.1	42
156	The Pathology of MS. Neurologist, 2007, 13, 45-56.	0.4	95
157	Expanding the spectrum of neuromyelitis optica: friend or foe?. Current Opinion in Ophthalmology, 2007, 18, 459-462.	1.3	3
158	ADVANCES IN THE NEUROPATHOLOGY OF MULTIPLE SCLEROSIS. CONTINUUM Lifelong Learning in Neurology, 2007, 13, 86-116.	0.4	0

#	Article	IF	Citations
159	DISEASE-MODIFYING THERAPIES. CONTINUUM Lifelong Learning in Neurology, 2007, 13, 144-180.	0.4	0
160	Diagnosis and Treatment of Neuromyelitis Optica. Neurologist, 2007, 13, 2-11.	0.4	109
161	Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Current Opinion in Neurology, 2007, 20, 343-350.	1.8	90
162	Neuromyelitis optica. Current Opinion in Neurology, 2007, 20, 255-260.	1.8	85
164	Neuromyelitis optica with clinical and histopathological involvement of the brain. Multiple Sclerosis Journal, 2007, 13, 679-682.	1.4	32
165	Rethinking Neuromyelitis Optica (Devic Disease). Journal of Neuro-Ophthalmology, 2007, 27, 57-60.	0.4	14
167	Natural History of the Visual Impairment of Relapsing Neuromyelitis Optica. Ophthalmology, 2007, 114, 810-815.e2.	2.5	138
168	Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain, 2007, 130, 1235-1243.	3.7	561
170	Neuromyelitis optica in a patient with an early onset demyelinating episode: Clinical and autoantibody findings. Clinical Neurology and Neurosurgery, 2007, 109, 926-930.	0.6	14
171	Encefalitis aguda diseminada. Leucoencefalitis aguda hemorr?gica. Otras enfermedades desmielinizantes. Medicine, 2007, 9, 4894-4900.	0.0	0
172	The CD8 T Cell in Multiple Sclerosis: Suppressor Cell Or Mediator of Neuropathology?. International Review of Neurobiology, 2007, 79, 73-97.	0.9	51
174	Skin rash associated with Sinemet does not equal levodopa allergy. Neurology, 2007, 68, 1078-1079.	1.5	14
175	Multiple sclerosis in KwaZulu Natal, South Africa: an epidemiological and clinical study. Multiple Sclerosis Journal, 2007, 13, 1095-1099.	1.4	36
176	Paraplegie spastiche. EMC - Neurologia, 2007, 7, 1-13.	0.0	0
180	New Therapeutic Approaches for Multiple Sclerosis. Annual Review of Medicine, 2007, 58, 417-432.	5.0	43
181	Multiple sclerosis: Disease biomarkers as indicated by pathophysiology. Journal of the Neurological Sciences, 2007, 259, 21-26.	0.3	39
182	Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. Journal of the Neurological Sciences, 2007, 252, 57-61.	0.3	160
183	Demyelinating and Infectious Diseases of the Spinal Cord. Neuroimaging Clinics of North America, 2007, 17, 37-55.	0.5	24

#	Article	IF	Citations
184	Role of IL-1 and potential therapies in multiple sclerosis. Drug Discovery Today: Therapeutic Strategies, 2007, 4, 19-24.	0.5	3
185	Multiple Sclerosis Pathology During Early and Late Disease Phases: Pathogenic and Clinical Relevance. , 2007, , 214-264.		5
186	How B Cells Contribute to Multiple Sclerosis Pathology. , 2007, , 66-86.		0
187	Demyelinating Disorders of the Central Nervous System. , 2007, , 1103-1133.		9
188	DÃ©vic's Disease. , 0, , 83-87.		0
190	Devic's syndrome in a woman with systemic lupus erythematosus: Diagnostic and therapeutic implications of testing for the neuromyelitis optica IgG autoantibody. Arthritis and Rheumatism, 2007, 57, 347-351.	6.7	43
191	Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Annals of Neurology, 2007, 62, 197-200.	2.8	17
192	The Immunopathology of Multiple Sclerosis: An Overview. Brain Pathology, 2007, 17, 210-218.	2.1	994
193	Neuromyelitis optica following CMV primo-infection. Journal of Internal Medicine, 2007, 261, 500-503.	2.7	32
194	Nosology of idiopathic transverse myelitis syndromes. Acta Neurologica Scandinavica, 2007, 115, 371-376.	1.0	59
195	Disseminated encephalomyelitis and multiple sclerosis: two different diseases ? a critical review. Acta Neurologica Scandinavica, 2007, 116, 201-206.	1.0	35
196	Neuromyelitis optica: Changing concepts. Journal of Neuroimmunology, 2007, 187, 126-138.	1.1	104
197	The spectrum of neuromyelitis optica. Lancet Neurology, The, 2007, 6, 805-815.	4.9	1,897
198	Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurology, The, 2007, 6, 887-902.	4.9	341
199	Building Different Mouse Models for Human MS. Annals of the New York Academy of Sciences, 2007, 1103, 11-18.	1.8	39
200	Autoimmune Modulation of Astrocyte-Mediated Homeostasis. NeuroMolecular Medicine, 2007, 9, 1-16.	1.8	7
201	Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology, 2007, 49, 393-409.	1.1	125
204	Successful treatment of a hypothalamic lesion in neuromyelitis optica by plasma exchange. Journal of Neurology, 2007, 254, 670-671.	1.8	16

#	Article	IF	Citations
205	Polymorphisms in the neuromyelitis optica auto-antigen AQP4 and susceptibility to multiple sclerosis. Journal of Neurology, 2007, 254, 398-399.	1.8	10
206	Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features. Journal of Neurology, 2007, 254, 488-492.	1.8	32
207	Revised diagnostic criteria for neuromyelitis optica (NMO). Journal of Neurology, 2007, 254, 1233-1237.	1.8	85
208	Cortical, subcortical and spinal alterations in neuroimmunological diseases. Journal of Neurology, 2007, 254, II15-II17.	1.8	5
209	Variable responses to rituximab treatment in neuromyelitis optica (Devicâ€™s disease). Neurological Sciences, 2007, 28, 209-211.	0.9	60
210	B cells: No longer the nondominant arm of multiple sclerosis. Current Neurology and Neuroscience Reports, 2007, 7, 231-238.	2.0	12
211	Optic neuritis: The role of disease-modifying therapy disease-modifying therapy in this clinically isolated syndrome. Current Treatment Options in Neurology, 2007, 9, 48-54.	0.7	0
212	Reversible stenosis of large cerebral arteries in a patient with combined SjÃ¶grenâ€™s syndrome and neuromyelitis optica spectrum disorder. Rheumatology International, 2008, 28, 1277-1280.	1.5	18
214	Neuromyelitis optica: Diagnosis, pathogenesis, and treatment. Current Neurology and Neuroscience Reports, 2008, 8, 427-433.	2.0	54
215	Neuromyelitis optica. Current Treatment Options in Neurology, 2008, 10, 55-66.	0.7	129
216	A case of longitudinally extensive transverse myelitis (LETM): neuromyelitis optica. Clinical Rheumatology, 2008, 27, 67-69.	1.0	53
217	Diagnosis of inflammatory demyelination in biopsy specimens: a practical approach. Acta Neuropathologica, 2008, 115, 275-287.	3.9	100
218	Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. Journal of Neurology, 2008, 255, 305-307.	1.8	86
219	Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. Journal of Neurology, 2008, 255, 1449-1463.	1.8	204
220	Preferential spinal central gray matter involvement in neuromyelitis optica. Journal of Neurology, 2008, 255, 163-170.	1.8	124
221	Characteristics of Devic's disease (neuromyelitis optica) in Mexico. Journal of Neurology, 2008, 255, 710-715.	1.8	103
222	Mycoplasma pneumonia as a cause of neuromyelitis optica?. Journal of Neurology, 2008, 255, 1268-1269.	1.8	9
223	Isolated, relapsing and progressive demyelinating diseases of the central nervous system. Journal of Neurology, 2008, 255, 69-76.	1.8	12

#	Article	IF	Citations
224	White matter spectroscopy in neuromyelitis optica. Journal of Neurology, 2008, 255, 1895-1899.	1.8	33
225	Autoimmune myelopathy associated with collapsin responseâ€mediator proteinâ€5 immunoglobulin G. Annals of Neurology, 2008, 63, 531-534.	2.8	69
226	Autoantibody-mediated disorders of the central nervous system. Autoimmunity, 2008, 41, 55-65.	1.2	58
227	Neuromyelitis Optica and Asian Phenotype of Multiple Sclerosis. Annals of the New York Academy of Sciences, 2008, 1142, 58-71.	1.8	60
228	Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurologica Scandinavica, 2008, 118, 209-217.	1.0	67
229	Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurologica Scandinavica, 2008, 118, 218-225.	1.0	69
230	The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nature Reviews Genetics, 2008, 9, 516-526.	7.7	294
231	Session 2: Thursday 17 January 2008. Developmental Medicine and Child Neurology, 2008, 50, 6-32.	1.1	6
232	Graphical presentation of diagnostic information. BMC Medical Research Methodology, 2008, 8, 20.	1.4	42
233	IntÃ©rÃªt des auto-anticorps dans deux maladies dysimmunes du systÃ¨me nerveux : myasthÃ©nie et neuromyÃ©lite optique. Option/Bio, 2008, 19, 18-19.	0.0	0
234	Interleukin-17 in transverse myelitis and multiple sclerosis. Journal of Neuroimmunology, 2008, 196, 124-132.	1.1	71
235	Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. Journal of Neuroimmunology, 2008, 196, 181-187.	1.1	102
236	8th Course of the European School of Neuroimmunology. Journal of Neuroimmunology, 2008, 203, 119-280.	1.1	0
237	Functions of aquaporins in the eye. Progress in Retinal and Eye Research, 2008, 27, 420-433.	7.3	165
238	Mechanisms of inflammation induced tissue injury in multiple sclerosis. Journal of the Neurological Sciences, 2008, 274, 45-47.	0.3	68
239	NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. Journal of the Neurological Sciences, 2008, 275, 148-150.	0.3	32
240	Neuromyelitis optica pathogenesis and aquaporin 4. Journal of Neuroinflammation, 2008, 5, 22.	3.1	138
241	Chapter 4 B Cells and Autoantibodies in the Pathogenesis of Multiple Sclerosis and Related Inflammatory Demyelinating Diseases. Advances in Immunology, 2008, 98, 121-149.	1.1	75

#	Article	IF	Citations
242	Advances in multiple Sclerosis and Experimental Demyelinating Diseases. Current Topics in Microbiology and Immunology, 2008, , .	0.7	4
243	Involvement of Nervous System Pathways in Primary SjÃ¶gren's Syndrome. Rheumatic Disease Clinics of North America, 2008, 34, 885-906.	0.8	50
244	Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Sclerosis Journal, 2008, 14, 1157-1174.	1.4	560
245	Variants of Multiple Sclerosis. Neuroimaging Clinics of North America, 2008, 18, 703-716.	0.5	33
246	The Pathologic Substrate of Magnetic Resonance Alterations in Multiple Sclerosis. Neuroimaging Clinics of North America, 2008, 18, 563-576.	0.5	83
247	Neuromyelitis Optica in a Young Child With Positive Serum Autoantibody. Pediatric Neurology, 2008, 39, 209-212.	1.0	8
248	A Woman with Unilateral Visual Loss and Bilateral Disk Edema. Survey of Ophthalmology, 2008, 53, 85-89.	1.7	17
249	NMO-IgG and Devic's neuromyelitis optica: a French experience. Multiple Sclerosis Journal, 2008, 14, 440-445.	1.4	107
250	Neuromyelitis Optica and Nonâ€“Organ-Specific Autoimmunity. Archives of Neurology, 2008, 65, 78-83.	4.9	497
251	Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome. Multiple Sclerosis Journal, 2008, 14, 425-427.	1.4	64
252	Optic Neuritis in Dogs and Cats. Veterinary Clinics of North America - Small Animal Practice, 2008, 38, 403-415.	0.5	25
253	NeuromyÃ©lite optique et NMO-IgG. Revue Francophone Des Laboratoires, 2008, 2008, 21-23.	0.0	0
254	Multiple sclerosis. Lancet, The, 2008, 372, 1502-1517.	6.3	3,988
255	Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. Journal of the Neurological Sciences, 2008, 267, 3-16.	0.3	205
256	Neuromieliti ottiche. EMC - Neurologia, 2008, 8, 1-13.	0.0	0
258	Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1075-1078.	0.9	130
259	Optic Neuritis: An Update Typical and Atypical Optic Neuritis. Neuro-Ophthalmology, 2008, 32, 237-248.	0.4	25
260	Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1084-1084.	0.9	38

#	Article	IF	Citations
261	Spectrum of Pediatric Neuromyelitis Optica. Pediatrics, 2008, 122, e1039-e1047.	1.0	160
262	Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. Nature Clinical Practice Neurology, 2008, 4, 202-214.	2.7	286
263	CNS aquaporin-4 autoimmunity in children. Neurology, 2008, 71, 93-100.	1.5	299
264	Seronegative neuromyelitis optica: improvement following lymphocytapheresis treatment. Multiple Sclerosis Journal, 2008, 14, 860-861.	1.4	13
265	Neuromyelitis Optica (NMO) Antibody Positivity in Patients with Transverse Myelitis and No Visual Manifestations. Seminars in Ophthalmology, 2008, 23, 191-200.	0.8	17
266	Acute Disseminated Encephalomyelitis: Current Understanding and Controversies. Seminars in Neurology, 2008, 28, 084-094.	0.5	143
267	Chapter 7 Inflammatory Optic Neuropathies Not Associated with Multiple Sclerosis. Blue Books of Neurology, 2008, , 153-190.	0.1	6
268	Clinical Features of Opticospinal Multiple Sclerosis with Anti-Aquaporin 4 Antibody. European Neurology, 2008, 60, 37-42.	0.6	12
269	RELAPSING INFLAMMATORY OPTICNEURITIS: IS IT NEUROMYELITIS OPTICA?. Neurology, 2008, 70, 2075-2076.	1.5	56
270	Antibody Test Differentiates Pediatric Neuromyelitis Optica from MS in Children. Neurology Today: an Official Publication of the American Academy of Neurology, 2008, 8, 9-10.	0.0	0
271	Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)?. Brain, 2008, 131, e93-e93.	3.7	17
272	Review: Treatment of neuromyelitis optica: Current debate. Therapeutic Advances in Neurological Disorders, 2008, 1, 43-52.	1.5	21
273	Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis. Archives of Neurology, 2008, 65, 913-9.	4.9	259
274	Use of rituximab in multiple sclerosis: current progress and future perspectives. Expert Review of Clinical Immunology, 2008, 4, 573-582.	1.3	4
275	NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology, 2008, 70, 2197-2200.	1.5	337
276	Minor salivary gland inflammation in Devicâ€™s disease and longitudinally extensive myelitis. Multiple Sclerosis Journal, 2008, 14, 809-814.	1.4	50
277	To test or not to test. Neurology, 2008, 70, 2192-2193.	1.5	18
278	Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology, 2008, 71, 974-981.	1.5	81

#	Article	IF	Citations
279	Finding NMO. Neurology, 2008, 70, 334-335.	1.5	4
280	Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1208-1213.	1.4	68
281	Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology, 2008, 70, 2277-2283.	1.5	334
282	Dyspnoea due to vocal fold abduction paresis in anti-MuSK myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1083-1084.	0.9	11
283	Neuroimaging of Demyelination and Remyelination Models. Current Topics in Microbiology and Immunology, 2008, 318, 241-266.	0.7	20
284	Is Neuromyelitis Optica Eyeing a Distinct Path From Multiple Sclerosis?. JAMA Ophthalmology, 2008, 126, 128.	2.6	2
285	Anterior periventricular linear lesions in optic-spinal multiple sclerosis: a combined neuroimaging and neuropathological study. Multiple Sclerosis Journal, 2008, 14, 343-353.	1.4	11
286	Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Multiple Sclerosis Journal, 2008, 14, 1061-1067.	1.4	35
287	Cognitive Functions in Neuromyelitis Optica. Archives of Neurology, 2008, 65, 84-8.	4.9	98
288	Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment. Journal of Immunology, 2008, 181, 5730-5737.	0.4	233
289	Neuromyelitis optica (Devic's disease) in a patient with syphilis. Multiple Sclerosis Journal, 2008, 14, 268-271.	1.4	20
290	Association of the HLA-DRB1 alleles with characteristic MRI features of Asian multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1181-1190.	1.4	37
291	An Approach to the Diagnosis of Acute Transverse Myelitis. Seminars in Neurology, 2008, 28, 105-120.	0.5	210
293	Optical Coherence Tomography in Neuromyelitis Optica. Archives of Neurology, 2008, 65, 920-3.	4.9	96
294	A case of paraneoplastic myelopathy associated with the neuromyelitis optica antibody. Nature Clinical Practice Neurology, 2008, 4, 284-288.	2.7	36
295	Picturing Multiple Sclerosis: Conventional and Diffusion Tensor Imaging. Seminars in Neurology, 2008, 28, 453-466.	0.5	46
300	Neuromyelitis Optica: A New Perspective. Seminars in Neurology, 2008, 28, 095-104.	0.5	31
301	The complex genetics of multiple sclerosis: pitfalls and prospects. Brain, 2008, 131, 3118-3131.	3.7	96

#	Article	IF	Citations
302	Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain, 2008, 131, 3072-3080.	3.7	397
303	Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1134-1136.	0.9	78
304	Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology, 2008, 70, 344-352.	1.5	247
305	Antibodies Against Aquaporin-4 Predict Risk for Neuromyelitis Optica. Neurology Today: an Official Publication of the American Academy of Neurology, 2008, 8, 5.	0.0	0
306	A Prominent Elevation of Glial Fibrillary Acidic Protein in the Cerebrospinal Fluid during Relapse in Neuromyelitis Optica. Tohoku Journal of Experimental Medicine, 2008, 215, 55-59.	0.5	24
307	NMO Antibodyâ€“Positive Recurrent Optic Neuritis Without Clear Evidence of Transverse Myelitis. JAMA Ophthalmology, 2008, 126, 566.	2.6	12
310	An Autopsy Case of Sjoegren's Syndrome with Acute Encephalomyelopathy. Internal Medicine, 2008, 47, 1675-1680.	0.3	8
311	Part 1â€”Baseline. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 245-256.	0.4	0
312	Acute Inflammatory Demyelinating Optic Neuritis. Neurologist, 2008, 14, 207-223.	0.4	31
313	10 Most Commonly Asked Questions About Cerebrospinal Fluid Characteristics in Demyelinating Disorders of the Central Nervous System. Neurologist, 2008, 14, 60-65.	0.4	6
314	INFECTIOUS AND INFLAMMATORY MYELOPATHIES. CONTINUUM Lifelong Learning in Neurology, 2008, 14, 36-57.	0.4	3
315	Optic neuritis and multiple sclerosis. Current Opinion in Neurology, 2008, 21, 16-21.	1.8	49
316	Epidemiology, immunopathogenesis and management of pediatric central nervous system inflammatory demyelinating conditions. Current Opinion in Neurology, 2008, 21, 366-372.	1.8	31
317	Seroprevalence of NMO-IgG antibody in Brazilian patients with neuromyelitis optica. Arquivos De Neuro-Psiquiatria, 2008, 66, 295-297.	0.3	25
318	Devicâ€™s neuromyelitis optica: a critical review. Arquivos De Neuro-Psiquiatria, 2008, 66, 120-138.	0.3	50
319	Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. Arquivos De Neuro-Psiquiatria, 2008, 66, 678-684.	0.3	15
320	A Case of Anti-aquaporin-4 and Anti-glutamate Receptor Antibodies Positive Myelitis Presented with Modest Clinical Signs. Magnetic Resonance in Medical Sciences, 2008, 7, 55-58.	1.1	6
321	Neuromyelitis optica: brain abnormalities in a Brazilian cohort. Arquivos De Neuro-Psiquiatria, 2008, 66, 1-4.	0.3	29

#	Article	IF	Citations
322	Association of anti-Helicobacter pylori neutrophil-activating protein antibody response with anti-aquaporin-4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2009, 15, 1411-1421.	1.4	75
323	Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Multiple Sclerosis Journal, 2009, 15, 613-619.	1.4	65
324	Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Multiple Sclerosis Journal, 2009, 15, 828-833.	1.4	50
325	Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 575-577.	0.9	134
326	Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology, 2009, 72, 712-717.	1.5	194
327	Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis. Journal of Immunology, 2009, 183, 4067-4076.	0.4	182
328	Spinal Cord Disorders. , 0, , 585-628.		1
329	Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions. Multiple Sclerosis Journal, 2009, 15, 1113-1117.	1.4	51
330	NMO-IgG DETECTED IN CSF IN SERONEGATIVE NEUROMYELITIS OPTICA. Neurology, 2009, 72, 1101-1103.	1.5	75
331	Effector Functions of Antiaquaporinâ€4 Autoantibodies in Neuromyelitis Optica. Annals of the New York Academy of Sciences, 2009, 1173, 478-486.	1.8	23
332	Treatment of Neuromyelitis Optica With Mycophenolate Mofetil. Archives of Neurology, 2009, 66, 1128-33.	4.9	283
333	Childhood Acute Transverse Myelitis: Clinical Profile, Outcome, and Association With Antiganglioside Antibodies. Journal of Child Neurology, 2009, 24, 466-471.	0.7	17
334	Diagnosis of Neuromyelitis Spectrum Disorders. Archives of Neurology, 2009, 66, 1134-8.	4.9	87
335	What insights have new imaging techniques given into aggressive forms of MS â€“ different forms of MS or different from MS?. Multiple Sclerosis Journal, 2009, 15, 285-293.	1.4	10
336	Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30Âyears. Multiple Sclerosis Journal, 2009, 15, 159-173.	1.4	145
337	INTRAMEDULLARY SJOÌˆGREN SYNDROME. Neurology, 2009, 73, 2041-2042.	1.5	3
338	Neuromyelitis Optica IgG Serostatus in Fulminant Central Nervous System Inflammatory Demyelinating Disease. Archives of Neurology, 2009, 66, 964-6.	4.9	29
339	Nineteen Episodes of Recurrent Myelitis in a Woman With Neuromyelitis Optica and Systemic Lupus Erythematosus. Archives of Neurology, 2009, 66, 1160-3.	4.9	34

#	Article	IF	Citations
340	Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology, 2009, 73, 1628-1637.	1.5	88
341	Plasma Exchange Therapy in Steroid-Unresponsive Relapses in Patients with Multiple Sclerosis. Blood Purification, 2009, 28, 108-115.	0.9	69
342	Monoclonal Antibodies in the Treatment of Multiple Sclerosis. Current Medicinal Chemistry, 2009, 16, 4858-4868.	1.2	2
344	Transverse myelitis spectrum disorders. Neurology India, 2009, 57, 126.	0.2	30
345	Relationship between Barkhof criteria and the clinical features of multiple sclerosis in northern Japan. Multiple Sclerosis Journal, 2009, 15, 1450-1458.	1.4	5
346	GLUT1 DEFICIENCY AND ALTERNATING HEMIPLEGIA OF CHILDHOOD. Neurology, 2009, 73, 2042-2044.	1.5	53
347	Is neuromyelitis optica associated with human leukocyte antigen?. Multiple Sclerosis Journal, 2009, 15, 571-579.	1.4	122
348	Neuromyelitis optica - an update: 2007-2009. Annals of Indian Academy of Neurology, 2009, 12, 231.	0.2	14
349	Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology, 2009, 73, 302-308.	1.5	263
350	Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Multiple Sclerosis Journal, 2009, 15, 1153-1163.	1.4	63
351	Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Multiple Sclerosis Journal, 2009, 15, 834-847.	1.4	68
352	Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2009, 15, 487-492.	1.4	178
353	Demyelinating Optic Neuritis in Children. Journal of Child Neurology, 2009, 24, 45-48.	0.7	43
354	Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Multiple Sclerosis Journal, 2009, 15, 304-310.	1.4	29
355	Magnetic Resonance Imaging in Multiple Sclerosis. Topics in Magnetic Resonance Imaging, 2009, 20, 313-323.	0.7	5
356	Prediction of Neuromyelitis Optica Attack Severity by Quantitation of Complement-Mediated Injury to Aquaporin-4â€“Expressing Cells. Archives of Neurology, 2009, 66, 1164-7.	4.9	106
357	Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica. Journal of Neuroimmunology, 2009, 211, 110-113.	1.1	38
358	Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: An in vitro study. Journal of Neuroimmunology, 2009, 215, 31-35.	1.1	91

#	Article	IF	Citations
359	Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. Journal of Neuroimmunology, 2009, 217, 95-101.	1.1	35
360	Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica. Journal of Neuroimmunology, 2009, 217, 74-79.	1.1	31
361	Patient with neuromyelitis optica and inflammatory demyelinating lesions comprising whole spinal cord from C2 level till conus: case report. BMC Neurology, 2009, 9, 56.	0.8	11
362	Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmunity Reviews, 2009, 9, 132-135.	2.5	53
363	Acute transverse myelitis: A practical reappraisal. Autoimmunity Reviews, 2009, 9, 128-131.	2.5	45
364	Immunoglobulins and complement in postmortem multiple sclerosis tissue. Annals of Neurology, 2009, 65, 32-46.	2.8	129
365	Intrathecal pathogenic antiâ€“aquaporinâ€4 antibodies in early neuromyelitis optica. Annals of Neurology, 2009, 66, 617-629.	2.8	516
366	Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Annals of Neurology, 2009, 66, 630-643.	2.8	504
367	Aquaporinâ€4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia, 2009, 57, 1363-1373.	2.5	143
368	Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle and Nerve, 2009, 39, 87-90.	1.0	123
369	Neuromyelitis optica with CSF examination mimicking bacterial meningomyelitis. Neurological Sciences, 2009, 30, 51-54.	0.9	21
370	A possible paraneoplastic neuromyelitis optica associated with lung cancer. Neurological Sciences, 2009, 30, 397-400.	0.9	40
371	An epidemiological study of neuromyelitis optica in Cuba. Journal of Neurology, 2009, 256, 35-44.	1.8	158
372	Long-term outcome of acute and subacute myelopathies. Journal of Neurology, 2009, 256, 980-988.	1.8	52
373	Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. Journal of Neurology, 2009, 256, 1891-1898.	1.8	112
374	Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases. Journal of Neurology, 2009, 256, 1906-1908.	1.8	6
376	The pathological spectrum of CNS inflammatory demyelinating diseases. Seminars in Immunopathology, 2009, 31, 439-453.	2.8	123
377	TNF-Î± and IL-10 downregulation and marked oxidative stress in Neuromyelitis Optica. Journal of Inflammation, 2009, 6, 18.	1.5	45

#	Article	IF	Citations
378	MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nature Immunology, 2009, 10, 1252-1259.	7.0	726
379	NMO-IgG-negative relapsing myelitis. Spinal Cord, 2009, 47, 531-537.	0.9	9
380	Isolated longitudinal myelitis: a report of six cases. Spinal Cord, 2009, 47, 257-261.	0.9	12
381	Intermittent Plasmapheresis Prevents Recurrence in Neuromyelitis Optica. Therapeutic Apheresis and Dialysis, 2009, 13, 505-508.	0.4	78
382	Antibodyâ€negative neuromyelitis optica with heavy Bâ€cell infiltration. Apmis, 2009, 117, 768-772.	0.9	0
383	Neuromyelitis Optica Preceded by Brain Demyelinating Episode. Journal of Neuroimaging, 2009, 19, 263-265.	1.0	7
384	Spinal cord biopsy findings of antiâ€aquaporinâ€4 antibodyâ€negative recurrent longitudinal myelitis in a patient with sicca symptoms and hepatitis C viral infection. Neuropathology, 2009, 29, 472-479.	0.7	6
385	Association of the HLAâ€DPB1*0501 allele with antiâ€aquaporinâ€4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens, 2009, 73, 171-176.	1.0	109
386	Frequency of Chronic Headaches in Japanese Patients With Multiple Sclerosis: With Special Reference to Opticospinal and Common Forms of Multiple Sclerosis. Headache, 2009, 49, 1513-1520.	1.8	20
387	Neuromyelitis opticaâ€IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese. European Journal of Neurology, 2009, 16, 310-316.	1.7	35
388	Neuromyelitis optica and the evolving spectrum of water channel autoimmunity: a new direction. European Journal of Neurology, 2009, 16, 433-435.	1.7	4
389	Relevance of clinical findings for diagnosis of neuromyelitis optica in MRI and NMOâ€IgG era. European Journal of Neurology, 2009, 16, e76-7.	1.7	1
390	Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. European Radiology, 2009, 19, 2535-2543.	2.3	92
391	Plasmapheresis for neurological disorders. Expert Review of Neurotherapeutics, 2009, 9, 1331-1339.	1.4	53
392	Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 679-682.	0.9	52
393	Prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis according to baseline MRI findings: comparison of revised McDonald criteria and Swanton modified criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1107-1109.	0.9	14
394	Acute Transverse Myelitis and Acute Disseminated Encephalomyelitis in Childhood: Spectrum or Separate Entities?. Journal of Child Neurology, 2009, 24, 287-296.	0.7	46
395	Magnetic resonance imaging of acute intramedullary myelopathy: radiological differential diagnosis for the on-call radiologist. Clinical Radiology, 2009, 64, 84-94.	0.5	36

#	Article	IF	Citations
396	Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochemical and Biophysical Research Communications, 2009, 386, 623-627.	1.0	233
398	A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions. Sleep Medicine, 2009, 10, 253-255.	0.8	37
399	Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Multiple Sclerosis Journal, 2009, 15, 695-700.	1.4	93
400	Current therapeutic recommendations in multiple sclerosis. Journal of the Neurological Sciences, 2009, 287, S37-S45.	0.3	21
401	Upregulation of water channel aquaporin-4 in experimental autoimmune encephalomyeritis. Journal of the Neurological Sciences, 2009, 276, 103-107.	0.3	26
402	Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey. Journal of the Neurological Sciences, 2009, 280, 22-28.	0.3	34
403	Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients. Journal of the Neurological Sciences, 2009, 281, 34-40.	0.3	24
404	Intractable hiccup caused by medulla oblongata lesions: A study of an autopsy patient with possible neuromyelitis optica. Journal of the Neurological Sciences, 2009, 285, 241-245.	0.3	30
405	Clinical and laboratory characteristics of atopic myelitis: Korean experience. Journal of the Neurological Sciences, 2009, 285, 154-158.	0.3	17
406	Anti-endothelial serum antibodies in a patient with Susac's syndrome. Journal of the Neurological Sciences, 2009, 285, 259-261.	0.3	77
407	Neuromyelitis optica: Effect of gender. Journal of the Neurological Sciences, 2009, 286, 18-23.	0.3	98
408	MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis. Journal of Neuroradiology, 2009, 36, 199-205.	0.6	49
409	B Cells and Antibodies in MS. Results and Problems in Cell Differentiation, 2009, 51, 99-113.	0.2	7
410	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics, 2009, 18, 767-778.	1.4	419
411	The borderland of neuromyelitis optica. Practical Neurology, 2009, 9, 335-340.	0.5	7
412	Antiâ€aquaporinâ€4 antibodyâ€positive optic neuritis. Acta Ophthalmologica, 2009, 87, 562-566.	0.6	24
413	NOMADâ€™ MUS : crÃ©ation dâ€™une cohorte franÃ§aise de neuro-optico-myÃ©lite aiguÃ« de Devic et des syndromes neurologiques apparentÃ©s. Revue Neurologique, 2009, 165, S57-S58.	0.6	0
416	NeuromyÃ©lite optique de Devic et patients Ã haut risquÃ© : enquÃªte rÃ©trospective nationale. Revue Neurologique, 2009, 165, S55-S56.	0.6	0

#	Article	IF	Citations
418	BILATERAL VISUAL LOSS APPROACH, LOCALIZATION, AND CAUSES. CONTINUUM Lifelong Learning in Neurology, 2009, 15, 68-84.	0.4	1
419	Absence of Neuromyelitis Optica IgG Antibody in an Active Relapsing-Remitting Multiple Sclerosis Population. Journal of Neuro-Ophthalmology, 2009, 29, 104-106.	0.4	9
420	Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. NeuroReport, 2009, 20, 508-512.	0.6	96
421	Neuromyelitis optica: current concepts and prospects for future management. Current Opinion in Ophthalmology, 2009, 20, 434-439.	1.3	11
422	The Genetics of Multiple Sclerosis. Results and Problems in Cell Differentiation, 2009, , 1-19.	0.2	3
427	3. Guideline for Nervous System Disease and Its Validation - Emphasis on Immune and Nervous System Diseases. The Journal of the Japanese Society of Internal Medicine, 2009, 98, 496-502.	0.0	0
428	5. Autoimmunity and Allergy of Central Nerve. The Journal of the Japanese Society of Internal Medicine, 2009, 98, 571-576.	0.0	0
429	Multiple Sclerosis and Demyelinating Diseases. , 0, , 411-447.		5
430	Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Archives of Neurology, 2009, 66, 226-33.	4.9	92
431	RETROBULBAR OPTIC NEUROPATHIES. CONTINUUM Lifelong Learning in Neurology, 2009, 15, 47-67.	0.4	1
432	Autoantibodies in Autoimmune Diseases. Current Pharmaceutical Design, 2010, 16, 1634-1643.	0.9	31
434	NEUROMYELITIS OPTICA SPECTRUM DISORDERS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 105-121.	0.4	28
435	A 32-year-old Man with Neuromyelitis Optica Presenting Peculiar Itching.. The Journal of the Japanese Society of Internal Medicine, 2010, 99, 1650-1652.	0.0	0
436	A Case of Neuromyelitis Optica Complicated by Posterior Reversible Encephalopathy Syndrome and a Papillary Thyroid Cancer.. The Journal of the Japanese Society of Internal Medicine, 2010, 99, 1913-1915.	0.0	2
441	Neuromyelitis optica antibodies. Pathology, 2010, 42, S47-S48.	0.3	0
442	Biomarkers in Multiple Sclerosis. Blue Books of Neurology, 2010, , 120-146.	0.1	0
443	Human T-lymphotropic virus type I or II (HTLV-I/II) associated with recurrent longitudinally extensive transverse myelitis (LETM): two case reports. Journal of NeuroVirology, 2010, 16, 249-253.	1.0	9
444	Oligodendrocytes: biology and pathology. Acta Neuropathologica, 2010, 119, 37-53.	3.9	669

#	Article	IF	Citations
445	Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathologica, 2010, 120, 223-236.	3.9	150
446	Aquaporin-4 astrocytopathy in BalÃ³â€™s disease. Acta Neuropathologica, 2010, 120, 651-660.	3.9	53
447	Acute transverse myelitis in psoriatic arthritis. Journal of Neurology, 2010, 257, 457-458.	1.8	11
448	Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis. Journal of Neurology, 2010, 257, 920-925.	1.8	18
449	The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. Journal of Neurology, 2010, 257, 992-998.	1.8	21
450	Antibodies to aquaporin-4 in non-small cell lung cancer: a study on 50 patients. Neurological Sciences, 2010, 31, 871-872.	0.9	9
451	The effect of interferon Î²-1a on optic neuritis relapse in patients with multiple sclerosis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 231-235.	1.0	2
452	Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 1777-1785.	1.0	113
453	Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems. Journal of Clinical Immunology, 2010, 30, 97-102.	2.0	36
454	The antibody response to oligodendrocyte specific protein in multiple sclerosis. Journal of Neuroimmunology, 2010, 221, 81-86.	1.1	9
455	Aquaporin-4 water channel expression by thymoma of patients with and without myasthenia gravis. Journal of Neuroimmunology, 2010, 227, 178-184.	1.1	31
456	Neuromyelitis optica, psychiatric symptoms and primary polydipsia: a case report. General Hospital Psychiatry, 2010, 32, 648.e5-648.e8.	1.2	953
457	Espectro clÃ¬nico asociado a anticuerpos contra acuaporina 4 (IgG-NMO). NeurologÃa, 2010, 25, 5-12.	0.3	9
459	Clinical applications of therapeutic apheresis. Journal of Clinical Apheresis, 2010, 25, 250-264.	0.7	19
460	Increased frontoparietal integration after stroke and cognitive recovery. Annals of Neurology, 2010, 68, 753-756.	2.8	60
461	Intractable vomiting as the initial presentation of neuromyelitis optica. Annals of Neurology, 2010, 68, 757-761.	2.8	168
462	Heightened neurologic complications in children with pandemic H1N1 influenza. Annals of Neurology, 2010, 68, 762-766.	2.8	83
463	Autoantibodies against aquaporinâ€4 in patients with neuropsychiatric systemic lupus erythematosus and primary SjÃ¶gren's syndrome. Arthritis and Rheumatism, 2010, 62, 1198-1200.	6.7	88

#	Article	IF	Citations
464	Relapsing Neuromyelitis Optica: demographic and clinical features in Iranian patients. European Journal of Neurology, 2010, 17, 794-799.	1.7	38
465	EFNS guidelines on diagnosis and management of neuromyelitis optica. European Journal of Neurology, 2010, 17, 1019-1032.	1.7	376
466	A 10â€¥EAR OLD GIRL WITH NECK PAIN. Brain Pathology, 2010, 20, 519-522.	2.1	2
467	NeuromyÃ©lite optique deÂDevic: uneÂforme particuliÃ¨re deÂSEP ouÂuneÂentitÃ© isolÃ©e?. Neurologie Com, 2010, 2, 34-36.	0.0	1
468	10 Inflammatory and Autoimmune Diseases. , 2010, , .		0
469	Pediatric Multiple Sclerosis. Blue Books of Neurology, 2010, , 185-205.	0.1	0
470	Anti-Î±-Internexin Autoantibody from Neuropsychiatric Lupus Induce Cognitive Damage via Inhibiting Axonal Elongation and Promote Neuron Apoptosis. PLoS ONE, 2010, 5, e11124.	1.1	38
471	Recurrent optic neuritis: clues from a long-term follow up study of recurrent and bilateral optic neuritis patients. Eye and Brain, 2010, 2, 15.	3.8	11
472	New developments in the treatment of optic neuritis. Eye and Brain, 2010, 2, 83.	3.8	6
473	Neuromyelitis Optica. Blue Books of Neurology, 2010, 35, 258-275.	0.1	4
474	Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics. Multiple Sclerosis Journal, 2010, 16, 81-86.	1.4	32
475	Neuromyelitis optica in France. Neurology, 2010, 74, 736-742.	1.5	196
476	Anti-aquaporin-4 antibodies in Devicâ€™s neuromyelitis optica: therapeutic implications. Therapeutic Advances in Neurological Disorders, 2010, 3, 311-321.	1.5	28
477	Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. Multiple Sclerosis Journal, 2010, 16, 147-155.	1.4	29
478	Pediatric Multiple Sclerosis. Neurologist, 2010, 16, 92-105.	0.4	32
479	CD8⁺CD11a^{high} Cells Decreased in Multiple Sclerosis but Not in Neuromyelitis Optica. European Neurology, 2010, 63, 159-163.	0.6	1
480	Should Most Patients With Optic Neuritis be Tested for Neuromyelitis Optica Antibodies and Should This Affect Their Treatment?. Journal of Neuro-Ophthalmology, 2010, 30, 376-379.	0.4	11
481	Neuromyelitis Optica Treatment. Archives of Neurology, 2010, 67, 1131-6.	4.9	101

#	Article	IF	Citations
482	IFNÎ²-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology, 2010, 75, 1423-1427.	1.5	183
483	Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 109-111.	0.9	116
485	Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clinical Chemistry and Laboratory Medicine, 2010, 48, 659-663.	1.4	35
486	Anti-AQP4-AntikÃ¶rper als Biomarker zur FrÃ¼herkennung von Neuromyelitis Optica-Spektrum-Erkrankungen / AQP4-IgG antibodies as biomarkers for early diagnosis of neuromyelitis optica spectrum disorders. Laboratoriums Medizin, 2010, 34, 337-342.	0.1	0
487	Anti-Aquaporin-4 Antibody-Positive Optic Neuritis Treated with Double-Filtration Plasmapheresis. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 381-385.	0.6	20
488	Neuromyelitis optica without typical opticospinal phenotype. Multiple Sclerosis Journal, 2010, 16, 1154-1155.	1.4	9
489	Evidences for a Leaky Scanning Mechanism for the Synthesis of the Shorter M23 Protein Isoform of Aquaporin-4. Journal of Biological Chemistry, 2010, 285, 4562-4569.	1.6	58
490	Attack Therapies in Multiple Sclerosis. Blue Books of Neurology, 2010, , 276-283.	0.1	0
491	Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Multiple Sclerosis Journal, 2010, 16, 1156-1172.	1.4	114
492	HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 21-29.	1.4	117
493	Astrocytic damage is far more severe than demyelination in NMO. Neurology, 2010, 75, 208-216.	1.5	209
494	Absence of cortical demyelination in neuromyelitis optica. Neurology, 2010, 75, 2103-2109.	1.5	101
495	Acute disseminated encephalomyelitis and multiple sclerosis. Brain, 2010, 133, 317-319.	3.7	25
496	Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain, 2010, 133, 1602-1611.	3.7	78
497	Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology, 2010, 74, 538-544.	1.5	58
498	Neuromyelitis optica and NMO-IgG in European pediatric patients. Neurology, 2010, 75, 1740-1744.	1.5	56
499	Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain, 2010, 133, 2578-2591.	3.7	180
500	Familial neuromyelitis optica. Neurology, 2010, 75, 310-315.	1.5	114

#	Article	IF	Citations
501	Differential Regulation of IgG-NMO Autoantibodies on S100Beta Protein and Disability in Relapsing Neuromyelitis Optica. NeuroImmunoModulation, 2010, 17, 177-179.	0.9	9
502	CSF GFAP. Neurology, 2010, 75, 200-201.	1.5	4
503	Diffuse White Matter Damage Is Absent in Neuromyelitis Optica. American Journal of Neuroradiology, 2010, 31, 76-79.	1.2	50
504	Aquaporins and Neurodegenerative Diseases. Current Neuropharmacology, 2010, 8, 112-121.	1.4	19
505	Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica. Archives of Neurology, 2010, 67, 1201-8.	4.9	82
506	Transverse Myelitis. New England Journal of Medicine, 2010, 363, 564-572.	13.9	158
507	Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. Journal of the Neurological Sciences, 2010, 291, 52-56.	0.3	189
508	Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status. Journal of the Neurological Sciences, 2010, 291, 37-43.	0.3	56
509	Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica. Journal of the Neurological Sciences, 2010, 293, 92-96.	0.3	29
510	CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. Journal of the Neurological Sciences, 2010, 295, 41-45.	0.3	16
511	Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences, 2010, 298, 158-162.	0.3	169
512	Differential Diagnosis and Diagnostic Criteria for Multiple Sclerosis. Blue Books of Neurology, 2010, 35, 19-42.	0.1	1
513	Advances in Multiple Sclerosis Imaging. Blue Books of Neurology, 2010, 35, 83-119.	0.1	0
514	Neuromyelitis optica: an overview. Postgraduate Medical Journal, 2010, 86, 153-159.	0.9	24
515	Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurology, 2010, 10, 45.	0.8	59
516	Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. Journal of Neuroinflammation, 2010, 7, 50.	3.1	52
517	Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. Journal of Neuroinflammation, 2010, 7, 52.	3.1	182
518	Neuromyelitis Optica: A Case Report. Pediatrics and Neonatology, 2010, 51, 347-352.	0.3	7

#	Article	IF	Citations
519	Clinical spectrum associated with aquaporin-4 antibodies (NMO-IgG). NeurologÃa (English Edition), 2010, 25, 5-12.	0.2	1
520	Treatments for Neuro-Ophthalmologic Conditions. Neurologic Clinics, 2010, 28, 1005-1035.	0.8	4
521	Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Multiple Sclerosis Journal, 2010, 16, 1229-1236.	1.4	171
522	Imaging evaluation of demyelinating processes of the central nervous system. Postgraduate Medical Journal, 2010, 86, 218-229.	0.9	14
523	Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochemistry International, 2010, 57, 662-667.	1.9	15
524	Neuromyelitis optica associated with subacute human T-lymphotropic virus type 1 infection. Journal of Clinical Neuroscience, 2010, 17, 1449-1451.	0.8	14
527	The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. Journal of Autoimmunity, 2010, 34, 371-379.	3.0	121
528	Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochemical and Biophysical Research Communications, 2010, 394, 205-210.	1.0	89
529	Aquaporin-4 in brain and spinal cord oedema. Neuroscience, 2010, 168, 1036-1046.	1.1	165
530	Neurological autoimmunity targeting aquaporin-4. Neuroscience, 2010, 168, 1009-1018.	1.1	77
531	Molecular disruptions of the panglial syncytium block potassium siphoning and axonal saltatory conduction: pertinence to neuromyelitis optica and other demyelinating diseases of the central nervous system. Neuroscience, 2010, 168, 982-1008.	1.1	143
532	Drug-induced Optic Neuropathyâ€"TB or Not TB. Survey of Ophthalmology, 2010, 55, 378-385.	1.7	15
533	Identifying targets for autoantibodies in CNS inflammation: Strategies and achievements. Clinical and Experimental Neuroimmunology, 2010, 1, 47-60.	0.5	11
534	Plasmapheresis for neuroinflammatory disorders. Clinical and Experimental Neuroimmunology, 2010, 1, 95-102.	0.5	6
535	Pathogenesis, diagnosis and treatment of neuromyelitis optica: Changing concept of an old disease. Clinical and Experimental Neuroimmunology, 2010, 1, 103-123.	0.5	4
536	The Swollen Optic Disc in Childhood. , 2010, , 97-154.		8
537	A case of cerebral aquaporinopathy. Multiple Sclerosis Journal, 2010, 16, 1252-1254.	1.4	6
538	Hiccups, nausea, and vomiting: water channels under attack!. Lancet, The, 2010, 375, 954.	6.3	11

#	Article	IF	Citations
540	Review: â€˜Gimme fiveâ€™: future challenges in multiple sclerosis. ECTRIMS Lecture 2009. Multiple Sclerosis Journal, 2010, 16, 3-14.	1.4	10
541	AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nature Reviews Neurology, 2010, 6, 383-392.	4.9	384
542	Molecular Basis of Multiple Sclerosis. Results and Problems in Cell Differentiation, 2010, , .	0.2	1
543	Immune Aspects of the Bloodâ€“Brain Barrier. NeuroImmune Biology, 2010, , 183-195.	0.2	2
544	The optic nerve head in acquired optic neuropathies. Nature Reviews Neurology, 2010, 6, 221-236.	4.9	14
545	The Prevalence of Long Spinal Cord Lesions and Anti-Aquaporin 4 Antibodies in Neuromyelitis Optica Patients in Taiwan. European Neurology, 2011, 65, 99-104.	0.6	16
546	A Comparison of Optic Neuritis in Asian and in Western Countries. Neuro-Ophthalmology, 2011, 35, 65-72.	0.4	19
547	Genetic analysis of aquaporin-4 in neuromyelitis optica. Neurology, 2011, 77, 1149-1155.	1.5	48
548	Hypothalamic lesions in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 819-822.	0.9	31
549	Relapsing demyelinating CNS disease in a Korean pediatric population: Multiple sclerosis versus neuromyelitis optica. Multiple Sclerosis Journal, 2011, 17, 67-73.	1.4	25
550	Lupus Related Longitudinal Myelitis. Journal of Rheumatology, 2011, 38, 1520-1520.	1.0	5
551	Optimizing rituximab therapy for neuromyelitis optica. Nature Reviews Neurology, 2011, 7, 664-665.	4.9	10
552	Neuroimaging in Acute Transverse Myelitis. Neuroimaging Clinics of North America, 2011, 21, 951-973.	0.5	24
553	Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1360-1364.	0.9	113
554	Historia de la enfermedad de Devic. Revista Colombiana De ReumatologÃa, 2011, 18, 271-284.	0.0	0
555	Demographic, Genetic, and Environmental Factors That Modify Disease Course. Neurologic Clinics, 2011, 29, 323-341.	0.8	7
557	Longitudinal extensive transverse myelitisâ€”it's not all neuromyelitis optica. Nature Reviews Neurology, 2011, 7, 688-698.	4.9	141
558	What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease. Expert Opinion on Medical Diagnostics, 2011, 5, 393-410.	1.6	5

#	Article	IF	Citations
559	Neuromyelitis optica and opticospinal multiple sclerosis: Mechanisms and pathogenesis. Pathophysiology, 2011, 18, 69-79.	1.0	72
560	Brain abnormalities in neuromyelitis optica. Journal of the Neurological Sciences, 2011, 302, 43-48.	0.3	55
561	Systemic sclerosis in aquaporin-4 antibody-positive longitudinally extensive transverse myelitis. Journal of the Neurological Sciences, 2011, 303, 139-141.	0.3	21
562	Neuromyelitis optica and astrocytic damage in its pathogenesis. Journal of the Neurological Sciences, 2011, 306, 183-187.	0.3	62
563	Clinical characteristics, therapeutic outcomes of isolated atypical optic neuritis in China. Journal of the Neurological Sciences, 2011, 305, 38-40.	0.3	13
564	Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures. Journal of the Neurological Sciences, 2011, 306, 82-90.	0.3	297
565	Seropositive antiaquaporin-4 antibody associated with multisegmental myelitis in a patient with paracoccidioidomycosis. Journal of the Neurological Sciences, 2011, 309, 151-153.	0.3	1
566	Untapped targets in multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, S12-S15.	0.3	3
567	Multiple sclerosis in childhood and adolescence. Journal of the Neurological Sciences, 2011, 311, S53-S57.	0.3	11
568	Myasthenia Gravisâ€“Associated Neuromyelitis Opticaâ€“Like Disease. Archives of Neurology, 2011, 68, 1557.	4.9	41
569	Azathioprine. Neurology, 2011, 77, 659-666.	1.5	236
570	Childhood optic neuritis clinical features and outcome. Archives of Disease in Childhood, 2011, 96, 860-862.	1.0	73
571	Clinical Neuroimmunology. , 2011, , .		0
572	Modeling a Complex Disease. Advances in Immunology, 2011, 110, 111-137.	1.1	9
573	Magnetic Resonance Imaging in Multiple Sclerosis: The Role of Conventional Imaging. Neurologic Clinics, 2011, 29, 343-356.	0.8	14
574	Clinical isolated syndrome: A 3-year follow-up study in China. Clinical Neurology and Neurosurgery, 2011, 113, 658-660.	0.6	16
575	Regional homogeneity changes in patients with neuromyelitis optica revealed by resting-state functional MRI. Clinical Neurophysiology, 2011, 122, 121-127.	0.7	42
576	Abnormal baseline brain activity in patients with neuromyelitis optica: A resting-state fMRI study. European Journal of Radiology, 2011, 80, 407-411.	1.2	56

#	Article	IF	Citations
577	Brain MRI abnormalities in neuromyelitis optica. European Journal of Radiology, 2011, 80, 445-449.	1.2	44
578	Cognitive impairment and whole brain diffusion in patients with neuromyelitis optica after acute relapse. Brain and Cognition, 2011, 77, 80-88.	0.8	36
579	The role of antibodies in multiple sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 239-245.	1.8	96
580	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Multiple Sclerosis Journal, 2011, 17, 1067-1073.	1.4	144
581	Fine specificity of antibodies against AQP4: Epitope mapping reveals intracellular epitopes. Journal of Autoimmunity, 2011, 36, 221-227.	3.0	36
582	Therapeutic efficacy of double filtration plasmapheresis in patients with anti-aquaporin-4 antibody-positive multiple sclerosis. Journal of Clinical Neuroscience, 2011, 18, 478-480.	0.8	27
583	Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. Journal of Clinical Neuroscience, 2011, 18, 1313-1317.	0.8	141
584	Acute disseminated encephalomyelitis and its place amongst other acute inflammatory demyelinating CNS disorders. Journal of the Neurological Sciences, 2011, 306, 188-191.	0.3	19
585	The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis. Expert Review of Neurotherapeutics, 2011, 11, 451-462.	1.4	3
586	Neuromyelitis optica: An update. Journal of the Neurological Sciences, 2011, 303, 13-21.	0.3	31
587	Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: Astrocytopathy as a common denominator in demyelinating disorders. Journal of the Neurological Sciences, 2011, 311, 69-77.	0.3	49
588	Otras enfermedades desmielinizantes. Medicine, 2011, 10, 5101-5107.	0.0	0
589	Atypical presentations of neuromyelitis optica. Arquivos De Neuro-Psiquiatria, 2011, 69, 824-828.	0.3	29
590	Dantrolene to Dysproteinaemias. , 0, , 114-137.		0
592	Plasma exchange treatment for CNS inflammatory demyelinating disease. , 0, , 454-464.		0
593	Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. , 0, , 614-631.		0
594	Neuromyelitis Optica. , 2011, , 237-251.		0
595	NMO-DBr: the Brazilian Neuromyelitis Optica Database System. Arquivos De Neuro-Psiquiatria, 2011, 69, 687-692.	0.3	8

#	Article	IF	Citations
596	Optical coherence tomography evaluation of retinal nerve fiber layer in longitudinally extensive transverse myelitis. Arquivos De Neuro-Psiquiatria, 2011, 69, 69-73.	0.3	8
598	NMO in pediatric patients: brain involvement and clinical expression. Arquivos De Neuro-Psiquiatria, 2011, 69, 34-38.	0.3	21
599			



#	Article	IF	Citations
616	Autoimmune Myelopathies. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 776-799.	0.4	8
620	Central nervous system infections and inflammation. , 0, , 430-444.		0
621	Recurrent isolated optic neuritis in the pediatric population. , 0, , 234-242.		0
624	Review: The architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathology and Applied Neurobiology, 2011, 37, 698-710.	1.8	101
625	Neuromyelitis optica after Japanese encephalitis vaccination. European Journal of Neurology, 2011, 18, e26-e27.	1.7	17
626	Cerebrospinal fluid Bâ€cell expansion in longitudinally extensive transverse myelitis associated with neuromyelitis optica immunoglobulin G. Developmental Medicine and Child Neurology, 2011, 53, 856-860.	1.1	9
627	Bilateral and recurrent optic neuritis in multiple sclerosis. Acta Neurologica Scandinavica, 2011, 123, 207-210.	1.0	41
628	Neuromyelitis optica (NMO) - an autoimmune disease of the central nervous system (CNS). Acta Neurologica Scandinavica, 2011, 123, 369-384.	1.0	31
629	Reappraisal of Aquaporinâ€4 Astrocytopathy in Asian Neuromyelitis Optica and Multiple Sclerosis Patients. Brain Pathology, 2011, 21, 516-532.	2.1	41
630	Noninfectious Central Nervous System Inflammatory Disorders. Seminars in Pediatric Neurology, 2011, 18, 91-94.	1.0	5
631	Neuromyelitis optica: Concepts in evolution. Journal of Neuroimmunology, 2011, 231, 100-104.	1.1	18
632	HLA-DPB1*0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in Southern Han Chinese. Journal of Neuroimmunology, 2011, 233, 181-184.	1.1	105
633	Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2011, 234, 124-130.	1.1	41
634	T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. Journal of Neuroimmunology, 2011, 235, 27-32.	1.1	31
635	Increased serum matrix metalloproteinase-9 in neuromyelitis optica: Implication of disruption of bloodâ€“brain barrier. Journal of Neuroimmunology, 2011, 236, 81-86.	1.1	42
636	Role of glial cells in innate immunity and their role in CNS demyelination. Journal of Neuroimmunology, 2011, 239, 13-20.	1.1	44
637	Role of aquaporins in cell migration and edema formation in human brain tumors. Experimental Cell Research, 2011, 317, 2391-2396.	1.2	46
638	Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. Journal of Neuroinflammation, 2011, 8, 184.	3.1	379

#	Article	IF	Citations
639	Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clinical Immunology, 2011, 138, 239-246.	1.4	24
640	Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: [RETIRED]. Neurology, 2011, 77, 2128-2134.	1.5	192
641	Pathogenic T cell responses against aquaporin 4. Acta Neuropathologica, 2011, 122, 21-34.	3.9	81
642	Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathologica, 2011, 122, 381-400.	3.9	138
643	Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. Journal of Neurology, 2011, 258, 464-470.	1.8	65
644	Multiple organ injury associated with neuromyelitis optica spectrum disorder in a low-grade B-cell lymphoma suspected of being follicular lymphoma. Journal of Neurology, 2011, 258, 691-693.	1.8	11
645	Aquaporin-4 seropositivity in a patient with coeliac disease but normal neurological examination and imaging. Journal of Neurology, 2011, 258, 702-703.	1.8	9
646	Homology between Klebsiella pneumoniae and human aquaporin-4: no evidence for cross-reactivity in neuromyelitis optica. A study on 114 patients. Journal of Neurology, 2011, 258, 929-931.	1.8	6
647	Anhidrosis associated with hypothalamic lesions related to anti-aquaporin 4 autoantibody. Journal of Neurology, 2011, 258, 2293-2295.	1.8	16
648	Detection of mumps virus RNA in cerebrospinal fluid of patients with neuromyelitis optica. Neurological Sciences, 2011, 32, 795-799.	0.9	11
651	Histoire de la neuromyÃ©lite optique de Devic. Pratique Neurologique - FMC, 2011, 2, 41-44.	0.1	3
652	Vasculitis in SjÃ¶grenâ€™s Syndrome. Current Rheumatology Reports, 2011, 13, 482-488.	2.1	43
653	Neuromyelitis Optica-AQP4: An Update. Current Rheumatology Reports, 2011, 13, 496-505.	2.1	8
654	Report on the 2nd scientific meeting of the "Verein zur FÃ¶rderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Oct. 29'th - Oct. 31'st, 2010. Experimental & Translational Stroke Medicine, 2011, 3, 3.	3.2	0
655	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	2.8	8,001
656	Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Annals of Neurology, 2011, 70, 943-954.	2.8	142
657	Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. Arthritis Care and Research, 2011, 63, 1203-1208.	1.5	24
658	The Relationship Between Aquaporinâ€4 Expression and Bloodâ€Brain and Spinal Cord Barrier Permeability Following Experimental Autoimmune Encephalomyelitis in the Rat. Anatomical Record, 2011, 294, 46-54.	0.8	14

#	Article	IF	Citations
659	A paraneoplastic neuromyelitis optica spectrum disorder associated with a mature B-cell neoplasm. Leukemia Research, 2011, 35, e111-e113.	0.4	15
660	Current and future treatment approaches for neuromyelitis optica. Therapeutic Advances in Neurological Disorders, 2011, 4, 111-121.	1.5	73
661	Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination. Archives of Neurology, 2011, 68, 870.	4.9	173
662	A patient with neuromyelitis optica with positive anti-Ro (SS-A) antibody presenting with intractable hiccup and nausea. Modern Rheumatology, 2011, 21, 561-562.	0.9	5
663	Impact of rituximab on relapse rate and disability in neuromyelitis optica. Multiple Sclerosis Journal, 2011, 17, 1225-1230.	1.4	141
664	Neuromyelitis Optica Antibodies in Patients With Severe Optic Neuritis in China. Journal of Neuro-Ophthalmology, 2011, 31, 16-19.	0.4	37
665	Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. International Immunology, 2011, 23, 565-573.	1.8	51
666	Ocular Oscillations in the Neuromyelitis Optica Spectrum. Journal of Neuro-Ophthalmology, 2011, 31, 255-259.	0.4	25
667	A Review of Cases of Neuromyelitis Optica. Neurologist, 2011, 17, 98-104.	0.4	10
668	Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System in Children. Topics in Magnetic Resonance Imaging, 2011, 22, 223-237.	0.7	4
669	Cognitive Function, Depression, Fatigue, and Activities of Daily Living in Patients With Neuromyelitis Optica After Acute Relapse. International Journal of Neuroscience, 2011, 121, 677-683.	0.8	36
670	Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. Multiple Sclerosis Journal, 2011, 17, 1527-1530.	1.4	39
671	Astrocytopathy in BalÃ³â€™s disease. Multiple Sclerosis Journal, 2011, 17, 771-779.	1.4	35
672	Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years. Archives of Neurology, 2011, 68, 1412.	4.9	267
673	AQP4 antibodyâ€“positive Thai cases. Neurology, 2011, 77, 827-834.	1.5	68
674	Insights into the Changing Perspectives of Multiple Sclerosis in India. Autoimmune Diseases, 2011, 2011, 1-5.	2.7	8
675	Identification of Two Major Conformational Aquaporin-4 Epitopes for Neuromyelitis Optica Autoantibody Binding. Journal of Biological Chemistry, 2011, 286, 9216-9224.	1.6	59
676	Effect of storage conditions and freeze/thaw cycles on aquaporin-4 antibody (NMO-IgG) serum levels. Clinical Chemistry and Laboratory Medicine, 2011, 49, 2121-2.	1.4	9

#	Article	IF	Citations
677	An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Multiple Sclerosis Journal, 2011, 17, 1384-1386.	1.4	30
678	A Benign Form of Neuromyelitis Optica. Archives of Neurology, 2011, 68, 918.	4.9	54
679	Viruses and Multiple Sclerosis. Neuroscientist, 2011, 17, 659-676.	2.6	60
680	Neuromyelitis Optica Spectrum Disorders. , 2011, , 219-232.		33
681	Devic Syndrome: A Diagnostic Dilemma. Journal of the National Medical Association, 2011, 103, 176-178.	0.6	1
682	Myasthenia Gravis during the Course of Neuromyelitis Optica. Case Reports in Neurology, 2011, 3, 268-273.	0.3	14
683	Evidence against Cellular Internalization in Vivo of NMO-IgG, Aquaporin-4, and Excitatory Amino Acid Transporter 2 in Neuromyelitis Optica. Journal of Biological Chemistry, 2011, 286, 45156-45164.	1.6	60
684	Neuromyelitis Optica: A Review. Seminars in Ophthalmology, 2011, 26, 337-341.	0.8	9
685	High-risk syndrome for neuromyelitis optica: a descriptive and comparative study. Multiple Sclerosis Journal, 2011, 17, 720-724.	1.4	17
687	Brain Involvement in Neuromyelitis Optica Spectrum Disorders. Archives of Neurology, 2011, 68, 1432.	4.9	97
688	Wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with neuromyelitis optica spectrum disorder and anti-aquaporin-4 antibody. Multiple Sclerosis Journal, 2011, 17, 885-887.	1.4	27
689	Pain in neuromyelitis optica and its effect on quality of life. Neurology, 2011, 77, 652-658.	1.5	111
690	Neuromyelitis optica unique area postrema lesions. Neurology, 2011, 76, 1229-1237.	1.5	262
691	First attack of Devicâ€™s neuromyelitis optica following endovascular treatment and rupture of brain arteriovenous malformation. Multiple Sclerosis Journal, 2011, 17, 895-896.	1.4	3
692	Neuromyelitis Optica Spectrum Disease with Positive Autoimmune Indices: A Case Report and Review of the Literature. Case Reports in Medicine, 2011, 2011, 1-4.	0.3	7
693	CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology, 2011, 76, 1108-1110.	1.5	73
694	Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. Therapeutic Advances in Neurological Disorders, 2011, 4, 123-134.	1.5	69
695	Painful Tonic Spasm in Neuromyelitis Optica. Archives of Neurology, 2012, 69, 1026-31.	4.9	95

#	Article	IF	Citations
696	Molecular Pathogenesis of Neuromyelitis Optica. International Journal of Molecular Sciences, 2012, 13, 12970-12993.	1.8	54
697	Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System. Neurology Research International, 2012, 2012, 1-13.	0.5	64
698	Value of NMO-IgG determination at the time of presentation as CIS. Neurology, 2012, 78, 1608-1611.	1.5	16
699	Interferon-Î²1b Increases Th2 Response in Neuromyelitis Optica. International Journal of Molecular Sciences, 2012, 13, 12213-12223.	1.8	5
700	Update on neuromyelitis optica: natural history and management. Eye and Brain, 2012, 4, 27.	3.8	5
701	Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Multiple Sclerosis Journal, 2012, 18, 108-112.	1.4	114
702	Notable Increased Cerebrospinal Fluid Levels of Soluble Interleukin-6 Receptors in Neuromyelitis Optica. NeuroImmunoModulation, 2012, 19, 304-308.	0.9	39
703	Bloodâ€"Brain Barrier Disruption is More Severe in Neuromyelitis Optica than in Multiple Sclerosis and Correlates with Clinical Disability. Journal of International Medical Research, 2012, 40, 1483-1491.	0.4	43
704	Acute Transverse Myelitis: Demyelinating, Inflammatory, and Infectious Myelopathies. Seminars in Neurology, 2012, 32, 097-113.	0.5	91
705	Advanced magnetic resonance imaging of neuromyelitis optica: a multiparametric approach. Multiple Sclerosis Journal, 2012, 18, 817-824.	1.4	58
706	Pediatric Optic Neuritis. International Ophthalmology Clinics, 2012, 52, 29-49.	0.3	26
707	Comparison of Visual Acuity and Automated Perimetry Findings in Patients With Neuromyelitis Optica or Multiple Sclerosis After Single or Multiple Attacks of Optic Neuritis. Journal of Neuro-Ophthalmology, 2012, 32, 102-106.	0.4	56
708	Neuromyelitis optica. Current Opinion in Neurology, 2012, 25, 215-220.	1.8	27
709	MS and NMO. Journal of Neuro-Ophthalmology, 2012, 32, 99-101.	0.4	3
710	Anti-aquaporin-4 Antibody-positive Definite Neuromyelitis Optica in a Patient With Thymectomy for Myasthenia Gravis. Neurologist, 2012, 18, 76-79.	0.4	15
711	Neuromyelitis Optica. Journal of Neuro-Ophthalmology, 2012, 32, 154-166.	0.4	55
712	Identifying autoantigens in demyelinating diseases. Current Opinion in Neurology, 2012, 25, 231-238.	1.8	30
715	Aquaporin 4 Antibodies in the Cerebrospinal Fluid Are Helpful in Diagnosing Chinese Patients with Neuromyelitis Optica. NeuroImmunoModulation, 2012, 19, 96-102.	0.9	28

#	Article	IF	Citations
716	B-cell-directed therapy: which B cells should be targeted and how?. Immunotherapy, 2012, 4, 455-457.	1.0	6
717	Diseases Involving Myelin. , 2012, , 691-704.		1
718	The Role of Demyelination in Neuromyelitis Optica Damage: Diffusion-Tensor MR Imaging Study. Radiology, 2012, 263, 235-242.	3.6	57
719	Human Aquaporin 4₂₈₁₋₃₀₀Is the Immunodominant Linear Determinant in the Context of HLA-DRB1*03:01. Archives of Neurology, 2012, 69, 1125-31.	4.9	16
720	Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neuromyelitis Optica. Current Neurovascular Research, 2012, 9, 250-255.	0.4	29
722	Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Multiple Sclerosis Journal, 2012, 18, 1022-1026.	1.4	105
723	Complement-dependent Cytotoxicity in Neuromyelitis Optica Requires Aquaporin-4 Protein Assembly in Orthogonal Arrays. Journal of Biological Chemistry, 2012, 287, 13829-13839.	1.6	124
724	Illuminating neuromyelitis optica pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1001-1002.	3.3	23
725	Pediatric idiopathic transverse myelitis presenting as an anterior cord syndrome: A case report. Journal of Pediatric Rehabilitation Medicine, 2012, 5, 1-6.	0.3	2
726	B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms. Biologics: Targets and Therapy, 2012, 6, 117.	3.0	17
727	Treatment of Optic Neuritis by Plasma Exchange (Add-On) in Neuromyelitis Optica. JAMA Ophthalmology, 2012, 130, 858.	2.6	140
728	The Diagnostic and Prognostic Value of Neurofilament Heavy Chain Levels in Immune-Mediated Optic Neuropathies. Multiple Sclerosis International, 2012, 2012, 1-5.	0.4	16
729	Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder. Multiple Sclerosis International, 2012, 2012, 1-10.	0.4	70
730	Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?. Multiple Sclerosis International, 2012, 2012, 1-6.	0.4	9
731	A Primer of Neuroimmunological Disease. , 2012, , .		5
732	Relationship Between NMO-Antibody and Antiâ€“MOG Antibody in Optic Neuritis. Journal of Neuro-Ophthalmology, 2012, 32, 107-110.	0.4	58
733	Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?. Multiple Sclerosis Journal, 2012, 18, 1480-1483.	1.4	149
734	Effects of Age and Sex on Aquaporin-4 Autoimmunity. Archives of Neurology, 2012, 69, 1039-43.	4.9	91

#	Article	IF	Citations
735	Anti-AQP4 antibody in idiopathic acute transverse myelitis with recurrent clinical course: frequency of positivity and influence in prognosis. Journal of Spinal Cord Medicine, 2012, 35, 251-255.	0.7	6
736	Biochemical Markers of Autoimmune Diseases of the Nervous System. Current Pharmaceutical Design, 2012, 18, 4556-4563.	0.9	13
737	Neuromyelitis Optica Immunoglobulin G in Chinese Patients Detected by Immunofluorescence Assay on a Monkey Brain Substrate. NeuroImmunoModulation, 2012, 19, 20-24.	0.9	5
738	Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. Modern Rheumatology, 2012, 22, 676-684.	0.9	14
740	A Rare Case of Mixed Connective Tissue Disease Complicated With Neuromyelitis Optica. Journal of Clinical Rheumatology, 2012, 18, 261-262.	0.5	4
741	Expression and localization of aquaporin 1, 2, 3, 4, and 5 in human nasal mucosa. American Journal of Rhinology and Allergy, 2012, 26, 167-171.	1.0	16
742	Acute Combined Central and Peripheral Demyelination Showing Anti-Aquaporin 4 Antibody Positivity. Internal Medicine, 2012, 51, 2443-2447.	0.3	25
743	New-Onset Type 1 Diabetes Mellitus and Anti-Aquaporin-4 Antibody Positive Optic Neuritis Associated with Type 1 Interferon Therapy for Chronic Hepatitis C. Internal Medicine, 2012, 51, 2625-2629.	0.3	14
744	Serum-Positive and -Negative AQP4 Antibody NMO in Chinese Patients. Canadian Journal of Neurological Sciences, 2012, 39, 232-235.	0.3	5
745	Autoimmune Encephalopathies and Epilepsies in Children and Teenagers. Canadian Journal of Neurological Sciences, 2012, 39, 134-144.	0.3	20
746	CD226 Gly307Ser Association With Neuromyelitis Optica in Southern Han Chinese. Canadian Journal of Neurological Sciences, 2012, 39, 488-490.	0.3	17
747	Cerebrospinal Fluid IL-21 Levels in Neuromyelitis Optica and Multiple Sclerosis. Canadian Journal of Neurological Sciences, 2012, 39, 813-820.	0.3	26
748	An early British case of neuromyelitis optica (1850). BMJ, The, 2012, 345, e6430-e6430.	3.0	14
749	Recurrent Brainstem Lesions Mimicking Infarctions in an Elderly Patient with Neuromyelitis Optica Spectrum Disorder. Internal Medicine, 2012, 51, 809-812.	0.3	8
750	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain, 2012, 135, 1834-1849.	3.7	361
751	Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica. Journal of Immunology, 2012, 189, 4602-4611.	0.4	33
752	Aquaporin 4: a player in cerebral edema and neuroinflammation. Journal of Neuroinflammation, 2012, 9, 279.	3.1	187
753	Disease-specific therapy of idiopathic inflammatory demyelinating disorders. Expert Review of Neurotherapeutics, 2012, 12, 1113-1124.	1.4	2

#	Article	IF	Citations
754	No MRI evidence of cortical lesions in neuromyelitis optica. Neurology, 2012, 79, 1671-1676.	1.5	107
755	Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Multiple Sclerosis Journal, 2012, 18, 1135-1143.	1.4	107
756	Comparison of clinical, immunological and neuroimaging features between anti-aquaporin-4 antibody-positive and antibody-negative SjÃ¶grenâ€™s syndrome patients with central nervous system manifestations. Multiple Sclerosis Journal, 2012, 18, 807-816.	1.4	33
757	Pathological study of subacute autoimmune encephalopathy with anti-AQP4 antibodies in a pregnant woman. Multiple Sclerosis Journal, 2012, 18, 683-687.	1.4	8
758	Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. Multiple Sclerosis Journal, 2012, 18, 1541-1551.	1.4	36
759	Detecting multiple sclerosis mimics early. Future Neurology, 2012, 7, 547-555.	0.9	3
760	IntÃ©rÃªt des anticorps anti-aquaporine-4 dans le diagnostic et le suivi de la neuromyÃ©lite optique. Revue Francophone Des Laboratoires, 2012, 2012, 32-34.	0.0	0
762	Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. Journal of Neurology, 2012, 259, 2743-2745.	1.8	28
763	Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmunity Reviews, 2012, 11, 863-872.	2.5	155
764	Atypical forms of optic neuritis. Revue Neurologique, 2012, 168, 697-701.	0.6	17
765	Mielitis transversa y neuritis Ã³ptica bilateral en una paciente con lupus eritematoso sistÃ©mico. ReumatologÃa ClÃnica, 2012, 8, 298-299.	0.2	5
766	The unfolding tale of an unusual brain stem syndrome. Practical Neurology, 2012, 12, 55-59.	0.5	0
767	Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain, 2012, 135, 1819-1833.	3.7	123
768	Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Multiple Sclerosis Journal, 2012, 18, 578-586.	1.4	65
769	The Spectrum of Neuromyelitis Optica (NMO) in Childhood. Journal of Child Neurology, 2012, 27, 1437-1447.	0.7	38
771	Recurrent acute rhombencephalomyelitis in an adult or neuromyelitis optica? Presentation of a case. NeurologÃa (English Edition), 2012, 27, 154-160.	0.2	1
772	Evidenceâ€Based Review of Therapeutic Plasma Exchange in Neurological Disorders. Seminars in Dialysis, 2012, 25, 132-139.	0.7	9
773	Serologic diagnosis of NMO. Neurology, 2012, 78, 665-671.	1.5	454

#	Article	IF	Citations
774	Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 115-123.	13.9	314
775	The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Multiple Sclerosis Journal, 2012, 18, 5-10.	1.4	192
777	Seroprevalence of NMO-IgG among patients with neuromyelitis optica and opticospinal multiple sclerosis. Clinical Neurology and Neurosurgery, 2012, 114, 17-20.	0.6	8
778	Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: Case report and review of the literature. Clinical Neurology and Neurosurgery, 2012, 114, 331-335.	0.6	61
779	Anti-aquaporin-4 antibody in Chinese patients with central nervous system inflammatory demyelinating disorders. Clinical Neurology and Neurosurgery, 2012, 114, 1131-1134.	0.6	10
780	Subacute encephalopathy associated with aquaporin-4 autoantibodies: A report of 2 adult cases. Clinical Neurology and Neurosurgery, 2012, 114, 1110-1113.	0.6	3
781	Comparison of grey matter atrophy between patients with neuromyelitis optica and multiple sclerosis: A voxel-based morphometry study. European Journal of Radiology, 2012, 81, e110-e114.	1.2	73
782	Iron deposition of the deep grey matter in patients with multiple sclerosis and neuromyelitis optica: A control quantitative study by 3D-enhanced susceptibility-weighted angiography (ESWAN). European Journal of Radiology, 2012, 81, e633-e639.	1.2	32
783	Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody. Neurology, 2012, 79, 1826-1828.	1.5	41
784	Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Annals of Neurology, 2012, 72, 385-394.	2.8	67
785	Spinal Cord Compression and Myelopathies. , 2012, , 235-257.		0
786	Cerebrospinal Fluid BAFF and APRIL Levels in Neuromyelitis Optica and Multiple Sclerosis Patients During Relapse. Journal of Clinical Immunology, 2012, 32, 1007-1011.	2.0	72
787	Antiâ€aquaporin 4 antibody binding character in clinical subtypes of neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2012, 3, 109-115.	0.5	2
789	The Brown Norway opticospinal model of demyelination: Does it mimic multiple sclerosis or neuromyelitis optica?. International Journal of Developmental Neuroscience, 2012, 30, 487-497.	0.7	12
790	Brain connexins in demyelinating diseases: Therapeutic potential of glial targets. Brain Research, 2012, 1487, 61-68.	1.1	28
791	The cervical spinal cord in neuromyelitis optica patients: A comparative study with multiple sclerosis using diffusion tensor imaging. European Journal of Radiology, 2012, 81, 2697-2701.	1.2	17
792	MR imaging findings of the corpus callosum region in the differentiation between multiple sclerosis and neuromyelitis optica. European Journal of Radiology, 2012, 81, 3491-3495.	1.2	13
793	A 72-year-old patient with neuromyelitis optica (NMO) spectrum disorder: A case report. European Geriatric Medicine, 2012, 3, 240-241.	1.2	0

#	Article	IF	Citations
794	Longitudinal change detection in diffusion MRI using multivariate statistical testing on tensors. NeuroImage, 2012, 60, 2206-2221.	2.1	11
795	Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. Neuroscience, 2012, 226, 510-516.	1.1	27
796	Transverse Myelitis and Bilateral Optic Neuritis in a Patient With Systemic Lupus Erythematosus. ReumatologÃa ClÃnica (English Edition), 2012, 8, 298-299.	0.2	1
797	Clinical and magnetic resonance imaging features of multiple sclerosis with autoreactive antibodies in Ishikawa Prefecture, Japan. Journal of Neuroimmunology, 2012, 250, 111-114.	1.1	3
798	Optic neuritis in an ethnically diverse population: Higher risk of atypical cases in patients of African or African-Caribbean heritage. Journal of the Neurological Sciences, 2012, 312, 21-25.	0.3	31
799	â€˜Noteomieliteâ€™ accompanied by acute amaurosis (1844).. Journal of the Neurological Sciences, 2012, 313, 182-184.	0.3	26
800	Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. Journal of the Neurological Sciences, 2012, 313, 48-53.	0.3	64
801	Interleukin 17 gene polymorphism is associated with anti-aquaporin 4 antibody-positive neuromyelitis optica in the Southern Han Chinese â€" A case control study. Journal of the Neurological Sciences, 2012, 314, 26-28.	0.3	41
802	Serum GFAP levels in optic neuropathies. Journal of the Neurological Sciences, 2012, 317, 117-122.	0.3	26
803	Neuromyelitis optica in a patient with pemphigus foliaceus. Journal of the Neurological Sciences, 2012, 319, 152-155.	0.3	11
804	Testing for antibodies to human aquaporin-4 by ELISA: Sensitivity, specificity, and direct comparison with immunohistochemistry. Journal of the Neurological Sciences, 2012, 320, 32-37.	0.3	60
805	Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients. Journal of the Neurological Sciences, 2012, 320, 118-120.	0.3	23
806	Spectrum disorder of neuromyelitis optica in a patient presenting with intractable vomiting and hiccups, transverse myelitis and acute encephalopathy. Journal of Clinical Neuroscience, 2012, 19, 1576-1578.	0.8	12
807	Genetic and environmental backgrounds responsible for the changes in the phenotype of MS in Japanese subjects. Multiple Sclerosis and Related Disorders, 2012, 1, 188-195.	0.9	15
808	Review of animal models of neuromyelitis optica. Multiple Sclerosis and Related Disorders, 2012, 1, 174-179.	0.9	16
809	Proteomic analysis of the cerebrospinal fluid in multiple sclerosis and neuromyelitis optica patients. Molecular Medicine Reports, 2012, 6, 1081-1086.	1.1	17
810	Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics. Annual Review of Medicine, 2012, 63, 389-404.	5.0	64
811	Sera from neuromyelitis optica patients disrupt the bloodâ€“brain barrier. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 288-297.	0.9	87

#	Article	IF	Citations
812	Spinal Cord Inflammatory and Demyelinating Diseases. , 2012, , 173-176.		1
814	Handbook of Multiple Sclerosis. , 2012, , .		9
815	Implications of water channel proteins in selected neurological disorders: Epilepsies, muscular dystrophies, amyotrophic lateral sclerosis, neuromyelitis optica, Parkinsonâ€™s disease, and spongiform encephalopathies. Molecular Aspects of Medicine, 2012, 33, 590-604.	2.7	6
816	Integrative Continuum: Accelerating Therapeutic Advances in Rare Autoimmune Diseases. Annual Review of Pharmacology and Toxicology, 2012, 52, 523-547.	4.2	8
817	Diseases of the Brain, Head & Neck, Spine 2012â€“2015. , 2012, , .		8
818	Early presentation of neuromyelitis optica. Indian Pediatrics, 2012, 49, 924-925.	0.2	8
819	Evaluation of a Multiparametric Immunofluorescence Assay for Standardization of Neuromyelitis Optica Serology. PLoS ONE, 2012, 7, e38896.	1.1	19
820	Aquaporin-4 Antibodies Are Not Related to HTLV-1 Associated Myelopathy. PLoS ONE, 2012, 7, e39372.	1.1	13
821	Multiple Sclerosis and Demyelinating Conditions of the Central Nervous System. , 2012, , 2347-2355.		4
822	Current options for the treatment of optic neuritis. Clinical Ophthalmology, 2012, 6, 1211.	0.9	28
823	Multiple sclerosis. Journal of Clinical Investigation, 2012, 122, 1180-1188.	3.9	449
824	Visual evoked potentials in early diagnosis of demyelinating diseases â€“ a case report of Devicâ€™s disease. Medical Science Monitor, 2012, 18, CS82-CS84.	0.5	3
825	Acquired Demyelinating Disorders of the CNS in Children. , 2012, , .		0
827	Treatment of neuromyelitis optica: an evidence based review. Arquivos De Neuro-Psiquiatria, 2012, 70, 59-66.	0.3	43
828	The expanded spectrum of neuromyelitis optica: evidences for a new definition. Arquivos De Neuro-Psiquiatria, 2012, 70, 807-813.	0.3	29
829	Multiple Sclerosis and Celiac Disease. , 0, , .		0
830	Neuromyelitis optica: multiple sclerosis variant or independent disease?. International Journal of Ophthalmic Practice, 2012, 3, 114-121.	0.0	0
831	Clinical Usefulness of Cell-based Indirect Immunofluorescence Assay for the Detection of Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder. Annals of Laboratory Medicine, 2012, 32, 331-338.	1.2	33

#	Article	IF	Citations
832	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of Neuroinflammation, 2012, 9, 14.	3.1	593
833	Pathology of Demyelinating Diseases. Annual Review of Pathology: Mechanisms of Disease, 2012, 7, 185-217.	9.6	303
834	The differential diagnosis of longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2012, 18, 271-285.	1.4	126
835	Neuroimmunological Diagnostic Tests. , 2012, , 175-188.		0
836	Detection of Antiâ€Aquaporinâ€4 Antibodies in Neuromyelitis Optica: Comparison of Tissueâ€Based and Cellâ€Based Indirect Immunofluorescence Assays and <scp>ELISA</scp>. Journal of Clinical Laboratory Analysis, 2012, 26, 184-189.	0.9	16
837	Neuromyelitis Optica Immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporinâ€4 expression and water permeability of the astrocyte plasma membrane. Journal of Neuroscience Research, 2012, 90, 1240-1248.	1.3	24
838	Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions. Glia, 2012, 60, 1468-1480.	2.5	131
839	Maintenance plasma exchange therapy for steroidâ€refractory neuromyelitis optica. Journal of Clinical Apheresis, 2012, 27, 183-192.	0.7	46
840	Myasthenia gravis and neuromyelitis optica spectrum disorder. Neurology, 2012, 78, 1601-1607.	1.5	177
841	Proteomic pattern analysis discriminates among multiple sclerosisâ€“related disorders. Annals of Neurology, 2012, 71, 614-623.	2.8	23
842	Neutrophil protease inhibition reduces neuromyelitis opticaâ€“immunoglobulin Gâ€“induced damage in mouse brain. Annals of Neurology, 2012, 71, 323-333.	2.8	153
843	Oligodendrocytes and the early multiple sclerosis lesion. Annals of Neurology, 2012, 72, 18-31.	2.8	113
844	Clinical spectrum of CNS aquaporin-4 autoimmunity. Neurology, 2012, 78, 1179-1185.	1.5	83
845	Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?. Neuroradiology, 2012, 54, 279-285.	1.1	41
846	Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathologica, 2012, 123, 861-872.	3.9	97
847	A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. Journal of Neurology, 2012, 259, 801-816.	1.8	49
848	The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. Journal of Neurology, 2012, 259, 1354-1357.	1.8	35
849	Antiâ€aquaporinâ€4 antibodies in the context of assorted immuneâ€mediated diseases. European Journal of Neurology, 2012, 19, 248-252.	1.7	18

#	Article	IF	Citations
850	An astrocyteâ€specific enhancer of the aquaporinâ€4 gene functions through a consensus sequence of POU transcription factors in concert with multiple upstream elements. Journal of Neurochemistry, 2012, 120, 899-912.	2.1	11
851	Transverse myelitis. Autoimmunity Reviews, 2012, 11, 231-248.	2.5	90
852	Aquaporin 4 and neuromyelitis optica. Lancet Neurology, The, 2012, 11, 535-544.	4.9	460
853	Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO. Acta Neurologica Scandinavica, 2012, 126, 287-291.	1.0	14
854	Neural antigenâ€specific autoimmune disorders. Immunological Reviews, 2012, 248, 104-121.	2.8	72
855	Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clinical and Experimental Neuroimmunology, 2012, 3, 58-73.	0.5	79
856	Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2012, 242, 26-32.	1.1	18
857	Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse. Journal of Neuroimmunology, 2012, 243, 52-55.	1.1	13
858	Aquaporin-4 autoantibodies cause asymptomatic aquaporin-4 loss and activate astrocytes in mouse. Journal of Neuroimmunology, 2012, 245, 32-38.	1.1	25
859	Autoantibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein in paediatric CNS demyelination: Recent developments and future directions. Multiple Sclerosis and Related Disorders, 2012, 1, 116-122.	0.9	3
861	The prevalence of neuromyelitis optica in South East Wales. European Journal of Neurology, 2012, 19, 655-659.	1.7	86
862	Conventional brain MRI in neuromyelitis optica. European Journal of Neurology, 2012, 19, 812-819.	1.7	46
863	Phagocytized corpora amylacea as a histological hallmark of astrocytic injury in neuromyelitis optica. Neuropathology, 2012, 32, 587-594.	0.7	14
864	The history of neuromyelitis optica. Journal of Neuroinflammation, 2013, 10, 8.	3.1	188
865	Increased Plasma Interleukin-32 Expression in Patients with Neuromyelitis Optica. Journal of Clinical Immunology, 2013, 33, 666-670.	2.0	22
866	The Ex Vivo Production of IL-6 and IL-21 by CD4+ T Cells is Directly Associated with Neurological Disability in Neuromyelitis Optica Patients. Journal of Clinical Immunology, 2013, 33, 179-189.	2.0	64
867	Progressive Multiple Sclerosis. , 2013, , .		0
868	Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions. BMC Neurology, 2013, 13, 72.	0.8	36

#	Article	IF	Citations
869	Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathologica Communications, 2013, 1, 5.	2.4	52
870	Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica. Journal of Neurology, 2013, 260, 663-664.	1.8	28
871	Variants in the promoter region of CYP7A1 are associated with neuromyelitis optica but not with multiple sclerosis in the Han Chinese population. Neuroscience Bulletin, 2013, 29, 525-530.	1.5	16
872	A case with neuromyelitis optica mimicking Susacâ€™s syndrome. Neurological Sciences, 2013, 34, 1255-1257.	0.9	1
873	The retina as a window to the brainâ€”from eye research to CNS disorders. Nature Reviews Neurology, 2013, 9, 44-53.	4.9	881
874	Aquaporin 4 Expression and Tissue Susceptibility to Neuromyelitis Optica. JAMA Neurology, 2013, 70, 1118.	4.5	70
876	Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: A potential link. Medical Hypotheses, 2013, 81, 1090-1095.	0.8	16
877	Enhanced accumulation of Kir4.1 protein, but not mRNA, in a murine model of cuprizone-induced demyelination. Brain Research, 2013, 1537, 340-349.	1.1	8
878	Aquaporinâ€4 Antibodies (<scp>NMO</scp>â€<scp>IgG</scp>) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature. Brain Pathology, 2013, 23, 661-683.	2.1	214
879	Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder. Journal of Neurology, 2013, 260, 3150-3157.	1.8	17
880	Life-threatening hypokalemia following rapid correction of respiratory acidosis. Heart and Lung: Journal of Acute and Critical Care, 2013, 42, 287-289.	0.8	2
881	Fulminant Demyelinating Diseases. Neurohospitalist, The, 2013, 3, 81-91.	0.3	51
882	Clinical Spectrum and Treatment of Neuromyelitis Optica Spectrum Disorders: Evolution and Current Status. Brain Pathology, 2013, 23, 647-660.	2.1	36
883	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2013, 19, 742-748.	1.4	35
884	The effect of intravenous immunoglobulin on neuromyelitis optica. NeurologÃa (English Edition), 2013, 28, 65-72.	0.2	15
885	Development, maintenance and disruption of the blood-brain barrier. Nature Medicine, 2013, 19, 1584-1596.	15.2	1,750
886	Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurology, The, 2013, 12, 554-562.	4.9	335
887	Glial influence on the blood brain barrier. Glia, 2013, 61, 1939-1958.	2.5	424

#	Article	IF	Citations
888	Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathologica, 2013, 126, 699-709.	3.9	95
889	Idiopathic acute transverse myelitis: outcome and conversion to multiple sclerosis in a large series. BMC Neurology, 2013, 13, 135.	0.8	38
890	T cell-activation in neuromyelitis optica lesions plays a role in their formation. Acta Neuropathologica Communications, 2013, 1, 85.	2.4	73
891	Optic neuritis in neuromyelitis optica. Progress in Retinal and Eye Research, 2013, 36, 159-171.	7.3	76
892	Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis. Clinica Chimica Acta, 2013, 417, 26-30.	0.5	31
893	Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Modern Rheumatology, 2013, 23, 827-831.	0.9	90
894	Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica. Multiple Sclerosis Journal, 2013, 19, 173-178.	1.4	33
895	Inflammatory Optic Neuritis: From Multiple Sclerosis to Neuromyelitis Optica. Neuro-Ophthalmology, 2013, 37, 141-145.	0.4	20
896	An approach to optic neuritis: the initial presentation. Expert Review of Ophthalmology, 2013, 8, 539-551.	0.3	4
897	Humoral-Targeted Immunotherapies in Multiple Sclerosis. Neurotherapeutics, 2013, 10, 34-43.	2.1	19
898	Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica. Clinica Chimica Acta, 2013, 415, 350-360.	0.5	8
899	Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatology International, 2013, 33, 259-263.	1.5	36
900	Clinical features of Chinese patients with multiple sclerosis with aquaporin-4 antibodies in cerebrospinal fluid but not serum. Journal of Clinical Neuroscience, 2013, 20, 233-237.	0.8	4
901	Neuromyelitis Optica. Neurologic Clinics, 2013, 31, 139-152.	0.8	29
902	Evaluation of new immunological targets in neuromyelitis optica. Journal of Peptide Science, 2013, 19, 25-32.	0.8	5
903	The expanding range of autoimmune disorders of the nervous system. Lancet Neurology, The, 2013, 12, 22-24.	4.9	14
904	Paraneoplastic Myelopathy. Neurologic Clinics, 2013, 31, 307-318.	0.8	43
905	Immunological follow-up of patients with neuromyelitis optica: Is there a good biomarker?. Lupus, 2013, 22, 229-232.	0.8	8

#	Article	IF	Citations
906	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 922-930.	0.9	149
907	Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Diseases with Compromise to the Blood Brain Barrier. Chemical Reviews, 2013, 113, 1877-1903.	23.0	187
908	On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. Journal of Neurology, 2013, 260, 100-104.	1.8	23
909	Preliminary study on the association of AQP4 promoter polymorphism with anti-aquaporin-4 antibody positivity in Southern Han Chinese patients with idiopathic demyelinating disorders of central nervous system. Journal of Neuroimmunology, 2013, 255, 75-80.	1.1	14
910	The astrocyte in multiple sclerosis revisited. Glia, 2013, 61, 453-465.	2.5	213
911	Protective role of brain water channel AQP4 in murine cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1035-1040.	3.3	52
913	Month of birth in multiple sclerosis with and without longitudinally extensive spinal cord lesions: A study of a Japanese national survey. Journal of the Neurological Sciences, 2013, 330, 67-70.	0.3	5
914	Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese. Journal of Neuroimmunology, 2013, 262, 100-105.	1.1	20
915	Intractable Nausea and Vomiting From Autoantibodies Against a Brain Water Channel. Clinical Gastroenterology and Hepatology, 2013, 11, 240-245.	2.4	49
916	Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis optica. Neurochemistry International, 2013, 63, 805-808.	1.9	15
917	Hunting for autoantibodies in multiple sclerosis. Neurology, 2013, 81, 944-945.	1.5	3
918	Neuromyelitis Optica IgG Causes Placental Inflammation and Fetal Death. Journal of Immunology, 2013, 191, 2999-3005.	0.4	90
919	Estudio del efecto del tratamiento con inmunoglobulinas por vÃa intravenosa en la neuromielitis Ã³ptica. NeurologÃa, 2013, 28, 65-72.	0.3	58
920	Clinical prospective study of visual function in patients with acute optic neuritis. Journal of the Formosan Medical Association, 2013, 112, 87-92.	0.8	3
921	Myelin oligodendrocyte glycoprotein induces aquaporin-4 autoantibodies in mouse experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2013, 261, 1-6.	1.1	5
922	Seropositive Neuromyelitis Optica: A Pediatric Case Report and 6-Year Follow-Up. Pediatric Neurology, 2013, 49, 198-202.	1.0	2
923	A recurrent longitudinally extensive transverse myelitis with Aquaporin-4(AQP4) antibody after herpes zoster. Journal of the Neurological Sciences, 2013, 334, 69-71.	0.3	24
924	Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. Journal of Autoimmunity, 2013, 40, 21-27.	3.0	67

#	Article	IF	Citations
925	Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid. Journal of Neuroimmunology, 2013, 254, 76-82.	1.1	38
926	NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement. Journal of the Neurological Sciences, 2013, 331, 136-144.	0.3	39
927	Neuromielitis Ã³ptica: actualizaciÃ³n clÃnica y terapÃ©utica. Neurologia Argentina, 2013, 5, 259-269.	0.1	3
930	Neuromyelitis Optica: Potential Roles for Intravenous Immunoglobulin. Journal of Clinical Immunology, 2013, 33, 33-37.	2.0	35
931	Aquaporin water channels in the nervous system. Nature Reviews Neuroscience, 2013, 14, 265-277.	4.9	600
932	<i>Helicobacter pylori</i> Infection in Neuromyelitis Optica and Multiple Sclerosis. NeuroImmunoModulation, 2013, 20, 107-112.	0.9	48
933	Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. Journal of Neuroimmunology, 2013, 254, 178-182.	1.1	47
934	Transverse Myelitis. Neurologic Clinics, 2013, 31, 79-138.	0.8	172
935	Can â€œdisseminationâ€•include the PNS in adults with acute disseminated encephalomyelitis?. Neurology, 2013, 80, 876-877.	1.5	2
936	Postinfectious neurologic syndromes. Neurology, 2013, 80, 882-889.	1.5	57
937	Evaluation of Inner Retinal Layers in Patients with Multiple Sclerosis or Neuromyelitis Optica Using Optical Coherence Tomography. Ophthalmology, 2013, 120, 387-394.	2.5	111
938	Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathologica, 2013, 125, 815-827.	3.9	199
939	Clinical Relevance of Serum Aquaporin-4 Antibody Levels in Neuromyelitis Optica. Neurochemical Research, 2013, 38, 997-1001.	1.6	11
940	Discovery of Peptoid Ligands for Anti-Aquaporin 4 Antibodies. Chemistry and Biology, 2013, 20, 351-359.	6.2	43
941	Microcystic Inner Nuclear Layer Abnormalities and Neuromyelitis Optica. JAMA Neurology, 2013, 70, 629.	4.5	107
942	Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4. Journal of Neuroimmunology, 2013, 260, 107-116.	1.1	29
943	The Immune Pathogenesis of Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2013, 8, 857-866.	2.1	67
944	The Pathogenesis of Glaucoma in the Interplay with the Immune System. , 2013, 54, 2393.		86

#	Article	IF	Citations
945	Diagnosing Neuromyelitis Optica. Neuroimaging Clinics of North America, 2013, 23, 279-291.	0.5	15
946	Modeling the heterogeneity of multiple sclerosis in animals. Trends in Immunology, 2013, 34, 410-422.	2.9	161
947	IL-22 secreting CD4 + T cells in the patients with neuromyelitis optica and multiple sclerosis. Journal of Neuroimmunology, 2013, 261, 87-91.	1.1	65
948	The spectrum of MOG autoantibody-associated demyelinating diseases. Nature Reviews Neurology, 2013, 9, 455-461.	4.9	330
949	Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. Journal of the Neurological Sciences, 2013, 328, 77-82.	0.3	22
950	Brain-Reactive Antibodies and Disease. Annual Review of Immunology, 2013, 31, 345-385.	9.5	115
951	The role of aquaporin-4 antibodies in Chinese patients with neuromyelitis optica. Journal of Clinical Neuroscience, 2013, 20, 94-98.	0.8	30
952	Longitudinal extensive transverse myelitis and optic neuritis: the elements for the diagnosis of neuromyelitis optica. Neurological Sciences, 2013, 34, 579-580.	0.9	3
953	Distinction and Temporal Stability of Conformational Epitopes on Myelin Oligodendrocyte Glycoprotein Recognized by Patients with Different Inflammatory Central Nervous System Diseases. Journal of Immunology, 2013, 191, 3594-3604.	0.4	126
954	Pediatric multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 112, 1263-1274.	1.0	4
955	Antibodies target microvessels in neuromyelitis optica and multiple sclerosis patients. Neurological Research, 2013, 35, 922-929.	0.6	7
956	In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology, 2013, 80, 1406-1414.	1.5	138
957	Aquaporin-4 antibodyâ€“negative neuromyelitis optica. Neurology, 2013, 80, 2194-2200.	1.5	157
958	Astrocytes differentially respond to inflammatory autoimmune insults and imbalances of neural activity. Acta Neuropathologica Communications, 2013, 1, 70.	2.4	37
960	Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology, 2013, 80, 1330-1337.	1.5	189
961	AQP4 antibody serostatus. Neurology, 2013, 81, 1186-1188.	1.5	12
962	Meningoencephalitis as an initial manifestation of neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2013, 19, 639-643.	1.4	15
963	Aquaporin-4 antibodyâ€“positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology, 2013, 80, 2210-2216.	1.5	98

#	Article	IF	Citations
964	Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience. Annals of Indian Academy of Neurology, 2013, 16, 371.	0.2	3
965	Recurrent longitudinally extensive transversal myelitis in a patient with SjÃ¶grenâ€™s syndrome. Vojnosanitetski Pregled, 2013, 70, 1056-1058.	0.1	2
966	Immunotherapy of Neuromyelitis Optica. Autoimmune Diseases, 2013, 2013, 1-7.	2.7	8
967	Paraneoplastic and Autoimmune Encephalopathies. Seminars in Neurology, 2013, 33, 357-364.	0.5	7
968	Intractable nausea and vomiting as presenting manifestation of neuromyelitis optica. Annals of Indian Academy of Neurology, 2013, 16, 400.	0.2	3
969	Role of Regulatory T Cells in Pathogenesis and Biological Therapy of Multiple Sclerosis. Mediators of Inflammation, 2013, 2013, 1-11.	1.4	71
970	Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2013, 19, 1216-1218.	1.4	49
971	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology, 2013, 81, 1197-1204.	1.5	206
972	Pathology of Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 901-921.	0.4	158
973	Spectral-Domain Optical Coherence Tomography of Retinal Nerve Fiber Layer Thickness in NMO Patients. Journal of Neuro-Ophthalmology, 2013, 33, 213-219.	0.4	45
974	Distinguishing Optic Neuritis in Neuromyelitis Optica Spectrum Disease From Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2013, 33, 123-127.	0.4	96
975	Inflammatory, vascular, and infectious myelopathies in children. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 112, 999-1017.	1.0	11
976	Intractable Vomiting as an Initial Presentation of Lupus-Related Neuromyelitis Optica. Journal of Clinical Rheumatology, 2013, 19, 154-155.	0.5	5
977	Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-Aquaporin 4 antibodies. Multiple Sclerosis Journal, 2013, 19, 299-307.	1.4	41
978	Role of Autoantibodies in Acquired Inflammatory Demyelinating Diseases of the Central Nervous System in Children. Neuropediatrics, 2013, 44, 297-301.	0.3	22
979	Longitudinally Extensive Transverse Myelitis With and Without Aquaporin 4 Antibodies. JAMA Neurology, 2013, 70, 1375.	4.5	100
980	Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Multiple Sclerosis Journal, 2013, 19, 308-315.	1.4	35
981	Acute Disseminated Encephalomyelitis, Transverse Myelitis, and Neuromyelitis Optica. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 944-967.	0.4	27

#	Article	IF	Citations
982	Anti-Aquaporin-4 Antibody Positivity in Neuromyelitis Optica Is Associated with Lesion Activity. European Neurology, 2013, 70, 113-116.	0.6	1
983	The Retinal Nerve Fiber Layer of Patients With Neuromyelitis Optica and Chronic Relapsing Optic Neuritis is More Severely Damaged than Patients With Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2013, 33, 220-224.	0.4	33
984	Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 289-298.	1.4	67
985	Multiple Sclerosis in Malaysia: Demographics, Clinical Features, and Neuroimaging Characteristics. Multiple Sclerosis International, 2013, 2013, 1-10.	0.4	11
986	Role of interleukinâ€6 in the pathogenesis of neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2013, 4, 167-172.	0.5	8
987	Cognitive impairment and cortical degeneration in neuromyelitis optica. Annals of Neurology, 2013, 73, 65-76.	2.8	137
988	Immunology of neuromyelitis optica: a T cellâ€“B cell collaboration. Annals of the New York Academy of Sciences, 2013, 1283, 57-66.	1.8	64
989	Reactive astrocytes express the potassium channel <scp>K</scp>ir4.1 in active multiple sclerosis lesions. Clinical and Experimental Neuroimmunology, 2013, 4, 19-28.	0.5	5
990	Connexin pathology in acute multiple sclerosis, <scp>B</scp>alÃ³'s disease and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2013, 4, 36-44.	0.5	6
991	Cortical degeneration in neuromyelitis optica: Potential pathogenesis of cognitive impairment. Clinical and Experimental Neuroimmunology, 2013, 4, 162-162.	0.5	1
992	Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?. Expert Review of Clinical Immunology, 2013, 9, 979-986.	1.3	4
993	Paraneoplastic and Other Autoimmune Disorders of the Central Nervous System. Neurohospitalist, The, 2013, 3, 53-64.	0.3	50
994	A Novel Monoclonal Antibody Against the C-Terminal Region of Aquaporin-4. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2013, 32, 270-276.	0.8	9
995	Glia is no longer glue: A new dawn of a decade of astrocytes. Clinical and Experimental Neuroimmunology, 2013, 4, 153-154.	0.5	0
996	Efficacy of methylprednisolone pulse therapy for acute relapse in <scp>J</scp>apanese patients with multiple sclerosis and neuromyelitis optica: A multicenter retrospective analysis â€“ 1. Whole group analysis. Clinical and Experimental Neuroimmunology, 2013, 4, 305-317.	0.5	9
997	Extragastric Diseases and <scp>H</scp>elicobacter pylori. Helicobacter, 2013, 18, 44-51.	1.6	72
998	Genetic and environmental factors underlying the rapid changes in epidemiological and clinical features of multiple sclerosis and neuromyelitis optica in <scp>J</scp>apanese. Clinical and Experimental Neuroimmunology, 2013, 4, 261-273.	0.5	8
999	Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations?. Multiple Sclerosis Journal, 2013, 19, 1493-1498.	1.4	24

#	Article	IF	Citations
1000	Neuroradiological evaluation of demyelinating disease. Therapeutic Advances in Neurological Disorders, 2013, 6, 249-268.	1.5	72
1001	Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 29-34.	0.9	118
1002	SjÃ¶grenâ€™s Syndrome. , 2013, , 821-836.		0
1003	11. Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO). The Journal of the Japanese Society of Internal Medicine, 2013, 102, 133b-134a.	0.0	0
1004	Neuromyelitis Optica: An Often Forgotten Cause of Intractable Nausea and Vomiting. Case Reports in Gastroenterology, 2013, 7, 281-286.	0.3	7
1005	Subclinical Optic Neuritis in Neuromyelitis Optica. Journal of Neuro-Ophthalmology, 2013, 33, 205-207.	0.4	17
1006	New Insights, Promises and Challenges. Brain Pathology, 2013, 23, 645-646.	2.1	0
1007	Radiolabeled anti-aquaporin-4 protein antibody imaging. Nuclear Medicine Communications, 2013, 34, 413-416.	0.5	1
1008	Anti-Aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with BalÃ³'s Concentric Lesions. Internal Medicine, 2013, 52, 1517-1521.	0.3	22
1010	Tonic spasms are a common clinical manifestation in patients with neuromyelitis optica. Arquivos De Neuro-Psiquiatria, 2013, 71, 280-283.	0.3	13
1011	The Incidence and Prevalence of Neuromyelitis Optica. International Journal of MS Care, 2013, 15, 113-118.	0.4	47
1012	Cerebrospinal fluid analysis in the context of CNS demyelinating diseases. Arquivos De Neuro-Psiquiatria, 2013, 71, 685-688.	0.3	10
1013	Cognitive performance of neuromyelitis optica patients: comparison with multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2013, 71, 357-361.	0.3	36
1014	Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis. Clinical Ophthalmology, 2013, 7, 1145.	0.9	33
1015	Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis. PLoS ONE, 2013, 8, e61835.	1.1	184
1016	The Major Brain Endocannabinoid 2-AG Controls Neuropathic Pain and Mechanical Hyperalgesia in Patients with Neuromyelitis Optica. PLoS ONE, 2013, 8, e71500.	1.1	39
1017	Anti-Aquaporin-1 Autoantibodies in Patients with Neuromyelitis Optica Spectrum Disorders. PLoS ONE, 2013, 8, e74773.	1.1	49
1018	An Optimized Immunohistochemistry Technique Improves NMO-IgG Detection: Study Comparison with Cell-Based Assays. PLoS ONE, 2013, 8, e79083.	1.1	39

#	Article	IF	Citations
1019	Plasmablasts as Migratory IgG-Producing Cells in the Pathogenesis of Neuromyelitis Optica. PLoS ONE, 2013, 8, e83036.	1.1	62
1020	Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity. PLoS ONE, 2013, 8, e79185.	1.1	38
1021	Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS ONE, 2013, 8, e66151.	1.1	162
1022	Ordered Disorder of the Astrocytic Dystrophin-Associated Protein Complex in the Norm and Pathology. PLoS ONE, 2013, 8, e73476.	1.1	12
1023	Neuromyelitis Optica Mimicking Intramedullary Tumor. Journal of Korean Neurosurgical Society, 2013, 53, 316.	0.5	6
1024	Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders. Frontiers in Genetics, 2013, 4, 181.	1.1	14
1025	Evaluation of Clinical Interest of Anti-Aquaporin-4 Autoantibody Followup in Neuromyelitis Optica. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	22
1026	Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and		

#	Article	IF	Citations
1037	Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients. Genetics and Molecular Research, 2014, 13, 9292-9299.	0.3	14
1039	Differentiation of neuromyelitis optica from multiple sclerosis in a cohort from the mainland of China. Chinese Medical Journal, 2014, 127, 3213-3218.	0.9	8
1040	Life on hold: the experience of living with neuromyelitis optica. Disability and Rehabilitation, 2014, 36, 1100-1107.	0.9	28
1042	Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 419-430.	0.9	47
1043	NMDA receptor antibodies associated with distinct white matter syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e2.	3.1	85
1044	Variants of autophagy-related gene 5 are associated with neuromyelitis optica in the Southern Han Chinese population. Autoimmunity, 2014, 47, 563-566.	1.2	18
1045	Neuromyelitis Optica Spectrum Disorder in a Chinese Woman with Ocular Myasthenia Gravis: First Reported Case in the Chinese Population. Neuro-Ophthalmology, 2014, 38, 140-144.	0.4	2
1046	Aquaporin 4 IgG Serostatus and Outcome in Recurrent Longitudinally Extensive Transverse Myelitis. JAMA Neurology, 2014, 71, 48.	4.5	51
1047	The Neuroepithelium Disruption Could Generate Autoantibodies against AQP4 and Cause Neuromyelitis Optica and Hydrocephalus. International Scholarly Research Notices, 2014, 2014, 1-5.	0.9	3
1048	Influence of drugs on gap junctions in glioma cell lines and primary astrocytes in vitro. Frontiers in Physiology, 2014, 5, 186.	1.3	23
1049	Antineutrophil Cytoplasmic Antibodies in Patients with Idiopathic Inflammatory-Demyelinating Diseases. NeuroImmunoModulation, 2014, 21, 297-303.	0.9	9
1050	Devic disease. Neurology, 2014, 82, 1294-1295.	1.5	4
1051	Case of atypical neuromyelitis optica or other condition?. Clinical and Experimental Neuroimmunology, 2014, 5, 227-229.	0.5	0
1052	Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. Clinical and Experimental Immunology, 2014, 176, 135-148.	1.1	8
1053	Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e40.	3.1	192
1054	Antigen-specific tolerization approaches in multiple sclerosis. Expert Opinion on Investigational Drugs, 2014, 23, 9-20.	1.9	31
1055	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Annals of Neurology, 2014, 75, 447-453.	2.8	43
1056	Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures. Glia, 2014, 62, 692-708.	2.5	78

#	Article	IF	Citations
1057	Immunopathogenesis of Neuromyelitis Optica. Advances in Immunology, 2014, 121, 213-242.	1.1	55
1058	Increased Soluble <scp>C</scp>5bâ€9 in <scp>CSF</scp> of Neuromyelitis Optica. Scandinavian Journal of Immunology, 2014, 79, 127-130.	1.3	29
1059	Evaluation of aquaporinâ€4 antibody assays. Clinical and Experimental Neuroimmunology, 2014, 5, 290-303.	0.5	106
1060	Genetic studies of multiple sclerosis and neuromyelitis optica: Current status in <scp>E</scp>uropean, <scp>A</scp>frican <scp>A</scp>merican and <scp>A</scp>sian populations. Clinical and Experimental Neuroimmunology, 2014, 5, 61-68.	0.5	7
1061	What we know and do not know about fingolimod: Outline and interpretation of results from the <scp>J</scp>apanese fingolimod core and extension studies. Clinical and Experimental Neuroimmunology, 2014, 5, 10-18.	0.5	0
1062	Seroprevalence of Aquaporin-4â€“IgG in a Northern California Population Representative Cohort of Multiple Sclerosis. JAMA Neurology, 2014, 71, 1433.	4.5	73
1063	Targeting B Cells in Neurological Autoimmune Diseases. Milestones in Drug Therapy, 2014, , 219-246.	0.1	0
1064	Serum analysis by¹H Nuclear Magnetic Resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 558-565.	1.4	38
1065	An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab. BMC Neurology, 2014, 14, 139.	0.8	8
1066	Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. Journal of Neuroinflammation, 2014, 11, 129.	3.1	24
1067	Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients. BMC Neurology, 2014, 14, 218.	0.8	19
1068	Etiologic Spectrum and Prognosis of Longitudinally Extensive Transverse Myelopathies. European Neurology, 2014, 72, 86-94.	0.6	22
1069	Neuro-Ophthalmology Annual Review. Asia-Pacific Journal of Ophthalmology, 2014, 3, 104-125.	1.3	2
1070	The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project. Multiple Sclerosis Journal, 2014, 20, 374-381.	1.4	19
1071	Positive or Negative Involvement of Heat Shock Proteins in Multiple Sclerosis Pathogenesis. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1092-1106.	0.9	19
1072	Longitudinally extensive transverse myelitis. Current Opinion in Neurology, 2014, 27, 279-289.	1.8	56
1073	Inflammatory Demyelinating Diseases. , 2014, , 22-38.		0
1074	Clinical Manifestations and Spinal Cord Magnetic Resonance Imaging Findings in Chinese Neuromyelitis Optica Patients. European Neurology, 2014, 71, 35-41.	0.6	10

#	Article	IF	Citations
1075	Urea Transporters. Sub-Cellular Biochemistry, 2014, , .	1.0	11
1076	Validity of the diagnostic criteria for chronic cerebrospinal venous insufficiency and association with multiple sclerosis. Cmaj, 2014, 186, E418-E426.	0.9	12
1077	Combined Screening for Serum Anti-Nuclear and Anti-Aquaporin-4 Antibodies Improves Diagnostic Accuracy for Distinguishing Neuromyelitis Optica from Multiple Sclerosis. European Neurology, 2014, 72, 103-108.	0.6	20
1078	The Frequency of Anti-Aquaporin-4 Ig G Antibody in Neuromyelitis Optica and Its Spectrum Disorders at a Single Tertiary Referral Center in Malaysia. Multiple Sclerosis International, 2014, 2014, 1-10.	0.4	19
1079	Neurologic Complications Associated with SjÃ¶grenâ€™s Disease: Case Reports and Modern Pathogenic Dilemma. Case Reports in Neurological Medicine, 2014, 2014, 1-11.	0.3	17
1080	Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2014, 20, 1189-1197.	1.4	70
1081	Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Multiple Sclerosis Journal, 2014, 20, 1086-1094.	1.4	87
1082	Inflammatory Optic Neuropathies. CONTINUUM Lifelong Learning in Neurology, 2014, 20, 816-837.	0.4	14
1083	Acute Cervical Segmental Denervation in Neuromyelitis Optica Spectrum Disorder. Journal of Clinical Neuromuscular Disease, 2014, 16, 90-97.	0.3	7
1084	White matter astrocytes in health and disease. Neuroscience, 2014, 276, 161-173.	1.1	228
1085	NMO spectrum disorders comprise the major portion of CNS inflammatory diseases in Thai patients: A cross sectional study. Multiple Sclerosis and Related Disorders, 2014, 3, 61-66.	0.9	7
1086	No evidence for genetic association between glutamate transporter EAAT2 and Devic's neuromyelitis optica in caucasians and afro-caribbeans. Multiple Sclerosis and Related Disorders, 2014, 3, 89-93.	0.9	0
1087	Sera from patients with seropositive neuromyelitis optica spectral disorders caused the degeneration of rodent optic nerve. Experimental Eye Research, 2014, 119, 61-69.	1.2	16
1088	Neuromyelitis optica: Concept, immunology and treatment. Journal of Clinical Neuroscience, 2014, 21, 12-21.	0.8	48
1089	The complement and immunoglobulin levels in NMO patients. Neurological Sciences, 2014, 35, 215-220.	0.9	24
1090	Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. Journal of Neurology, 2014, 261, 17-26.	1.8	106
1091	Differential diagnoses to MS: experiences from an optic neuritis clinic. Journal of Neurology, 2014, 261, 98-105.	1.8	26
1092	Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathologica, 2014, 127, 523-538.	3.9	38

#	Article	IF	Citations
1093	Aquaporins: important but elusive drug targets. Nature Reviews Drug Discovery, 2014, 13, 259-277.	21.5	462
1094	Aquaporin and brain diseases. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 1554-1565.	1.1	170
1095	â€˜Spinal amaurosisâ€™ (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. Journal of Neurology, 2014, 261, 400-404.	1.8	8
1096	Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases. Expert Review of Neurotherapeutics, 2014, 14, 449-463.	1.4	22
1097	Acute inflammatory myelopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 613-667.	1.0	23
1098	MRI in transverse myelitis. Journal of Magnetic Resonance Imaging, 2014, 40, 1267-1279.	1.9	70
1099	Antibodies to AQP4. , 2014, , 605-611.		2
1100	To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 271-279.	1.4	41
1101	The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2014, 20, 695-704.	1.4	69
1102	Optic neuritis. Lancet Neurology, The, 2014, 13, 83-99.	4.9	463
1103	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of Neurology, 2014, 261, 1-16.	1.8	494
1104	The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica. Brain Pathology, 2014, 24, 83-97.	2.1	336
1105	Diagnosis and classification of autoimmune optic neuropathy. Autoimmunity Reviews, 2014, 13, 539-545.	2.5	65
1106	Encephalomyelopathies. , 2014, , 817-833.		1
1107	Childhood inflammatory brain diseases: pathogenesis, diagnosis and therapy. Rheumatology, 2014, 53, 1359-1368.	0.9	39
1108	Body fluid biomarkers in multiple sclerosis. Lancet Neurology, The, 2014, 13, 113-126.	4.9	204
1110	Protective environmental factors for neuromyelitis optica. Neurology, 2014, 83, 1923-1929.	1.5	23
1111	Identification of a Point Mutation Impairing the Binding between Aquaporin-4 and Neuromyelitis Optica Autoantibodies. Journal of Biological Chemistry, 2014, 289, 30578-30589.	1.6	26

#	Article	IF	Citations
1112	The diagnostic value of aquaporin-4 antibodies in central nervous system diseases. Neurochemical Journal, 2014, 8, 214-220.	0.2	2
1113	Towards more-accurate diagnosis in neuromyelitis optica. Nature Reviews Neurology, 2014, 10, 679-681.	4.9	7
1114	Antibodies to neural and non-neural autoantigens in Japanese patients with CNS demyelinating disorders. Journal of Neuroimmunology, 2014, 274, 155-160.	1.1	4
1115	Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology, 2014, 274, 185-191.	1.1	54
1116	â€œBright spotty lesionsâ€•on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 331-337.	1.4	104
1117	Active and progressive. Neurology, 2014, 83, 206-207.	1.5	7
1118	DesÃ³rdenes del espectro de la neuromielitis Ã³ptica: estudio retrospectivo multicÃ©ntrico. Neurologia Argentina, 2014, 6, 207-211.	0.1	0
1119	Gray matter involvement in multiple sclerosis and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2014, 5, 69-76.	0.5	3
1120	Cerebrospinal fluid aquaporinâ€4 antibody levels in neuromyelitis optica attacks. Annals of Neurology, 2014, 76, 305-309.	2.8	49
1121	Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 15-58.	1.0	231
1122	Monoclonal antibodies in treatment of multiple sclerosis. Clinical and Experimental Immunology, 2014, 175, 373-384.	1.1	56
1123	Acute disseminated encephalomyelitis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 123, 705-717.	1.0	35
1124	Dextran as a Generally Applicable Multivalent Scaffold for Improving Immunoglobulin-Binding Affinities of Peptide and Peptidomimetic Ligands. Bioconjugate Chemistry, 2014, 25, 1479-1491.	1.8	16
1125	Utility of Redundant Combinatorial Libraries in Distinguishing High and Low Quality Screening Hits. ACS Combinatorial Science, 2014, 16, 259-270.	3.8	61
1126	Clinical Features and Sera Antiâ€Aquaporin 4 Antibody Positivity in Patients with Demyelinating Disorders of the Central Nervous System from Tianjin, China. CNS Neuroscience and Therapeutics, 2014, 20, 32-39.	1.9	30
1127	Targeting of aquaporin 4 into lipid rafts and its biological significance. Brain Research, 2014, 1583, 237-244.	1.1	9
1128	Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1699-1703.	1.4	50
1129	Development of a cell-based assay for the detection of anti-aquaporin 1 antibodies in neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2014, 273, 103-110.	1.1	22

#	Article	IF	Citations
1130	KIR4.1: another misleading expectation in multiple sclerosis?. Lancet Neurology, The, 2014, 13, 753-755.	4.9	10
1131	Neuromyelitis Optica Spectrum Disorders. Current Neurology and Neuroscience Reports, 2014, 14, 483.	2.0	42
1132	Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nature Reviews Neurology, 2014, 10, 493-506.	4.9	220
1133	Pain in neuromyelitis opticaâ€"prevalence, pathogenesis and therapy. Nature Reviews Neurology, 2014, 10, 529-536.	4.9	77
1134	Cerebrospinal fluid analysis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 681-702.	1.0	31
1135	Acute disseminated encephalomyelitis and other inflammatory demyelinating variants. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 601-611.	1.0	13
1136	Targets of the humoral autoimmune response in multiple sclerosis. Autoimmunity Reviews, 2014, 13, 1126-1137.	2.5	74
1137	Fatal anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder in tuberculosis. BMC Infectious Diseases, 2014, 14, 470.	1.3	12
1138	Neuromyelitis optica spectrum disorders without and with autoimmune diseases. BMC Neurology, 2014, 14, 162.	0.8	39
1139	Cytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and Therapeutic Implications. Brain Pathology, 2014, 24, 67-73.	2.1	79
1140	Diagnosis of multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 317-342.	1.0	8
1141	CD19 as a molecular target in CNS autoimmunity. Acta Neuropathologica, 2014, 128, 177-190.	3.9	22
1142	Long-term benefits of induction therapy in NMO: a case report. Neurological Sciences, 2014, 35, 1831-1832.	0.9	2
1143	Neuromyelitis optica (Devicâ€™s syndrome). Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 581-599.	1.0	53
1144	Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions. Annals of Neurology, 2014, 75, 810-828.	2.8	41
1145	Diagnosis and classification of neuromyelitis optica (Devic's Syndrome). Autoimmunity Reviews, 2014, 13, 531-533.	2.5	40
1146	The impact of neuromyelitis optica on the recognition of emotional facial expressions: A preliminary report. Social Neuroscience, 2014, 9, 1-6.	0.7	8
1147	No association between identified multiple sclerosis non-MHC risk loci and neuromyelitis optica. Neuroscience Bulletin, 2014, 30, 1036-1044.	1.5	8

#	Article	IF	Citations
1148	Association between neuromyelitis optica and tuberculosis in a Chinese population. BMC Neurology, 2014, 14, 33.	0.8	22
1149	Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status. BMC Neurology, 2014, 14, 93.	0.8	15
1150	In vivo assessment of white matter damage in neuromyelitis optica: A diffusion tensor and diffusion kurtosis MR imaging study. Journal of the Neurological Sciences, 2014, 345, 172-175.	0.3	18
1151	Multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 269-290.	1.0	98
1152	Neuromyelitis optica and the evolving spectrum of autoimmune aquaporinâ€4 channelopathies. Clinical and Experimental Neuroimmunology, 2014, 5, 175-187.	0.5	18
1153	Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clinical and Experimental Immunology, 2014, 176, 149-164.	1.1	277
1154	Magnetic resonance imaging in neuromyelitis optica. Multiple Sclerosis Journal, 2014, 20, 1153-1164.	1.4	55
1155	Finding the missing link in neuromyelitis optica presenting with recurrent transverse myelitis flares. Journal of Clinical Neuroscience, 2014, 21, 861-862.	0.8	0
1156	A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity, 2014, 47, 154-161.	1.2	109
1157	Anti-neuronal autoantibodies: Current diagnostic challenges. Multiple Sclerosis and Related Disorders, 2014, 3, 303-320.	0.9	39
1159	Pathologic yawning in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2014, 3, 527-532.	0.9	9
1160	Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid. Journal of Neuroimmunology, 2014, 269, 62-67.	1.1	25
1161	The role of imaging in diagnosing neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2014, 3, 284-293.	0.9	11
1162	Lack of association between AQP4 polymorphisms and risk of inflammatory demyelinating disease in a Korean population. Gene, 2014, 536, 302-307.	1.0	9
1164	A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission. Molecular Immunology, 2014, 57, 200-209.	1.0	19
1165	Relapsing optic neuritis: a multicentre study of 62 patients. Multiple Sclerosis Journal, 2014, 20, 848-853.	1.4	41
1166	Clinical spectrum of neuromyelitis optica 2013. Neurology and Clinical Neuroscience, 2014, 2, 23-27.	0.2	2
1167	Where is lupus hidden?. Presse Medicale, 2014, 43, e143-e150.	0.8	2

#	Article	IF	Citations
1169	Conventional and Advanced Imaging in Neuromyelitis Optica. American Journal of Neuroradiology, 2014, 35, 1458-1466.	1.2	56
1172	Biomarkers for Multiple Sclerosis. Internal Medicine, 2014, 53, 361-365.	0.3	36
1173	Cognitive and Affective Assessments of Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) Patients Utilizing Computerized Touch Panel-type Screening Tests. Internal Medicine, 2014, 53, 2281-2290.	0.3	16
1174	Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO â€“ Devic's Disease): Clinic-Pathological Report and Review of the Literature. Clinical Medicine Insights: Case Reports, 2014, 7, CCRep.S15177.	0.3	23
1175	Experimental Models of Neuromyelitis Optica. Brain Pathology, 2014, 24, 74-82.	2.1	48
1176	Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes. Journal of Neuroinflammation, 2015, 12, 119.	3.1	85
1177	The role of granulocyteâ€macrophage colonyâ€stimulating factor in the pathogenesis of neuromyelitis optica: A white or black knight?. Clinical and Experimental Neuroimmunology, 2015, 6, 70-77.	0.5	0
1178	Early disruption of glial communication via connexin gap junction in multiple sclerosis, <scp>B</scp>alÃ³'s disease and neuromyelitis optica. Neuropathology, 2015, 35, 469-480.	0.7	44
1180	Prolonged effect of temporary rituximab therapy in neuromyelitis optica â€“ A case study. Postepy Psychiatrii I Neurologii, 2015, 24, 239-243.	0.2	1
1181	Treatment of neuromyelitis optica. Current Opinion in Ophthalmology, 2015, 26, 476-483.	1.3	15
1182	The Clinical Characteristics of Primary Sjogren's Syndrome With Neuromyelitis Optica Spectrum Disorder in China. Medicine (United States), 2015, 94, e1145.	0.4	33
1183	Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 196.	3.1	27
1184	Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositive patients in a Chinese population. BMC Neurology, 2015, 15, 160.	0.8	31
1185	Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody. Acta Neuropathologica Communications, 2015, 3, 82.	2.4	54
1186	Efficacy of Tryptophan Immunoadsorption Plasmapheresis for Neuromyelitis Optica in Two Cases. Therapeutic Apheresis and Dialysis, 2015, 19, 411-412.	0.4	12
1188	Therapeutic Plasma Exchange in Children with Acute Autoimmune Central Nervous System Disorders. International Journal of Artificial Organs, 2015, 38, 494-500.	0.7	11
1189	Distinct features of immunoglobulin G2 aquaporinâ€4 antibody carriers with neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2015, 6, 154-158.	0.5	2
1190	Early insights into neuromyelitis optica recounted by a past member of the Executive Committee of the Japanese Society for Neuroimmunology. Clinical and Experimental Neuroimmunology, 2015, 6, 9-10.	0.5	0

#	Article	IF	Citations
1191	Bloodâ€“brain barrier and neurological diseases. Clinical and Experimental Neuroimmunology, 2015, 6, 351-361.	0.5	7
1192	Glucose-Lowering Effect of Sevelamer Hydrochloride in Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 2015, 19, 412-413.	0.4	1
1193	Leaving the Executive Committee of the Japanese Society for Neuroimmunology. Clinical and Experimental Neuroimmunology, 2015, 6, 7-8.	0.5	0
1194	Fatty acidâ€binding protein 7 regulates function of caveolae in astrocytes through expression of caveolinâ€1. Glia, 2015, 63, 780-794.	2.5	49
1195	Copy number variations in multiple sclerosis and neuromyelitis optica. Annals of Neurology, 2015, 78, 762-774.	2.8	34
1196	Detection of aquaporinâ€4 antibody status of <scp>T</scp>hai patients with neuromyelitis optica spectrum disorders using a recombinant <scp>E</scp>scherichia coli aquaporinâ€4 enzymeâ€linked immunosorbent assay. Clinical and Experimental Neuroimmunology, 2015, 6, 57-66.	0.5	0
1197	The Fc Receptor-Like 3 Polymorphisms (rs7528684, rs945635, rs3761959 and rs2282284) and The Risk of Neuromyelitis Optica in A Chinese Population. Medicine (United States), 2015, 94, e1320.	0.4	8
1198	Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort. Neurologist, 2015, 20, 61-66.	0.4	8
1199	Galactorrhea in a Patient With Aquaporin-4 Antibodyâ€positive Neuromyelitis Optica Spectrum Disorder. Neurologist, 2015, 20, 101-103.	0.4	6
1201	Variants of Interferon Regulatory Factor 5 are Associated with Neither Neuromyelitis Optica Nor Multiple Sclerosis in the Southeastern Han Chinese Population. Chinese Medical Journal, 2015, 128, 1743-1747.	0.9	3
1202	Variants of Interleukin-7/Interleukin-7 Receptor Alpha are Associated with Both Neuromyelitis Optica and Multiple Sclerosis Among Chinese Han Population in Southeastern China. Chinese Medical Journal, 2015, 128, 3062-3068.	0.9	13
1203	B Cells and Autoantibodies in Multiple Sclerosis. International Journal of Molecular Sciences, 2015, 16, 16576-16592.	1.8	46
1204	Hypersensitivity Responses in the Central Nervous System. Frontiers in Immunology, 2015, 6, 517.	2.2	7
1205	Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins. Frontiers in Immunology, 2015, 6, 600.	2.2	37
1206	B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. Frontiers in Immunology, 2015, 6, 636.	2.2	120
1207	Bypassing hazard of housekeeping genes: their evaluation in rat granule neurons treated with cerebrospinal fluid of multiple sclerosis subjects. Frontiers in Cellular Neuroscience, 2015, 9, 375.	1.8	9
1208	Lipid rafts and their possible involvements in neuroimmunological disorders. Frontiers in Bioscience - Landmark, 2015, 20, 303-313.	3.0	2
1209	Markedly Increased IP-10 Production by Blood-Brain Barrier in Neuromyelitis Optica. PLoS ONE, 2015, 10, e0122000.	1.1	25

#	Article	IF	Citations
1210	Pediatric Acute Longitudinal Extensive Transverse Myelitis Secondary to Neuroborreliosis. Case Reports in Neurology, 2015, 7, 162-166.	0.3	17
1211	Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study. PLoS ONE, 2015, 10, e0127757.	1.1	38
1212	Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection. PLoS ONE, 2015, 10, e0143679.	1.1	7
1213	Optical coherence tomography in acute optic neuritis. , 0, , 28-41.		0
1214	Detection of Antibodies against Human and Plant Aquaporins in Patients with Multiple Sclerosis. Autoimmune Diseases, 2015, 2015, 1-10.	2.7	15
1215	Epidemiology of Neuromyelitis Optica in the World: A Systematic Review and Meta-Analysis. Multiple Sclerosis International, 2015, 2015, 1-8.	0.4	65
1216	A Case Study of Intractable Vomiting with Final Diagnosis of Neuromyelitis Optica. Case Reports in Pediatrics, 2015, 2015, 1-7.	0.2	4
1217	Follicular Helper CD4⁺T Cells in Human Neuroautoimmune Diseases and Their Animal Models. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	25
1218	Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases. Current Immunology Reviews, 2015, 11, 85-92.	1.2	9
1219	Profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Journal of Neurosciences in Rural Practice, 2015, 6, 295-296.	0.3	0
1220	Short Myelitis Lesions in Aquaporin-4-IgGâ€“Positive Neuromyelitis Optica Spectrum Disorders. JAMA Neurology, 2015, 72, 81.	4.5	209
1221	Neuromyelitis optica in Portugal (NEMIPORT) â€“ A multicentre study. Clinical Neurology and Neurosurgery, 2015, 134, 79-84.	0.6	5
1222	Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review. Journal of the Neurological Sciences, 2015, 355, 7-17.	0.3	49
1223	Relapse of neuromyelitis optica during pregnancyâ€”Treatment options and literature review. Clinical Neurology and Neurosurgery, 2015, 130, 159-161.	0.6	19
1224	Spinal cord MRI in multiple sclerosisâ€”diagnostic, prognostic and clinical value. Nature Reviews Neurology, 2015, 11, 327-338.	4.9	177
1225	Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases. Frontiers in Immunology, 2015, 6, 322.	2.2	84
1226	Significance of gray matter brain lesions in multiple sclerosis and neuromyelitis optica. Neuropathology, 2015, 35, 481-486.	0.7	10
1227	Aquaporin-4â€“positive myelitis associated with SjÃ¶gren syndrome and colonic adenocarcinoma. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e103.	3.1	4

#	Article	IF	Citations
1228	Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. Acta Neuropathologica, 2015, 130, 783-798.	3.9	55
1229	Fulminant demyelinating encephalomyelitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e175.	3.1	75
1230	Fulminant Demyelinating Diseases of the Central Nervous System. Seminars in Neurology, 2015, 35, 656-666.	0.5	17
1231	Clinical manifestations of neuromyelitis optica in male and female patients. Neurological Research, 2015, 37, 967-973.	0.6	6
1232	Neuromyelitis optica (NMO) and autoimmune thyroiditis. Oxford Medical Case Reports, 2015, 2015, 325-329.	0.2	4
1233	No Overlap among Serum GAD65, NMDAR and AQP4 Antibodies in Patients with Neuromyelitis Optica Spectrum Disorders. NeuroImmunoModulation, 2015, 22, 337-341.	0.9	6
1234	The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. Experimental Neurology, 2015, 265, 8-21.	2.0	59
1235	Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis. Multiple Sclerosis Journal, 2015, 21, 710-717.	1.4	25
1236	Longitudinally extensive transverse myelitis in systemic lupus erythematosus: Case report and review of the literature. Clinical Neurology and Neurosurgery, 2015, 129, 57-61.	0.6	22
1238	The role of cerebellar abnormalities in neuromyelitis optica â€“ a comparison with multiple sclerosis and healthy controls. Multiple Sclerosis Journal, 2015, 21, 757-766.	1.4	9
1239	Regulation of neurovascular coupling in autoimmunity to water and ion channels. Autoimmunity Reviews, 2015, 14, 258-267.	2.5	19
1240	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Multiple Sclerosis Journal, 2015, 21, 678-688.	1.4	209
1241	Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. Rheumatology International, 2015, 35, 243-253.	1.5	34
1242	Sex Disparities in Neuro-Ophthalmologic Disorders. Current Eye Research, 2015, 40, 247-265.	0.7	7
1243	Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica. BBA Clinical, 2015, 3, 126-134.	4.1	16
1244	Classification algorithms with multi-modal data fusion could accurately distinguish neuromyelitis optica from multiple sclerosis. NeuroImage: Clinical, 2015, 7, 306-314.	1.4	37
1245	Aicardiâ€“GoutiÃ¨res syndrome harbours abundant systemic and brain-reactive autoantibodies. Annals of the Rheumatic Diseases, 2015, 74, 1931-1939.	0.5	35
1246	Longitudinally extensive myelopathy in children. Pediatric Radiology, 2015, 45, 244-257.	1.1	11

#	Article	IF	Citations
1247	Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2015, 348, 132-135.	0.3	32
1248	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Multiple Sclerosis Journal, 2015, 21, 189-197.	1.4	56
1249	Neuromyelitis optica: a positive appraisal of seronegative cases. European Journal of Neurology, 2015, 22, 1511.	1.7	29
1250	Neuropathology Simplified. , 2015, , .		0
1251	Analysis of the treatment of neuromyelitis optica. Journal of the Neurological Sciences, 2015, 351, 31-35.	0.3	86
1252	Aquaporin 4 antibody [NMO Ab] status in patients with severe optic neuritis in India. International Ophthalmology, 2015, 35, 801-806.	0.6	10
1253	Report on the 6th scientific meeting of the â€œVerein zur FÃ¶rderung des Wissenschaftlichen Nachwuchses in der Neurologieâ€•(NEUROWIND e.V.) held in Motzen, Germany, Oct. 31th â€“ Nov. 2nd, 2014. Experimental & Translational Stroke Medicine, 2015, 7, 1.	3.2	0
1254	Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: A meta-analysis. Multiple Sclerosis and Related Disorders, 2015, 4, 345-349.	0.9	48
1255	Pushing the boundaries of neuromyelitis optica. Neurology, 2015, 85, 118-119.	1.5	14
1256	SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transplantation, 2015, 50, 173-180.	1.3	71
1257	Neuropsychiatric Symptoms of Inflammatory Demyelinating Diseases. Neuropsychiatric Symptoms of Neurological Disease, 2015, , .	0.3	3
1258	Utility of Autoantibodies as Biomarkers for Diagnosis and Staging of Neurodegenerative Diseases. International Review of Neurobiology, 2015, 122, 1-51.	0.9	39
1259	Aquaporin-4 autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e110.	3.1	173
1260	Experimental models of neuromyelitis optica: current status, challenges and future directions. Neuroscience Bulletin, 2015, 31, 735-744.	1.5	25
1261	Neuromyelitis Optica: Atypical Clinical and Neuroradiological Presentation. Neuroradiology Journal, 2015, 28, 41-45.	0.6	5
1262	Spontaneous Recovery of Neuromyelitis Optica Spectrum Disorder during Pregnancy. Neuro-Ophthalmology, 2015, 39, 30-33.	0.4	4
1263	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015, 85, 177-189.	1.5	3,275
1264	Paraneoplastic neuromyelitis optica spectrum disorders: three new cases and a review of the literature. International Journal of Neuroscience, 2016, 126, 1-9.	0.8	29

#	Article	IF	Citations
1265	Familial forms of multiple sclerosis and neuromyelitis optica at an MS center in Rio de Janeiro State, Brazil. Journal of the Neurological Sciences, 2015, 356, 196-201.	0.3	23
1266	Diagnostic value of aquaporin 4 antibody in assessing idiopathic inflammatory demyelinating central nervous system diseases in Egyptian patients. Journal of Clinical Neuroscience, 2015, 22, 670-675.	0.8	3
1267	The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. Journal of Neuroimmunology, 2015, 282, 45-53.	1.1	61
1268	Autoimmune Encephalopathies. Pediatric Clinics of North America, 2015, 62, 667-685.	0.9	27
1269	Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2015, 281, 38-43.	1.1	16
1270	Longitudinally extensive transverse myelitis with neuro-lymphatic protein expressionin systemic lupus erithematosus patient. An autopsy case report. Revista Espanola De Patologia, 2015, 48, 217-221.	0.6	0
1271	Syndrome of inappropriate antidiuretic hormone secretion in patients with aquaporin-4 antibody. Journal of Neurology, 2015, 262, 101-107.	1.8	22
1272	The use of flow cytometry to assess a novel drug efficacy in multiple sclerosis. Metabolic Brain Disease, 2015, 30, 877-884.	1.4	2
1273	Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. Journal of Neuroinflammation, 2015, 12, 46.	3.1	149
1274	Gaze palsy, hypogeusia and a probable association with miscarriage of pregnancy - the expanding clinical spectrum of non-opticospinal neuromyelitis optica spectrum disorders: a case report. BMC Research Notes, 2015, 8, 36.	0.6	6
1275	Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. Neurology: Clinical Practice, 2015, 5, 175-177.	0.8	21
1276	Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review. Acta Neurologica Belgica, 2015, 115, 635-642.	0.5	7
1277	Demographic and clinical features of neuromyelitis optica: A review. Multiple Sclerosis Journal, 2015, 21, 845-853.	1.4	278
1278	Novel diagnostic tools and solutions for multiple sclerosis treatment: a patent review (2009 â€“ 2014). Expert Opinion on Therapeutic Patents, 2015, 25, 873-884.	2.4	7
1279	Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment. Journal of Child Neurology, 2015, 30, 1366-1370.	0.7	16
1280	Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibodyâ€“Consuming Effect?. Journal of Neuropathology and Experimental Neurology, 2015, 74, 194-197.	0.9	6
1281	Mutagenesis of the Aquaporin 4 Extracellular Domains Defines Restricted Binding Patterns of Pathogenic Neuromyelitis Optica IgG. Journal of Biological Chemistry, 2015, 290, 12123-12134.	1.6	33
1282	Retinal damage and vision loss in <scp>A</scp>frican <scp>A</scp>merican multiple sclerosis patients. Annals of Neurology, 2015, 77, 228-236.	2.8	53

#	Article	IF	Citations
1283	MRI characteristics of neuromyelitis optica spectrum disorder. Neurology, 2015, 84, 1165-1173.	1.5	523
1284	Lesser-known myelin-related disorders: Focal tumour-like demyelinating lesions. NeurologÃa (English) Tj ETQq1 1 0.784314 rgBT /Ove	0.2	1
1285	Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e62.	3.1	242
1286	Neuromyelitis optica spectrum disorder presenting with repeated hypersomnia due to involvement of the hypothalamus and hypothalamus-amygdala linkage. Multiple Sclerosis Journal, 2015, 21, 960-962.	1.4	21
1287	Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology, 2015, 84, 1805-1815.	1.5	39
1288	Neuromyelitis optica in a child with Aicardi-GoutiÂ^res syndrome. Neurology, 2015, 85, 381-383.	1.5	22
1289	Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis. Neuro-Ophthalmology, 2015, 39, 213-219.	0.4	29
1290	Body fluid biomarkers for multiple sclerosisâ€"the long road to clinical application. Nature Reviews Neurology, 2015, 11, 585-596.	4.9	88
1291	Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e163.	3.1	203
1292	Antibodies as Mediators of Brain Pathology. Trends in Immunology, 2015, 36, 709-724.	2.9	47
1293	Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research. Expert Review of Proteomics, 2015, 12, 637-650.	1.3	10
1294	The growing spectrum of antibody-associated inflammatory brain diseases in children. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e92.	3.1	30
1295	Clinical update in optic nerve disorders. Expert Review of Ophthalmology, 2015, 10, 145-166.	0.3	0
1297	Gamma-aminobutyric acid receptor agonists, aquaporin-4, and neuromyelitis optica: a potential link. Medical Hypotheses, 2015, 85, 628-630.	0.8	6
1298	Atypical Optic Neuritis. Current Neurology and Neuroscience Reports, 2015, 15, 76.	2.0	18
1299	Neuropsychiatry of Neuromyelitis Optica. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 249-256.	0.3	0
1300	Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach. Multiple Sclerosis and Related Disorders, 2015, 4, 515-520.	0.9	10
1301	Neuromyelitis Optica with Cutaneous Findings: Case Report and Review of the Literature. Dermatology, 2015, 230, 289-292.	0.9	6

#	Article	IF	Citations
1302	Update on biomarkers in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e134.	3.1	104
1303	Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations. Journal of the Neurological Sciences, 2015, 358, 118-124.	0.3	40
1304	Devic's disease before Devic: Bilateral optic neuritis and simultaneous myelitis in a young woman (1874). Journal of the Neurological Sciences, 2015, 358, 419-421.	0.3	6
1305	Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder. Neurological Sciences, 2015, 36, 2301-2302.	0.9	7
1307	The putative acceleration of optic neuritis when combined with chronic hepatitis B. Journal of the Neurological Sciences, 2015, 358, 207-212.	0.3	9
1308	Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. Journal of Neuroimmunology, 2015, 289, 8-11.	1.1	30
1309	A placebo controlled trial for an NMO relapse prevention treatment: Ethical considerations. Multiple Sclerosis and Related Disorders, 2015, 4, 580-584.	0.9	4
1310	Perivascular Enhancement in a Patient with Neuromyelitis Optica Spectrum Disease during an Optic Neuritis Attack. Journal of Neuroimaging, 2015, 25, 686-687.	1.0	8
1311	Neuromyelitis optica spectrum disorder initiated with hemiageusia and pruritus: A case report. Journal of the Neurological Sciences, 2015, 348, 288-289.	0.3	5
1312	Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 20-25.	0.9	72
1313	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology, 2015, 84, 148-158.	1.5	49
1314	Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2015, 278, 108-111.	1.1	12
1315	Quantitative analysis of aquaporin-4 antibody in longitudinally extensive transverse myelitis. Journal of Neuroimmunology, 2015, 278, 26-29.	1.1	9
1316	Biomarkers for neuromyelitis optica. Clinica Chimica Acta, 2015, 440, 64-71.	0.5	31
1317	Aquaporin-4 autoimmunity in a child without optic neuritis and myelitis. Brain and Development, 2015, 37, 149-152.	0.6	5
1318	Anti-aquaporin 4 antibody-positive acute disseminated encephalomyelitis. Brain and Development, 2015, 37, 339-343.	0.6	5
1319	White matter involvement beyond the optic nerves in CRION as assessed by diffusion tensor imaging. International Journal of Neuroscience, 2015, 125, 10-17.	0.8	10
1320	Enfermedades menos conocidas de la mielina: lesiones desmielinizantes focales seudotumorales. NeurologÃa, 2015, 30, 97-105.	0.3	1

#	Article	IF	Citations
1321	The natural course of clinically isolated syndrome in pediatric patients. Brain and Development, 2015, 37, 432-438.	0.6	15
1322	Increased anti-KIR4.1 antibodies in multiple sclerosis: Could it be a marker of disease relapse?. Multiple Sclerosis Journal, 2015, 21, 572-579.	1.4	29
1323	Current symptomatology in multiple sclerosis and neuromyelitis optica. European Journal of Neurology, 2015, 22, 299-304.	1.7	25
1324	Treatment-Resistant Depression and Aquaporin-4 Autoantibodies: Is There a Link?. Biological Psychiatry, 2015, 78, e1-e2.	0.7	6
1325	Imaging of multiple sclerosis and related acquired demyelinating disorders in childhood. Journal of Pediatric Neuroradiology, 2015, 02, 057-072.	0.1	1
1326	Optic neuritis in Hong Kong: a 1-year follow-up study. International Ophthalmology, 2015, 35, 303-310.	0.6	7
1328	Pediatric-Onset Multiple Sclerosis as a Window Into Early Disease Targets and Mechanisms. , 2016, , 67-82.		0
1329	Autoantibodies in Neuropsychiatric Disorders. Antibodies, 2016, 5, 9.	1.2	22
1330	Personalized Medicine and Theranostics. , 2016, , 387-414.		1
1331	Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders. Mediators of Inflammation, 2016, 2016, 1-13.	1.4	39
1333	Visual impairment. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 136, 887-903.	1.0	1
1334	Astrocyte Differentiation of Human Pluripotent Stem Cells: New Tools for Neurological Disorder Research. Frontiers in Cellular Neuroscience, 2016, 10, 215.	1.8	120
1335	KIR4.1: K+ Channel Illusion or Reality in the Autoimmune Pathogenesis of Multiple Sclerosis. Frontiers in Molecular Neuroscience, 2016, 9, 90.	1.4	17
1336	The Immunology of Neuromyelitis Opticaâ€"Current Knowledge, Clinical Implications, Controversies and Future Perspectives. International Journal of Molecular Sciences, 2016, 17, 273.	1.8	95
1337	Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders. International Journal of Molecular Sciences, 2016, 17, 1195.	1.8	10
1338	Efficacy of Polyvalent Human Immunoglobulins in an Animal Model of Neuromyelitis Optica Evoked by Intrathecal Anti-Aquaporin 4 Antibodies. International Journal of Molecular Sciences, 2016, 17, 1407.	1.8	10
1339	Aquaporins in the Spinal Cord. International Journal of Molecular Sciences, 2016, 17, 2050.	1.8	36
1340	Seronegative Neuromyelitis Optica After Cardiac Transplantation. Baylor University Medical Center Proceedings, 2016, 29, 70-72.	0.2	1

#	Article	IF	Citations
1341	Retinal Morphology and Sensitivity Are Primarily Impaired in Eyes with Neuromyelitis Optica Spectrum Disorder (NMOSD). PLoS ONE, 2016, 11, e0167473.	1.1	7
1342	Quantitative Susceptibility Mapping Indicates a Disturbed Brain Iron Homeostasis in Neuromyelitis Optica â€“ A Pilot Study. PLoS ONE, 2016, 11, e0155027.	1.1	7
1343	Hydroxycholesterol Levels in the Serum and Cerebrospinal Fluid of Patients with Neuromyelitis Optica Revealed by LC-Ag+CIS/MS/MS and LC-ESI/MS/MS with Picolinic Derivatization: Increased Levels and Association with Disability during Acute Attack. PLoS ONE, 2016, 11, e0167819.	1.1	12
1344	Cerebral Cortex Involvement in Neuromyelitis Optica Spectrum Disorder. Journal of Clinical		

#	Article	IF	Citations
1359	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	0.9	228
1360	No association of AQP4 polymorphisms with neuromyelitis optica and multiple sclerosis. Translational Neuroscience, 2016, 7, 76-83.	0.7	5
1361	Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2016, 293, 100-104.	1.1	14
1362	Increased frequency and severity of restless legs syndrome in patients with neuromyelitis optica spectrum disorder. Sleep Medicine, 2016, 17, 121-123.	0.8	9
1363	Neuromyelitis optica accompanied by nephrotic syndrome and autoimmune-related pancytopenia. Multiple Sclerosis and Related Disorders, 2016, 7, 8-11.	0.9	6
1365	Neuromyelitis optica and Wernicke encephalopathy share the similar imagings, any correlations?. Radiology of Infectious Diseases, 2016, 3, 79-83.	2.4	3
1367	Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder. Journal of Neurology, 2016, 263, 1343-1348.	1.8	67
1368	K_V1 channels identified in rodent myelinated axons, linked to Cx29 in innermost myelin: support for electrically active myelin in mammalian saltatory conduction. Journal of Neurophysiology, 2016, 115, 1836-1859.	0.9	31
1369	Glial fibrillary acidic protein as a marker of astrocytic activation in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Journal of Clinical Neuroscience, 2016, 26, 75-78.	0.8	18
1370	Glio-vascular modifications caused by Aquaporin-4 deletion in the mouse retina. Experimental Eye Research, 2016, 146, 259-268.	1.2	42
1371	Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology, 2016, 86, 1772-1779.	1.5	72
1372	Evoked potentials are useful for diagnosis of neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2016, 364, 97-101.	0.3	14
1373	Isotetrandrine Reduces Astrocyte Cytotoxicity in Neuromyelitis Optica by Blocking the Binding of NMO-IgG to Aquaporin 4. NeuroImmunoModulation, 2016, 23, 98-108.	0.9	9
1374	Astrocytes in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1114-1124.	1.4	108
1375	Inherited and acquired disorders of myelin: The underlying myelin pathology. Experimental Neurology, 2016, 283, 452-475.	2.0	96
1376	Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders. Journal of the Neurological Sciences, 2016, 366, 3-7.	0.3	24
1377	Imaging in Pediatric Demyelinating and Inflammatory Diseases of Brain- Part 2. Indian Journal of Pediatrics, 2016, 83, 965-982.	0.3	5
1378	Autoimmune myelopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 327-351.	1.0	42

#	Article	IF	Citations
1379	Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy. Neuropediatrics, 2016, 47, 245-252.	0.3	21
1381	Immunopathology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 95-106.	1.0	15
1382	Neurologic autoimmunity. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 121-143.	1.0	4
1383	Detection methods for neural autoantibodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 147-163.	1.0	26
1384	Autoimmunity in visual loss. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 353-376.	1.0	13
1385	Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 377-403.	1.0	69
1386	Autoimmune neurologic disorders in children. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 485-510.	1.0	9
1387	Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder. Current Allergy and Asthma Reports, 2016, 16, 42.	2.4	24
1388	Neuromyelitis optica spectrum disorder (NMOSD): A new concept. Revue Neurologique, 2016, 172, 256-262.	0.6	31
1389	Specific MRI findings help distinguish acute transverse myelitis of Neuromyelitis Optica from spinal cord infarction. Multiple Sclerosis and Related Disorders, 2016, 9, 62-67.	0.9	43
1390	Transverse Myelitis and Neuromyelitis Optica Spectrum Disorders. Seminars in Ultrasound, CT and MRI, 2016, 37, 384-395.	0.7	5
1391	Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis. Clinica Chimica Acta, 2016, 462, 118-126.	0.5	55
1392	The binding property of a monoclonal antibody against the extracellular domains of aquaporin-4 directs aquaporin-4 toward endocytosis. Biochemistry and Biophysics Reports, 2016, 7, 77-83.	0.7	15
1393	Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders. JAMA Neurology, 2016, 73, 1342.	4.5	220
1394	CFHR1-Modified Neural Stem Cells Ameliorated Brain Injury in a Mouse Model of Neuromyelitis Optica Spectrum Disorders. Journal of Immunology, 2016, 197, 3471-3480.	0.4	23
1395	Serum concentration of CD40L is elevated in inflammatory demyelinating diseases. Journal of Neuroimmunology, 2016, 299, 66-69.	1.1	9
1396	The role of AQP4 in neuromyelitis optica: More answers, more questions. Journal of Neuroimmunology, 2016, 298, 63-70.	1.1	37
1397	Glycyrrhizic acid prevents astrocyte death by neuromyelitis optica-specific IgG via inhibition of C1q binding. Biochemical and Biophysical Research Communications, 2016, 478, 553-558.	1.0	9

#	Article	IF	Citations
1398	Imaging of noninfectious inflammatory disorders of the spinal cord. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 136, 733-746.	1.0	3
1399	In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis opticaâ€related pathology. Annals of Neurology, 2016, 79, 794-805.	2.8	45
1400	Voiding dysfunction in patients with neuromyelitis optica spectrum disorders. Neurourology and Urodynamics, 2016, 35, 39-43.	0.8	19
1401	Immunoinflammatory diseases of the central nervous system â€“ the tale of two cytokines. British Journal of Pharmacology, 2016, 173, 716-728.	2.7	29
1402	High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporinâ€4 competing with the neuromyelitis optica autoantibody, NMOâ€IgG. British Journal of Pharmacology, 2016, 173, 103-114.	2.7	10
1403	Complementing the inflammasome. Immunology, 2016, 147, 152-164.	2.0	55
1404	Increased plasma levels of epithelial neutrophil-activating peptide 78/CXCL5 during the remission of Neuromyelitis optica. BMC Neurology, 2016, 16, 96.	0.8	26
1405	Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders. Journal of Neuroinflammation, 2016, 13, 176.	3.1	14
1406	Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. Neurology, 2016, 87, S12-9.	1.5	49
1407	Neuromyelitis optica spectrum disorders in children and adolescents. Neurology, 2016, 87, S59-66.	1.5	78
1408	Eleven episodes of recurrent optic neuritis of the same eye for 22 years eventually diagnosed as neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2016, 10, 22-25.	0.9	1
1409	Heterogeneity in oligodendroglia: Is it relevant to mouse models and human disease?. Journal of Neuroscience Research, 2016, 94, 1421-1433.	1.3	17
1410	Etiological, clinical, and radiological features of longitudinally extensive myelopathy in Chinese patients. Journal of Clinical Neuroscience, 2016, 32, 61-66.	0.8	7
1413	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Journal of Neuroinflammation, 2016, 13, 279.	3.1	351
1414	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation, 2016, 13, 280.	3.1	686
1415	Epidemiology of Multiple Sclerosis. Neurologic Clinics, 2016, 34, 919-939.	0.8	214
1416	Other noninfectious inflammatory disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 425-446.	1.0	8
1417	Role of regulatory b cells in neuroimmunologic disorders. Journal of Neuroscience Research, 2016, 94, 693-701.	1.3	42

#	Article	IF	Citations
1418	Neuromyelitis Optica (Devicâ€™s Syndrome): an Appraisal. Current Rheumatology Reports, 2016, 18, 54.	2.1	13
1419	Multiple Sclerosis and Neurodegenerative Diseases. , 2016, , 63-84.		9
1420	CD14+CD16++ monocytes are increased in patients with NMO and are selectively suppressed by glucocorticoids therapy. Journal of Neuroimmunology, 2016, 300, 1-8.	1.1	20
1421	Aquaporin 4 Antibody in the Korean Patient with New-Onset Optic Neuritis. Seminars in Ophthalmology, 2018, 33, 1-4.	0.8	16
1422	Immunology of neuromyelitis optica during pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e288.	3.1	45
1423	Diagnostic Utility of Systematic Aquaporin-4 Antibodies Determination in the First Event of Immune-Mediated Optic Neuritis. European Neurology, 2016, 76, 227-233.	0.6	5
1424	Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system. Journal of Neuroinflammation, 2016, 13, 219.	3.1	39
1425	Inpatient Multidisciplinary Rehabilitation Intervention Outcomes for Neuromyelitis Optica Spectrum Disorder: A Retrospective Observational Study. Progress in Rehabilitation Medicine, 2016, 1, n/a.	0.3	1
1426	Fulminant neuromyelitis optica in a Finnish woman â€“ a case report. Clinical Case Reports (discontinued), 2016, 4, 782-785.	0.2	1
1427	Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD. Acta Neuropathologica Communications, 2016, 4, 82.	2.4	41
1428	The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. BMC Neurology, 2016, 16, 203.	0.8	16
1429	Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. Journal of Neuro-Ophthalmology, 2016, 36, 238-245.	0.4	23
1430	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Annals of Neurology, 2016, 79, 437-447.	2.8	148
1432	Clinical proteomics of enervated neurons. Clinical Proteomics, 2016, 13, 10.	1.1	2
1433	Demyelinating diseases in Asia. Current Opinion in Neurology, 2016, 29, 222-228.	1.8	40
1434	Neuromyelitis optica and pregnancy. Acta Neurologica Belgica, 2016, 116, 431-438.	0.5	9
1435	Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI. American Journal of Neuroradiology, 2016, 37, 1223-1230.	1.2	61
1436	Three cases of neuromyelitis optica spectrum disorder. Acta Radiologica Open, 2016, 5, 205846011664145.	0.3	1

#	Article	IF	Citations
1438	Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE. Lupus, 2016, 25, 823-829.	0.8	18
1439	Detection of aquaporin-4 antibody using aquaporin-4 extracellular loop-based carbon nanotube biosensor for the diagnosis of neuromyelitis optica. Biosensors and Bioelectronics, 2016, 78, 87-91.	5.3	33
1440	Antibodies in acquired demyelinating disorders in children. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	4
1442	Longitudinally extensive transverse myelitis: A retrospective analysis of sixty-four patients at tertiary care center of North-West India. Clinical Neurology and Neurosurgery, 2016, 148, 5-12.	0.6	22
1443	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Annals of Neurology, 2016, 79, 206-216.	2.8	315
1444	Significant Association Between Fc Receptor-Like 3 Polymorphisms (-1901A>G and -658C>T) and Neuromyelitis Optica (NMO) Susceptibility in the Chinese Population. Molecular Neurobiology, 2016, 53, 686-694.	1.9	13
1446	Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. Journal of Neurology, 2016, 263, 25-29.	1.8	39
1447	Seronegative neuromyelitis optica presenting with life-threatening respiratory failure. Journal of Spinal Cord Medicine, 2016, 39, 734-736.	0.7	4
1448	Neuromyelitis optica spectrum disorders in Algeria: A preliminary study in the region of Tizi Ouzou. Multiple Sclerosis and Related Disorders, 2016, 6, 37-40.	0.9	14
1449	Cognitive and psychiatric comorbidities in neuromyelitis optica. Journal of the Neurological Sciences, 2016, 360, 4-9.	0.3	61
1450	Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel. Journal of Neuroimmunology, 2016, 293, 65-70.	1.1	28
1451	Immunoregulation at the gliovascular unit in the healthy brain: A focus on Connexin 43. Brain, Behavior, and Immunity, 2016, 56, 1-9.	2.0	33
1452	Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e188.	3.1	60
1453	Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. Journal of Neurology, 2016, 263, 575-582.	1.8	53
1454	Brain parenchymal damage in neuromyelitis optica spectrum disorder â€“ A multimodal MRI study. European Radiology, 2016, 26, 4413-4422.	2.3	45
1455	Increased resistin levels in the serum and cerebrospinal fluid of patients with neuromyelitis optica. Clinica Chimica Acta, 2016, 456, 176-179.	0.5	3
1456	Effectiveness of multi-disciplinary rehabilitation for patients with Neuromyelitis Optica. Journal of Spinal Cord Medicine, 2016, 39, 311-316.	0.7	10
1457	Painful tonic spasms and brainstem involvement in a patient with neuromyelitis optica spectrum disorder. Neurologia I Neurochirurgia Polska, 2016, 50, 55-58.	0.6	10

#	Article	IF	Citations
1458	Consultative and Comanagement. , 2016, , 107-148.		0
1459	Detection of autoantibodies against aquaporin-5 in the sera of patients with primary SjÃ¶grenâ€™s syndrome. Immunologic Research, 2016, 64, 848-856.	1.3	39
1460	Therapeutic options in neuromyelitis optica spectrum disorders. Expert Review of Neurotherapeutics, 2016, 16, 319-329.	1.4	25
1461	Th17 cells in neuromyelitis optica spectrum disorder: a review. International Journal of Neuroscience, 2016, 126, 1051-1060.	0.8	37
1462	Investigation-Directed Approach to Inflammatory Optic Neuropathies. Seminars in Ophthalmology, 2016, 31, 117-130.	0.8	12
1463	Linear lesions may assist early diagnosis of neuromyelitis optica and longitudinally extensive transverse myelitis, two subtypes of NMOSD. Journal of the Neurological Sciences, 2016, 360, 88-93.	0.3	8
1464	Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmunity Reviews, 2016, 15, 307-324.	2.5	229
1465	The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurology, The, 2016, 15, 317-331.	4.9	160
1466	Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID). Journal of NeuroImmune Pharmacology, 2016, 11, 1-8.	2.1	33
1467	A previously misdiagnosed cohort of aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder with disease duration of >10 years in multi-ethnic Penang, Malaysia: Clinical features and disease course. Multiple Sclerosis and Related Disorders, 2016, 5, 89-90.	0.9	3
1468	Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics, 2016, 13, 70-83.	2.1	90
1469	Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2016, 22, 1337-1348.	1.4	32
1470	Pregnancy outcomes in aquaporin-4â€“positive neuromyelitis optica spectrum disorder. Neurology, 2016, 86, 79-87.	1.5	95
1471	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 2016, 263, 140-149.	1.8	60
1472	A research update on the potential roles of aquaporin 4 in neuroinflammation. Acta Neurologica Belgica, 2016, 116, 127-134.	0.5	18
1473	Hypothalamic abnormality in patients with inflammatory demyelinating disorders. International Journal of Neuroscience, 2016, 126, 1036-1043.	0.8	6
1474	The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. Multiple Sclerosis Journal, 2016, 22, 964-968.	1.4	31
1476	Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 442-451.	1.8	238

#	Article	IF	Citations
1477	Abnormal distribution of AQP5 in labial salivary glands is associated with poor saliva secretion in patients with SjÃ¶gren's syndrome including neuromyelitis optica complicated patients. Modern Rheumatology, 2016, 26, 384-390.	0.9	40
1478	What do we know about brain contrast enhancement patterns in neuromyelitis optica?. Clinical Imaging, 2016, 40, 573-580.	0.8	25
1479	OCT Findings in Neuromyelitis Optica Spectrum Disorders. , 2016, , 85-96.		2
1480	Optical Coherence Tomography in Multiple Sclerosis. , 2016, , .		5
1481	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Multiple Sclerosis Journal, 2016, 22, 511-519.	1.4	76
1482	Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2016, 22, 160-173.	1.4	59
1483	Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 470-482.	1.4	284
1484	Neuromyelitis optica spectrum disorders with multiple brainstem manifestations: a case report. Neurological Sciences, 2016, 37, 309-313.	0.9	9
1485	Association Between the Single Nucleotide Polymorphism and the Level of Aquaporin-4 Protein Expression in Han and Minority Chinese with Inflammatory Demyelinating Diseases of the Central Nervous System. Molecular Neurobiology, 2016, 53, 2878-2885.	1.9	2
1486	Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report. Modern Rheumatology, 2016, 26, 294-296.	0.9	29
1487	Microarray Analysis of lncRNA and mRNA Expression Profiles in Patients with Neuromyelitis Optica. Molecular Neurobiology, 2017, 54, 2201-2208.	1.9	22
1488	DiagnÃ³sticos diferenciales y pronÃ³stico de las mielitis longitudinales extensas en Buenos Aires, Argentina. NeurologÃa, 2017, 32, 99-105.	0.3	10
1489	Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. Expert Review of Neurotherapeutics, 2017, 17, 579-591.	1.4	13
1490	The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients. Journal of Neuroimmunology, 2017, 302, 49-55.	1.1	29
1491	Deletional tolerance prevents AQP4â€‘directed autoimmunity in mice. European Journal of Immunology, 2017, 47, 458-469.	1.6	19
1492	Etiologic spectrum and functional outcome of the acute inflammatory myelitis. Acta Neurologica Belgica, 2017, 117, 507-513.	0.5	11
1493	Clinical characteristics of autoimmune optic neuritis. Clinical and Experimental Neuroimmunology, 2017, 8, 8-16.	0.5	10
1494	Pediatric Autoimmune Epileptic Encephalopathies. Journal of Child Neurology, 2017, 32, 418-428.	0.7	13

#	Article	IF	Citations
1495	Assessment and Diagnosis of Relapsing Multiple Sclerosis. , 2017, , 41-66.		0
1496	MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients. Journal of Neuroimmunology, 2017, 305, 19-28.	1.1	84
1497	Neuromyelitis optica: Application of computer diagnostics to historical case reports. Journal of the History of the Neurosciences, 2017, 26, 341-350.	0.1	1
1498	Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody. Multiple Sclerosis and Related Disorders, 2017, 13, 58-66.	0.9	14
1499	Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathologica, 2017, 133, 597-612.	3.9	53
1500	Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. Multiple Sclerosis Journal, 2017, 23, 182-184.	1.4	12
1501	Headache in Neuromyelitis Optica. Current Pain and Headache Reports, 2017, 21, 20.	1.3	15
1502	Neuromielite ottica acuta (malattia di Devic). EMC - Neurologia, 2017, 17, 1-13.	0.0	0
1503	Metabolic changes in normal-appearing white matter in patients with neuromyelitis optica and multiple sclerosis: a comparative magnetic resonance spectroscopy study. Acta Radiologica, 2017, 58, 1132-1137.	0.5	14
1504	Neutrophil perversion in demyelinating autoimmune diseases: Mechanisms to medicine. Autoimmunity Reviews, 2017, 16, 294-307.	2.5	39
1505	Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 218-225.	0.9	53
1506	Lesions of the posterior limb of the internal capsule in neuromyelitis optica spectrum disorder. Neurological Research, 2017, 39, 448-452.	0.6	2
1507	Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients. Journal of Neuroimmunology, 2017, 307, 82-90.	1.1	14
1508	Pediatric Optic Neuritis. Seminars in Pediatric Neurology, 2017, 24, 122-128.	1.0	24
1509	Elevated Câ€Xâ€C motif ligand 13 and Bâ€cellâ€activating factor levels in neuromyelitis optica during remission. Brain and Behavior, 2017, 7, e00648.	1.0	6
1510	Boundary between multiple sclerosis and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2017, 8, 54-57.	0.5	0
1511	An extensive spinal cord lesion: tumour or inflammation?. Archives of Disease in Childhood, 2017, 102, 754-754.	1.0	0
1512	Blood-Brain Barrier Dysfunction during Central Nervous System Autoimmune Diseases. , 2017, , 175-186.		1

#	Article	IF	Citations
1514	Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy. Journal of Neuro-Ophthalmology, 2017, 37, 291-299.	0.4	28
1515	Etiologies of acute demyelinating optic neuritis: an observational study of 110 patients. European Journal of Neurology, 2017, 24, 875-879.	1.7	32
1516	Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 5491-5496.	3.3	57
1517	Association of CD58 gene polymorphisms with NMO spectrum disorders in a Han Chinese population. Journal of Neuroimmunology, 2017, 309, 23-30.	1.1	17
1518	Formyl Peptide Receptor 1-Mediated Glial Cell Activation in a Mouse Model of Cuprizone-Induced Demyelination. Journal of Molecular Neuroscience, 2017, 62, 232-243.	1.1	15
1519	NMOSD triggered by yellow fever vaccination â€“ An unusual clinical presentation with segmental painful erythema. Multiple Sclerosis and Related Disorders, 2017, 11, 43-44.	0.9	19
1520	Cognitive dysfunction in adult patients with neuromyelitis optica: a systematic review and meta-analysis. Journal of Neurology, 2017, 264, 1549-1558.	1.8	25
1521	The link between morphology and complement in ocular disease. Molecular Immunology, 2017, 89, 84-99.	1.0	21
1522	Acquired Disorders Affecting the White Matter. , 2017, , 759-766.		0
1523	Optic neuritis: the eye as a window to the brain. Current Opinion in Neurology, 2017, 30, 61-66.	1.8	47
1524	Citation classics in central nervous system inflammatory demyelinating disease. Brain and Behavior, 2017, 7, e00700.	1.0	5
1525	Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer. Journal of Neuroimmunology, 2017, 309, 38-40.	1.1	16
1526	Suspected bacterial meningomyelitis: The first presenting clinical feature of neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2017, 309, 68-71.	1.1	7
1527	Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 632-638.	0.9	108
1528	NMO Spectrum Disorders. Neurology International Open, 2017, 01, E36-E47.	0.4	3
1529	Pediatric Neuromyelitis Optica Spectrum Disorder and SjÃ¶gren Syndrome: More Common Than Previously Thought?. Journal of Rheumatology, 2017, 44, 959-960.	1.0	16
1530	CNS Aquaporinâ€4â€specific B cells connect with multiple Bâ€cell compartments in neuromyelitis optica spectrum disorder. Annals of Clinical and Translational Neurology, 2017, 4, 369-380.	1.7	53
1531	Devic's disease before Devic: On the contribution of Friedrich Albin Schanz (1863â€“1923). Journal of the Neurological Sciences, 2017, 379, 99-102.	0.3	6

#	Article	IF	Citations
1532	Differential diagnosis of neuromyelitis optica spectrum disorders. Therapeutic Advances in Neurological Disorders, 2017, 10, 265-289.	1.5	80
1533	Neuromyelitis optica and neuromyelitis optica spectrum disorders. Current Opinion in Neurology, 2017, 30, 208-215.	1.8	38
1534	Convergence spasm due to aquaporin-positive neuromyelitis optica spectrum disorder. ENeurologicalSci, 2017, 7, 7-8.	0.5	6
1535	Differential diagnosis and prognosis for longitudinally extensive myelitis in Buenos Aires, Argentina. NeurologÃa (English Edition), 2017, 32, 99-105.	0.2	4
1536	Neuromyelitis Optica: Immunopathogenesis, Clinical Manifestations, and Treatments. , 2017, , 187-202.		0
1537	Pediatric Multiple Sclerosis. Neuroimaging Clinics of North America, 2017, 27, 229-250.	0.5	15
1538	Searching the Footprints of Pioneers on Neurology: A Bibliometric Analysis. European Neurology, 2017, 77, 152-161.	0.6	9
1539	Neuromyelitis Spectrum Disorders. Mayo Clinic Proceedings, 2017, 92, 663-679.	1.4	224
1540	Circulating regulatory B cell subsets in patients with neuromyelitis optica spectrum disorders. Neurological Sciences, 2017, 38, 1205-1212.	0.9	11
1541	MÃ¼ller cells and retinal axons can be primary targets in experimental neuromyelitis optica spectrum disorder. Clinical and Experimental Neuroimmunology, 2017, 8, 3-7.	0.5	10
1543	Practice Current: How do you treat neuromyelitis optica?. Neurology: Clinical Practice, 2017, 7, 170-178.	0.8	7
1544	Whatâ€™s new in neuromyelitis optica? A short review for the clinical neurologist. Journal of Neurology, 2017, 264, 2330-2344.	1.8	26
1545	Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders. American Journal of Neuroradiology, 2017, 38, 949-953.	1.2	8
1546	Longitudinally extensive transverse myelitis immune-mediated in aquaporin-4 antibody negative patients: Disease heterogeneity. Journal of the Neurological Sciences, 2017, 373, 134-137.	0.3	6
1547	Effects of neuromyelitis opticaâ€“IgG at the bloodâ€“brain barrier in vitro. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e311.	3.1	153
1548	Finding NMO. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e313.	3.1	4
1549	Aquaporin-4 antibody titration in NMO patients treated with rituximab. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e317.	3.1	53
1550	Acute disseminated encephalomyelitis in China, Singapore and Japan: a comparison with the USA. European Journal of Neurology, 2017, 24, 391-396.	1.7	8

#	Article	IF	Citations
1552	The characteristics of spinal imaging in different types of demyelinating diseases. Journal of the Neurological Sciences, 2017, 372, 138-143.	0.3	12
1553	Nausea and Vomiting Related to the Central Nervous System Diseases. , 2017, , 109-118.		2
1554	The single nucleotide polymorphism site of aquaporin-4 gene in patients with neuromyelitis optica. Experimental and Therapeutic Medicine, 2017, 14, 6017-6021.	0.8	6
1555	Neurological Complications of SjÃ¶grenâ€™s Syndrome: Diagnosis and Management. Current Treatment Options in Rheumatology, 2017, 3, 275-288.	0.6	45
1556	Association of serum gamma-glutamyltransferase and C-reactive proteins with neuromyelitis optica and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 18, 65-70.	0.9	19
1558	Epidemiology of neuromyelitis optica in Latin America. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731773009.	0.5	34
1559	AQP4e-Based Orthogonal Arrays Regulate Rapid Cell Volume Changes in Astrocytes. Journal of Neuroscience, 2017, 37, 10748-10756.	1.7	34
1560	Infectious and inflammatory diseases of the central nervous systemâ€"the spectrum of imaging findings and differential diagnosis. Emergency Radiology, 2017, 24, 619-633.	1.0	6
1561	Data of indirect immunofluorescence labeling of the mouse brain sections with sera from SLE and MS patients. Data in Brief, 2017, 15, 170-173.	0.5	0
1562	Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurological Sciences, 2017, 38, 231-236.	0.9	14
1563	Cognitive impairment in neuromyelitis optica spectrum disorders: What do we know?. Multiple Sclerosis and Related Disorders, 2017, 18, 225-229.	0.9	20
1564	Association of TNFSF4 Polymorphisms with Neuromyelitis Optica Spectrum Disorders in a Chinese Population. Journal of Molecular Neuroscience, 2017, 63, 396-402.	1.1	11
1566	Supramolecular aggregation of aquaporinâ€4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica. Journal of Cellular and Molecular Medicine, 2018, 22, 1236-1246.	1.6	14
1567	Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. Journal of Neurology, 2017, 264, 2420-2430.	1.8	120
1568	Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Science Translational Medicine, 2017, 9, .	5.8	110
1569	Autoimmune aquaporin-4 induced damage beyond the central nervous system. Multiple Sclerosis and Related Disorders, 2017, 18, 41-46.	0.9	18
1570	Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. Journal of Neurology, 2017, 264, 2130-2140.	1.8	21
1571	Neuromyelitis Optica. Rheumatic Disease Clinics of North America, 2017, 43, 579-591.	0.8	42

#	Article	IF	Citations
1572	Multimodal magnetic resonance imaging in relation to cognitive impairment in neuromyelitis optica spectrum disorder. Scientific Reports, 2017, 7, 9180.	1.6	21
1573	Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4. Journal of Visualized Experiments, 2017, , .	0.2	4
1574	Methotrexate-associated lymphoproliferative disorder in a patient with neuromyelitis optica spectrum disorder: An implication for pathogenesis mediated by Epstein-Barr virus. Journal of the Neurological Sciences, 2017, 379, 219-221.	0.3	3
1575	Neuromyelitis optica spectrum disorders: Emerging therapies. Clinical and Experimental Neuroimmunology, 2017, 8, 107-116.	0.5	10
1576	Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2017, 310, 150-157.	1.1	6
1577	Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. Multiple Sclerosis and Related Disorders, 2017, 17, 116-122.	0.9	43
1578	A Haystack Heuristic for Autoimmune Disease Biomarker Discovery Using Next-Gen Immune Repertoire Sequencing Data. Scientific Reports, 2017, 7, 5338.	1.6	3
1579	Mielopatie acute. EMC - Neurologia, 2017, 17, 1-14.	0.0	0
1580	Gender differences among Chinese patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2017, 17, 5-8.	0.9	9
1581	Brain antibodies in the cortex and blood of people with schizophrenia and controls. Translational Psychiatry, 2017, 7, e1192-e1192.	2.4	21
1582	A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection. Multiple Sclerosis and Related Disorders, 2017, 17, 148-150.	0.9	36
1583	Neutrophil to lymphocyte ratio may be a helpful marker to evaluate disease activity in NMOSD. Neurological Sciences, 2017, 38, 1859-1863.	0.9	19
1584	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. Multiple Sclerosis Journal, 2017, 23, 1808-1817.	1.4	35
1587	A case of seropositive Neuromyelitis Optica in a paediatric patient with co-existing acute nephrotic syndrome. Multiple Sclerosis and Related Disorders, 2017, 18, 103-105.	0.9	4
1588	Painful tonic spasm in neuromyelitis optica spectrum disorders: Prevalence, clinical implications and treatment options. Multiple Sclerosis and Related Disorders, 2017, 17, 99-102.	0.9	22
1589	Analysis of brain and spinal cord lesions to occult brain damage in seropositive and seronegative neuromyelitis optica. European Journal of Radiology, 2017, 94, 25-30.	1.2	4
1590	Comparisons of presentations and outcomes of neuromyelitis optica patients with and without SjÃ¶grenâ€™s syndrome. Neurological Sciences, 2017, 38, 271-277.	0.9	13
1591	Diffusionâ€weighted imaging helps differentiate multiple sclerosis and neuromyelitis opticaâ€related acute optic neuritis. Journal of Magnetic Resonance Imaging, 2017, 45, 1780-1785.	1.9	16

#	Article	IF	Citations
1592	Aquaporin-4 antibody in neuromyelitis optica: re-testing study in a large population from China. International Journal of Neuroscience, 2017, 127, 790-799.	0.8	5
1593	Development of a patientâ€centred conceptual framework of healthâ€related quality of life in neuromyelitis optica: a qualitative study. Health Expectations, 2017, 20, 47-58.	1.1	15
1594	Association of CD40 Gene Polymorphisms with Susceptibility to Neuromyelitis Optica Spectrum Disorders. Molecular Neurobiology, 2017, 54, 5236-5242.	1.9	13
1595	Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future. International Journal of Neuroscience, 2017, 127, 735-744.	0.8	8
1596	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1377-1384.	1.4	89
1597	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. Journal of the Neurological Sciences, 2017, 372, 92-96.	0.3	25
1598	Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2017, 23, 946-955.	1.4	42
1600	Autonomic Dysregulation, Cognitive Impairment, and Symptoms of Psychosis as an Unusual Presentation in an Anti-Aquaporin 4-Positive Patient. Case Reports in Neurology, 2017, 9, 12-16.	0.3	5
1601	MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?. Brain, 2017, 140, 3072-3075.	3.7	10
1602	Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis. Human Antibodies, 2017, 25, 121-129.	0.6	7
1603	Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731774242.	0.5	10
1605	Commentary. Journal of Neurosciences in Rural Practice, 2017, 08, 138-139.	0.3	0
1606	MOG-IgG associated optic neuritis is not multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2017, 75, 687-691.	0.3	8
1607	Recurrent Longitudinally Extensive Myelitis and Aquaporin-4 Seronegativity â€“ The Expanding Spectrum of Neuromyelitis Optica. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, OD05-OD07.	0.8	2
1608	Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2653-2660.	1.0	18
1609	Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis		

#	Article	IF	Citations
1612	Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Frontiers in Immunology, 2017, 8, 529.	2.2	184
1613	Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System. Frontiers in Immunology, 2017, 8, 652.	2.2	62
1614	Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica. Frontiers in Immunology, 2017, 8, 1785.	2.2	37
1615	Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity. Frontiers in Neurology, 2017, 8, 62.	1.1	16
1616	Increased Circulating T Follicular Helper Cells Are Inhibited by Rituximab in Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2017, 8, 104.	1.1	26
1617	The Contribution of Optical Coherence Tomography in Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology, 2017, 8, 493.	1.1	12
1618	Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study. PLoS ONE, 2017, 12, e0170847.	1.1	63
1619	Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review. PLoS ONE, 2017, 12, e0175538.	1.1	12
1620	Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology, 2017, 89, 1995-2001.	1.5	75
1621	Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease. Acta Neuropathologica Communications, 2017, 5, 95.	2.4	35
1622	Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. Journal of Neuroinflammation, 2017, 14, 171.	3.1	34
1623	The Role of Peripheral CNSâ€Directed Antibodies in Promoting Inflammatory CNS Demyelination. Brain Sciences, 2017, 7, 70.	1.1	16
1624	Neuromyelitis optica: phenotypic characteristics in a Brazilian case series. Arquivos De Neuro-Psiquiatria, 2017, 75, 81-86.	0.3	15
1625	Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Research, 2017, 6, 83.	0.8	23
1626	Neuromyelitis Optica Spectrum Disorder with Recurrent Intracranial Hemorrhage. Internal Medicine, 2017, 56, 1729-1732.	0.3	3
1627	Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets. Journal of Neuroimmunology, 2018, 318, 45-52.	1.1	7
1628	Myointimal Hyperplasia in a Patient with Neuromyelitis Optica (Devicâ€™s Disease) after the Creation of an Arteriovenous Graft. Case Reports in Neurology, 2018, 9, 252-255.	0.3	2
1629	Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opinion on Investigational Drugs, 2018, 27, 265-271.	1.9	40

#	Article	IF	Citations
1630	Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Current Opinion in Neurology, 2018, 31, 325-333.	1.8	48
1631	The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder. Neurological Sciences, 2018, 39, 1307-1308.	0.9	1
1632	A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. Journal of the Neurological Sciences, 2018, 388, 222-231.	0.3	25
1633	Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2018, 317, 1-4.	1.1	19
1634	Myelin oligodendrocyte glycoprotein and aquaporinâ€4 antibodies are highly specific in children with acquired demyelinating syndromes. Developmental Medicine and Child Neurology, 2018, 60, 958-962.	1.1	105
1635	Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. EPMA Journal, 2018, 9, 21-33.	3.3	75
1636	Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4â€“IgG in Patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmology, 2018, 136, 419.	1.4	104
1637	Default-mode network and deep gray-matter analysis in neuromyelitis optica patients. Journal of Neuroradiology, 2018, 45, 256-260.	0.6	2
1638	Extensive bilateral brain lesions in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2018, 24, 1262-1263.	1.4	1
1639	Classification and diagnostic criteria for demyelinating diseases of the central nervous system: Where do we stand today?. Revue Neurologique, 2018, 174, 378-390.	0.6	15
1640	Plasma Exchange for Neuromyelitis Optica Spectrum Disorders in Chinese Patients and Factors Predictive of Short-term Outcome. Clinical Therapeutics, 2018, 40, 603-612.	1.1	25
1641	Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641876208.	1.5	137
1642	Normal brain imaging accompanies neuroimmunologically justified, autoimmune encephalomyelitis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e456.	3.1	12
1643	Natural history of longitudinally extensive transverse myelitis in 35 Hispanic patients with systemic lupus erythematosus: good short-term functional outcome and paradoxical increase in long-term mortality. Lupus, 2018, 27, 1279-1286.	0.8	8
1644	Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies. Mayo Clinic Proceedings, 2018, 93, 1299-1304.	1.4	24
1645	MRI Features of Aquaporin-4 Antibodyâ€“Positive Longitudinally Extensive Transverse Myelitis: Insights into the Diagnosis of Neuromyelitis Optica Spectrum Disorders. American Journal of Neuroradiology, 2018, 39, 782-787.	1.2	21
1646	Neuroimmunological Registries in Germany. Neurology International Open, 2018, 02, E25-E39.	0.4	9
1647	Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. British Journal of Ophthalmology, 2018, 102, 1372-1377.	2.1	79

#	Article	IF	Citations
1648	Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation. Scientific Reports, 2018, 8, 1319.	1.6	41
1649	Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. Acta Neurologica Scandinavica, 2018, 137, 582-588.	1.0	17
1650	Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2018, 384, 91-95.	0.3	5
1651	Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients. Multiple Sclerosis and Related Disorders, 2018, 20, 109-114.	0.9	23
1652	The Gut Microbiome in Neuromyelitis Optica. Neurotherapeutics, 2018, 15, 92-101.	2.1	54
1653	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	4.9	4,605
1654	Diagnosis and management of neuromyelitis optica spectrum disorders - An update. Autoimmunity Reviews, 2018, 17, 195-200.	2.5	89
1655	Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2018, 385, 192-197.	0.3	58
1656	Inhibition of RGMa alleviates symptoms in a rat model of neuromyelitis optica. Scientific Reports, 2018, 8, 34.	1.6	17
1657	Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis. Radiographics, 2018, 38, 169-193.	1.4	109
1658	Comparison of olfactory function between neuromyelitis optica and multiple sclerosis. International Journal of Neuroscience, 2018, 128, 772-777.	0.8	7
1659	Toll-Like Receptor 2-Mediated Glial Cell Activation in a Mouse Model of Cuprizone-Induced Demyelination. Molecular Neurobiology, 2018, 55, 6237-6249.	1.9	22
1660	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40
1661	Pediatric Neuromyelitis Optica Spectrum Disorders. Current Treatment Options in Neurology, 2018, 20, 19.	0.7	32
1662	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology, 2018, 125, 1628-1637.	2.5	108
1663	A woman with intractable nausea and vomiting. BMJ: British Medical Journal, 2018, 361, k1082.	2.4	0
1665	B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641876169.	1.5	67
1666	Insights into the aquaporin 4 of zebrafish (Danio rerio) through evolutionary analysis, molecular modeling and structural dynamics. Gene Reports, 2018, 11, 101-109.	0.4	11

#	Article	IF	Citations
1667	Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2018, 318, 97-102.	1.1	12
1668	Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. Multiple Sclerosis Journal, 2018, 24, 331-339.	1.4	45
1669	Neuropsychological outcomes of pediatric demyelinating diseases: a review. Child Neuropsychology, 2018, 24, 575-597.	0.8	8
1670	Low reliability of anti-KIR4.183â€“120 peptide auto-antibodies in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 910-918.	1.4	5
1671	Multiple sclerosis: Serum anti-CNS autoantibodies. Multiple Sclerosis Journal, 2018, 24, 610-622.	1.4	18
1672	Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. European Radiology, 2018, 28, 96-103.	2.3	24
1673	B-cells as therapeutic targets in neuro-inflammatory diseases. Clinical Immunology, 2018, 186, 51-53.	1.4	6
1674	Multimodal characterization of gray matter alterations in neuromyelitis optica. Multiple Sclerosis Journal, 2018, 24, 1308-1316.	1.4	15
1675	Astroglial vesicular network: evolutionary trends, physiology and pathophysiology. Acta Physiologica, 2018, 222, e12915.	1.8	27
1676	Mutation of the cellular adhesion molecule NECL2 is associated with neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2018, 388, 133-138.	0.3	6
1677	Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence. Multiple Sclerosis and Related Disorders, 2018, 19, 20-24.	0.9	55
1678	Diagnostic Challenges in Pediatric Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Journal of Pediatric Neurology, 2018, 16, 185-191.	0.0	0
1679	Specific myelopathy diagnoses using advancing diagnostics. Neurology, 2018, 90, 51-52.	1.5	2
1680	Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients. Multiple Sclerosis and Related Disorders, 2018, 19, 73-78.	0.9	24
1681	Th2 axisâ€related cytokines in patients with neuromyelitis optica spectrum disorders. CNS Neuroscience and Therapeutics, 2018, 24, 64-69.	1.9	18
1682	Psychiatric comorbidities and suicidality among patients with neuromyelitis optica spectrum disorders in Argentina. Multiple Sclerosis and Related Disorders, 2018, 19, 40-43.	0.9	18
1683	The immunogenetics of neurological disease. Immunology, 2018, 153, 399-414.	2.0	59
1684	A Young Woman With Sudden Urinary Retention and Sensory Deficits. Arthritis Care and Research, 2018, 70, 635-642.	1.5	3

#	Article	IF	Citations
1685	Inflammatory demyelinating diseases of the central nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 263-283.	1.0	117
1686	Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 67-84.	1.0	39
1687	Paraneoplastic neuromyelitis optica spectrum disorder: A case report and review of the literature. Journal of Clinical Neuroscience, 2018, 48, 7-10.	0.8	19
1688	Neuromyelitis optica in Sub-Saharan Africa: the first case report from Togo. Medecine Et Sante Tropicales, 2018, 28, 221-223.	0.3	2
1689	Epidural Labor Analgesia for a Patient with Neuromyelitis Optica: A Case Report and Review of the Literature. Case Reports in Anesthesiology, 2018, 2018, 1-3.	0.2	1
1690	Pediatric Optic Neuritis and Other Demyelinating Optic Neuropathies. International Ophthalmology Clinics, 2018, 58, 113-123.	0.3	1
1691	A multi-facet comparative analysis of neuromyelitis optica spectrum disorders in patients with seropositive and seronegative AQP4-IgG. Medicine (United States), 2018, 97, e13100.	0.4	9
1692	Neuromyelitis optica with unilateral diaphragmatic paralysis. BMJ Case Reports, 2018, 2018, bcr-2018-225984.	0.2	2
1693	Spastic Paraplegias Due to Non-Traumatic Spinal Cord Disorders. , 2018, , .		0
1694	CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders. BioMed Research International, 2018, 2018, 1-11.	0.9	13
1695	Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology, 2018, 91, e2265-e2275.	1.5	84
1696	Cerebrospinal Fluid Level of Soluble CD27 Is Associated with Disease Severity in Neuromyelitis Optica Spectrum Disorder. NeuroImmunoModulation, 2018, 25, 185-192.	0.9	8
1697	Increased expression of the membrane-bound CD40 ligand on peripheral CD4+ T cells in the acute phase of AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2018, 325, 64-68.	1.1	6
1698	Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Frontiers in Neurology, 2018, 9, 888.	1.1	194
1699	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?. Frontiers in Immunology, 2018, 9, 2753.	2.2	49
1700	Updated diagnostic criteria for neuromyelitis optica spectrum disorder: Similar outcomes of previously separate cohorts. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731881592.	0.5	6
1701	Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6. NeuroImmunoModulation, 2018, 25, 215-224.	0.9	27
1702	Detection of aquaporinâ€4 antibodies for patients with CNS inflammatory demyelinating diseases other than typical MS in Lithuania. Brain and Behavior, 2018, 8, e01129.	1.0	5

#	Article	IF	Citations
1703	Reduced expression of the IL7Ra signaling pathway in Neuromyelitis optica. Journal of Neuroimmunology, 2018, 324, 81-89.	1.1	4
1704	Area postrema syndrome. Neurology, 2018, 91, e1642-e1651.	1.5	129
1705	Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China. Frontiers in Immunology, 2018, 9, 2066.	2.2	34
1706	Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia. Journal of Neuroimmunology, 2018, 324, 76-80.	1.1	6
1707	The role of the laboratory in the expanding field of neuroimmunology: Autoantibodies to neural targets. Journal of Immunological Methods, 2018, 463, 1-20.	0.6	5
1708	Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. Revue Neurologique, 2018, 174, 675-679.	0.6	7
1709	The first Japanese report on neuromyelitis optica rediscovered: acute bilateral blindness, tetraparesis and respiratory insufficiency in a 35-year-old man (1891). Journal of the Neurological Sciences, 2018, 395, 121-125.	0.3	4
1710	Neuromyelitis optica spectrum disorders with and without connective tissue disorders. BMC Neurology, 2018, 18, 177.	0.8	10
1711	Involvement of Aquaporins in the Pathogenesis, Diagnosis and Treatment of SjÃ¶grenâ€™s Syndrome. International Journal of Molecular Sciences, 2018, 19, 3392.	1.8	31
1712	Treatment strategies for neuromyelitis optica. Tzu Chi Medical Journal, 2018, 30, 204.	0.4	3
1713	Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis. Frontiers in Neurology, 2018, 9, 841.	1.1	60
1714	Refining the Nosology of Antigen-Specific Diseases Within the Spectrum of Neuromyelitis Optica. Multiple Sclerosis and Related Disorders, 2018, 25, A1-A2.	0.9	2
1715	A prospective case-control study comparing optical coherence tomography characteristics in neuromyelitis optica spectrum disorder- optic neuritis and idiopathic optic neuritis. BMC Ophthalmology, 2018, 18, 247.	0.6	21
1716	Present Drug Therapy of Demyelinating Disorders. Current Drug Therapy, 2018, 13, 25-42.	0.2	0
1717	Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders. Multiple Sclerosis and Related Disorders, 2018, 26, 1-7.	0.9	26
1718	Glial Fibrillary Acidic Protein Antibody: Another Antibody in the Multiple Sclerosis Diagnostic Mix. Journal of Neuro-Ophthalmology, 2018, 38, 281-284.	0.4	3
1719	Resilience and depression/anxiety symptoms in multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2018, 25, 309-315.	0.9	32
1720	Acute Management of Optic Neuritis: An Evolving Paradigm. Journal of Neuro-Ophthalmology, 2018, 38, 358-367.	0.4	26

#	Article	IF	Citations
1721	The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review. Frontiers in Immunology, 2018, 9, 2056.	2.2	67
1722	Intractable nausea and vomiting as an uncommon presentation in an anti-aquaporin 4-positive patient. Journal of International Medical Research, 2018, 46, 3411-3416.	0.4	1
1724	A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nature Communications, 2018, 9, 1929.	5.8	73
1725	Neurologic manifestations of antiphospholipid syndrome. Lupus, 2018, 27, 1404-1414.	0.8	49
1726	Cocaine as a potential trigger for Neuromyelitis Optica. Journal of the Neurological Sciences, 2018, 390, 99-101.	0.3	3
1727	Differentiating Neuromyelitis Opticaâ€“Related and Multiple Sclerosisâ€“Related Acute Optic Neuritis Using Conventional Magnetic Resonance Imaging Combined With Readout-Segmented Echo-Planar Diffusion-Weighted Imaging. Journal of Computer Assisted Tomography, 2018, 42, 502-509.	0.5	17
1728	Proteomic approach to profiling immune complex antigens in cerebrospinal fluid samples from patients with central nervous system autoimmune diseases. Clinica Chimica Acta, 2018, 484, 26-31.	0.5	20
1729	Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders. Japanese Journal of Ophthalmology, 2018, 62, 525-530.	0.9	21
1730	NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	2
1731	Multiple Sklerose und andere autoimmune ZNS-Erkrankungen. , 2018, , 1-103.		0
1732	Persistent microscopic active inflammatory lesions in the central nervous system of a patient with neuromyelitis optica treated with oral prednisolone for more than 40â€¯years. ENeurologicalSci, 2018, 11, 17-19.	0.5	2
1733	An interesting PRESentation of NMO. Multiple Sclerosis and Related Disorders, 2018, 25, 163-164.	0.9	0
1734	Specificities of Children with Multiple Sclerosis and Neuromyelitis Optica. Central Nervous System Agents in Medicinal Chemistry, 2018, 18, 16-20.	0.5	4
1735	Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. American Journal of Ophthalmology, 2018, 195, 8-15.	1.7	295
1736	Azathioprine-induced pellagra in neuromyelitis optica: A case report and review of literature. Multiple Sclerosis and Related Disorders, 2018, 25, 104-107.	0.9	8
1737	New biological agents in the treatment of multiple sclerosis. Bratislava Medical Journal, 2018, 119, 191-197.	0.4	8
1738	Aquaporin-4 Autoantibodies From Neuromyelitis Optica Spectrum Disorder Patients Induce Complement-Independent Immunopathologies in Mice. Frontiers in Immunology, 2018, 9, 1438.	2.2	35
1740	Myelin Antigens and Antimyelin Antibodies. Antibodies, 2018, 7, 2.	1.2	7

#	Article	IF	Citations
1741	Disturbed Glucose Metabolism in Rat Neurons Exposed to Cerebrospinal Fluid Obtained from Multiple Sclerosis Subjects. Brain Sciences, 2018, 8, 1.	1.1	69
1742	Autoimmune Neurologic Diseases in Children. Seminars in Neurology, 2018, 38, 355-370.	0.5	5
1743	Autoimmune and Paraneoplastic Myelopathies. Seminars in Neurology, 2018, 38, 278-289.	0.5	21
1744	Visual function and inner retinal structure correlations in aquaporin-4 antibody-positive optic neuritis. Japanese Journal of Ophthalmology, 2018, 62, 598-604.	0.9	4
1745	Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence?. Multiple Sclerosis and Related Disorders, 2018, 25, 87-94.	0.9	16
1746	MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2018, 9, 217.	1.1	156
1747	Neuromyelitis Optica Spectrum Disorders. , 2018, , 313-335.		1
1748	C5a-Preactivated Neutrophils Are Critical for Autoimmune-Induced Astrocyte Dysregulation in Neuromyelitis Optica Spectrum Disorder. Frontiers in Immunology, 2018, 9, 1694.	2.2	22
1749	Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders. Neurology and Therapy, 2018, 7, 373-383.	1.4	31
1750	Multiple sclerosis pathogenesis: missing pieces of an old puzzle. Reviews in the Neurosciences, 2018, 30, 67-83.	1.4	16
1751	Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. Revue Neurologique, 2018, 174, 458-470.	0.6	27
1752	Structural and visual functional deficits in a rat model of neuromyelitis optica spectrum disorders related optic neuritis. Experimental Eye Research, 2018, 175, 124-132.	1.2	16
1753	Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Ophthalmology, 2019, 126, 445-453.	2.5	69
1754	Lack of short-chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: A Chinese pilot study. Multiple Sclerosis Journal, 2019, 25, 1316-1325.	1.4	40
1755	Helicobacter pylori infection and demyelinating disease of the central nervous system. Journal of Neuroimmunology, 2019, 329, 14-19.	1.1	22
1756	Increased serum IL-36Î² and IL-36Î³ levels in patients with neuromyelitis optica spectrum disorders: association with disease activity. BMC Neurology, 2019, 19, 185.	0.8	6
1757	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurology, 2019, 76, 1359.	4.5	129
1758	Significance of Autoantibodies. , 2019, , 109-142.		0

#	Article	IF	Citations
1759	Genetic Factors in Neuroimmune Diseases. , 2019, , 357-386.		0
1760	General Principles of Immunotherapy in Neurological Diseases. Contemporary Clinical Neuroscience, 2019, , 387-421.	0.3	3
1761	Validation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of South Indian patients. Multiple Sclerosis and Related Disorders, 2019, 35, 164-169.	0.9	8
1762	Retinal and optic nerve degeneration in liver X receptor Î² knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16507-16512.	3.3	21
1763	Controversies in the management of neuromyelitis optica spectrum disorder. Expert Review of Neurotherapeutics, 2019, 19, 1127-1133.	1.4	8
1764	A new M23-based ELISA assay for anti-aquaporin 4 autoantibodies: diagnostic accuracy and clinical correlation. Autoimmunity Highlights, 2019, 10, 5.	3.9	10
1765	Autoimmunity in psychotic disorders. Where we stand, challenges and opportunities. Autoimmunity Reviews, 2019, 18, 102348.	2.5	30
1766	Devic's index case: A critical reappraisal â€“ AQP4-IgG-mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis?. Journal of the Neurological Sciences, 2019, 407, 116396.	0.3	15
1767	Neuromyelitis Optica Spectrum Disorders. , 2019, , 187-195.		0
1768	Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity. Acta Neuropathologica Communications, 2019, 7, 112.	2.4	45
1769	Neuropathological features of â€œnonâ€•motorâ€•symptoms in multiple sclerosis and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2019, 10, 161-168.	0.5	3
1770	Neurorheumatology. , 2019, , .		2
1771	Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes. Frontiers in Neurology, 2019, 10, 604.	1.1	17
1772	The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2019, 35, 1-4.	0.9	11
1774	Late Onset of Neuromyelitis Optica Spectrum Disorders. Neurology and Therapy, 2019, 8, 477-482.	1.4	16
1775	Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2019, 33, A1-A2.	0.9	8
1776	Acute Disseminated Encephalomyelitis in Children: An Updated Review Based on Current Diagnostic Criteria. Pediatric Neurology, 2019, 100, 26-34.	1.0	86
1777	Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia. Multiple Sclerosis and Related Disorders, 2019, 36, 101413.	0.9	14

#	Article	IF	Citations
1778	Astrocytes in the Pathogenesis of Multiple Sclerosis: An In Situ MicroRNA Study. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1130-1146.	0.9	13
1779	B cells in autoimmune and neurodegenerative central nervous system diseases. Nature Reviews Neuroscience, 2019, 20, 728-745.	4.9	190
1780	A highly specific and sensitive nanoimmunosensor for the diagnosis of neuromyelitis optica spectrum disorders. Scientific Reports, 2019, 9, 16136.	1.6	6
1781	AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Frontiers in Neurology, 2019, 10, 1028.	1.1	56
1782	Pregnancy-Related Immune Changes and Demyelinating Diseases of the Central Nervous System. Frontiers in Neurology, 2019, 10, 1070.	1.1	17
1783	GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica. Annals of Clinical and Translational Neurology, 2019, 6, 2079-2087.	1.7	18
1784	Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis. International Immunopharmacology, 2019, 75, 105793.	1.7	28
1785	A new era for neuromyelitis optica spectrum disorder. Lancet, The, 2019, 394, 1304-1305.	6.3	7
1786	Neuromyelitis optica spectrum disorders: still evolving and broadening. Current Opinion in Neurology, 2019, 32, 385-394.	1.8	122
1787	Outer Retinal Dysfunction on Multifocal Electroretinography May Help Differentiating Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2019, 10, 928.	1.1	12
1788	The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population. Journal of Neuroimmunology, 2019, 337, 577045.	1.1	10
1789	Multidisciplinary rehabilitation for adults with neuromyelitis optica spectrum disorders: A pilot study. Journal of Rehabilitation Medicine, 2019, 51, 692-697.	0.8	6
1790	Unbalanced Expression of ICOS and PD-1 in Patients with Neuromyelitis Optica Spectrum Disorder. Scientific Reports, 2019, 9, 14130.	1.6	9
1791	The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOGâ€“antibody-associated demyelination. Multiple Sclerosis and Related Disorders, 2019, 36, 101397.	0.9	18
1792	Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience. Lupus, 2019, 28, 1302-1311.	0.8	16
1793	Diagnostic Approach to Intrinsic Abnormality of Spinal Cord Signal Intensity. Radiographics, 2019, 39, 1824-1839.	1.4	23
1794	Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease. Cells, 2019, 8, 90.	1.8	144
1795	Foxp3+ regulatory T cells expression in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2019, 30, 114-118.	0.9	14

#	Article	IF	Citations
1796	Semaphorin 4A as a biomarker of multiple sclerosis and neuromyelitis optica spectrum disorder. Clinical and Experimental Neuroimmunology, 2019, 10, 18-26.	0.5	2
1797	Neuromyelitis optica spectrum and myelin oligodendrocyte glycoprotein antibodyâ€related disseminated encephalomyelitis. Clinical and Experimental Neuroimmunology, 2019, 10, 9-17.	0.5	4
1798	Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008â€'2018: A nationwide, population-based cohort study. Multiple Sclerosis and Related Disorders, 2019, 33, 162-167.	0.9	35
1799	Spinal cord swelling in patients with cervical compression myelopathy. BMC Musculoskeletal Disorders, 2019, 20, 284.	0.8	10
1800	Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. Biomedicines, 2019, 7, 42.	1.4	90
1801	Normal-Appearing Cerebellar Damage in Neuromyelitis Optica Spectrum Disorder. American Journal of Neuroradiology, 2019, 40, 1156-1161.	1.2	6
1802	Critical review: Typical and atypical optic neuritis. Survey of Ophthalmology, 2019, 64, 770-779.	1.7	76
1803	TLR-2 and TLR-4 agonists favor expansion of CD4+ T cell subsets implicated in the severity of neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2019, 34, 66-76.	0.9	12
1804	Differential Diagnosis of Pediatric Multiple Sclerosis. Children, 2019, 6, 75.	0.6	5
1805	Epidemiology of NMOSD in Sweden from 1987 to 2013. Neurology, 2019, 93, e181-e189.	1.5	51
1806	Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features. Frontiers in Neurology, 2019, 10, 608.	1.1	42
1807	Type 2 Inflammatory Responses in Autoimmune Demyelination of the Central Nervous System: Recent Advances. Journal of Immunology Research, 2019, 2019, 1-10.	0.9	7
1808	Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan. Ophthalmology, 2019, 126, 1385-1398.	2.5	86
1809	Blood Biomarkers for Traumatic Brain Injury: A Quantitative Assessment of Diagnostic and Prognostic Accuracy. Frontiers in Neurology, 2019, 10, 446.	1.1	127
1810	Myelin in the Central Nervous System: Structure, Function, and Pathology. Physiological Reviews, 2019, 99, 1381-1431.	13.1	336
1811	Neuromyelitis optica spectrum disorder with lung adenocarcinoma and intraductal papillary mucinous neoplasm. Multiple Sclerosis and Related Disorders, 2019, 32, 77-80.	0.9	7
1812	Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain, 2019, 142, 1598-1615.	3.7	62
1813	A comparison between spinal cord infarction and neuromyelitis optica spectrum disorders: Clinical and MRI studies. Scientific Reports, 2019, 9, 7435.	1.6	17

#	Article	IF	Citations
1814	HLA-alleles class I and II associated with genetic susceptibility to neuromyelitis optica in Brazilian patients. Arquivos De Neuro-Psiquiatria, 2019, 77, 239-247.	0.3	11
1815	Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. Journal of Neuroimmunology, 2019, 332, 126-134.	1.1	14
1816	Myelin Oligodendrocyte Glycoprotein-IgG Contributes to Oligodendrocytopathy in the Presence of Complement, Distinct from Astrocytopathy Induced by AQP4-IgG. Neuroscience Bulletin, 2019, 35, 853-866.	1.5	11
1817	Microglia responses to interleukinâ€6 and type I interferons in neuroinflammatory disease. Glia, 2019, 67, 1821-1841.	2.5	63
1818	Comparison of sleep complaints and quality of life between patients with neuromyelitis optica spectrum disorder (NMOSD) and healthy controls. Multiple Sclerosis and Related Disorders, 2019, 32, 81-87.	0.9	15
1819	Curcumin and Inflammatory Brain Diseases. , 2019, , 437-458.		4
1820	Complement Therapeutics in Autoimmune Disease. Frontiers in Immunology, 2019, 10, 672.	2.2	46
1821	Multiple Sclerosis Misdiagnosis: A Persistent Problem to Solve. Frontiers in Neurology, 2019, 10, 466.	1.1	17
1822	Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity. Immunobiology, 2019, 224, 397-401.	0.8	6
1823	Neuromyelitis optica spectrum disorder in pediatrics. Case report. Case Reports, 2019, 5, 11-18.	0.2	0
1824	Repetitive intrathecal injection of human NMO-IgG with complement exacerbates disease severity with NMO pathology in experimental allergic encephalomyelitis mice. Multiple Sclerosis and Related Disorders, 2019, 30, 225-230.	0.9	6
1825	Comparison of Ocular Motor Findings Between Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Involving the Brainstem and Cerebellum. Cerebellum, 2019, 18, 511-518.	1.4	8
1826	Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurological Sciences, 2019, 40, 1383-1391.	0.9	11
1829	Neuromyelitis optica spectrum disorders. Clinical Medicine, 2019, 19, 169-176.	0.8	163
1830	A to Z of Some New Autoimmune Diseases. , 2019, , 593-597.		0
1831	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain, 2019, 142, 1310-1323.	3.7	131
1832	Co-existing of Neuromyelitis Optica and Fulminant Type 1 Diabetes. Internal Medicine, 2019, 58, 1913-1916.	0.3	1
1833	AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding. Acta Neuropathologica Communications, 2019, 7, 51.	2.4	48

#	Article	IF	Citations
1834	Neuromyelitis optica spectrum disorder in a tertiary hospital in the Philippines: a case series. Multiple Sclerosis and Related Disorders, 2019, 31, 124-130.	0.9	6
1835	Study of the cytological features of bone marrow mesenchymal stem cells from patients with neuromyelitis optica. International Journal of Molecular Medicine, 2019, 43, 1395-1405.	1.8	7
1836	Clinical course of neuromyelitis optica spectrum disorder in a moroccan cohort. Multiple Sclerosis and Related Disorders, 2019, 30, 141-148.	0.9	11
1837	Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. International Ophthalmology, 2019, 39, 2477-2483.	0.6	24
1838	Diagnosis of Multiple Sclerosis. , 0, , .		0
1839	A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (United States), 2019, 98, e15944.	0.4	42
1840	Association Between BDNF Val66Met Polymorphism and Optic Neuritis Damage in Neuromyelitis Optica Spectrum Disorder. Frontiers in Neuroscience, 2019, 13, 1236.	1.4	2
1841	Antibodies associated with neuropsychiatric lupus: Pathophysiological role, prevalence and diagnostic usefulness. Revista Colombiana De ReumatologÃa (English Edition), 2019, 26, 111-117.	0.1	2
1842	Aquaporin-4 Serostatus and Visual Outcomes in Clinically Isolated Acute Optic Neuritis. Journal of Neuro-Ophthalmology, 2019, 39, 165-169.	0.4	22
1843	Prognostic Factors for Recovery of Vision in Canine Optic Neuritis of Unknown Etiology: 26 Dogs (2003â€“2018). Frontiers in Veterinary Science, 2019, 6, 415.	0.9	3
1844	Predictive Value of Serum Antibodies and Point Mutations of AQP4, AQP1 and MOG in A Cohort of Spanish Patients with Neuromyelitis Optica Spectrum Disorders. International Journal of Molecular Sciences, 2019, 20, 5810.	1.8	6
1845	The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab. Frontiers in Immunology, 2019, 10, 2686.	2.2	25
1846	The history of neuromyelitis optica. Part 2: â€˜Spinal amaurosisâ€™, or how it all began. Journal of Neuroinflammation, 2019, 16, 280.	3.1	32
1847	What You Need to Know About AQP4, MOG, and NMOSD. Seminars in Neurology, 2019, 39, 718-731.	0.5	34
1848	Tuberculous (TB) myelopathy associated with longitudinally extensive lesion: A case report. Journal of Neuroradiology, 2021, 48, 453-455.	0.6	0
1849	Neuromyelitis Optica: Review and Utility of Testing Aquaporin-4 Antibody in Typical Optic Neuritis. Asia-Pacific Journal of Ophthalmology, 2019, 7, 229-234.	1.3	7
1850	Clinical Course and Treatment Response of Neuromyelitis Optica Spectrum Disease: An 8-Year Experience. Asia-Pacific Journal of Ophthalmology, 2019, 8, 206-210.	1.3	8
1851	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 â€“ continuity and change. Current Opinion in Neurology, 2019, 32, 327-337.	1.8	32

#	Article	IF	Citations
1852	Do Myelin Oligodendrocyte Glycoprotein Antibodies Represent a Distinct Syndrome?. Journal of Neuro-Ophthalmology, 2019, 39, 416-423.	0.4	10
1853	Demyelinating Optic Neuritis and its Subtypes. International Ophthalmology Clinics, 2019, 59, 23-37.	0.3	7
1854	The changing concepts in the neuropathology of acquired demyelinating central nervous system disorders. Current Opinion in Neurology, 2019, 32, 313-319.	1.8	44
1856	Workup for Optic Atrophy. , 2019, , 167-199.		0
1857	Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD). Multiple Sclerosis and Related Disorders, 2019, 27, 392-396.	0.9	19
1858	Quantitative radiomic biomarkers for discrimination between neuromyelitis optica spectrum disorder and multiple sclerosis. Journal of Magnetic Resonance Imaging, 2019, 49, 1113-1121.	1.9	21
1859	2 Optic Neuritis. , 2019, , .		0
1860	Optic Neuritis as theÂPresenting Feature of Neuromyelitis Optica (NMO): Diagnosis and Management. , 2019, , 11-22.		0
1861	Brain and cord imaging features in neuromyelitis optica spectrum disorders. Annals of Neurology, 2019, 85, 371-384.	2.8	66
1862	Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. Drugs, 2019, 79, 125-142.	4.9	50
1863	Blockade of IL-6 signaling in neuromyelitis optica. Neurochemistry International, 2019, 130, 104315.	1.9	34
1864	Neuromyelitis optica spectrum disorders (NMO-SD) in a Sub-Saharan Africa country: A preliminary study of sixteen Senegalese cases. Multiple Sclerosis and Related Disorders, 2019, 27, 179-183.	0.9	11
1865	Clinical Characteristics of Anti-aquaporin 4 Antibody Positive Optic Neuritis in Japan. Neuro-Ophthalmology, 2019, 43, 71-80.	0.4	8
1866	Neuroinflammation in the central nervous system: Symphony of glial cells. Glia, 2019, 67, 1017-1035.	2.5	287
1867	Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy. British Journal of Ophthalmology, 2019, 103, 1423-1428.	2.1	29
1868	The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. Journal of the Neurological Sciences, 2019, 396, 225-231.	0.3	49
1869	Imaging Approach to Myelopathy. Radiologic Clinics of North America, 2019, 57, 257-279.	0.9	23
1870	The clinical and prognostic value of antinuclear antibodies in NMO-IgG seropositive neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2019, 328, 1-4.	1.1	18

#	Article	IF	Citations
1871	Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder. Neurochemistry International, 2019, 130, 104347.	1.9	34
1872	Resolution of inflammation in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2019, 27, 34-41.	0.9	31
1873	Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders. Schizophrenia Bulletin, 2019, 45, 233-246.	2.3	28
1874	Neuromyelitis Optica Spectrum Disorder in a Patient With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2019, 25, e38-e40.	0.5	0
1875	Magnetic resonance imaging in immune-mediated myelopathies. Journal of Neurology, 2020, 267, 1233-1244.	1.8	1
1876	Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients. Multiple Sclerosis Journal, 2020, 26, 945-954.	1.4	11
1877	CNS Inflammatory Demyelinating Disorders: MS, NMOSD and MOG Antibody Associated Disease. Journal of Investigative Medicine, 2020, 68, 321-330.	0.7	36
1878	Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. Multiple Sclerosis and Related Disorders, 2020, 37, 101452.	0.9	57
1879	Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry. Multiple Sclerosis and Related Disorders, 2020, 38, 101448.	0.9	7
1880	Optic neuritis in the era of biomarkers. Survey of Ophthalmology, 2020, 65, 12-17.	1.7	60
1881	Angiotensin AT2 receptorâ€“induced interleukin-10 attenuates neuromyelitis optica spectrum disorderâ€“like pathology. Multiple Sclerosis Journal, 2020, 26, 1187-1196.	1.4	9
1882	Lower serum interleukinâ€22 and interleukinâ€35 levels are associated with disease status in neuromyelitis optica spectrum disorders. CNS Neuroscience and Therapeutics, 2020, 26, 251-259.	1.9	4
1883	Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. Neuropathology and Applied Neurobiology, 2020, 46, 199-218.	1.8	33
1884	Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee. Journal of Clinical Apheresis, 2020, 35, 25-32.	0.7	13
1885	Current Concepts in Ophthalmology. , 2020, , .		1
1886	Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis Journal, 2020, 26, 1929-1937.	1.4	22
1887	A populationâ€based epidemiological study of neuromyelitis optica spectrum disorder in Hungary. European Journal of Neurology, 2020, 27, 308-317.	1.7	27
1888	Autoimmune and Autoantibody-Associated Encephalomyelopathies. , 2020, , 1067-1114.		1

#	Article	IF	Citations
1889	Neuromyelitis optica spectrum disorders in South of Tunisia: A rare entity with low seroprevalence of anti-aquaporin 4 autoantibodies. Revue Neurologique, 2020, 176, 261-267.	0.6	7
1890	Pediatric multiple sclerosis: from clinical basis to imaging spectrum and differential diagnosis. Pediatric Radiology, 2020, 50, 776-792.	1.1	17
1891	Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort. Journal of Neurology, 2020, 267, 1260-1268.	1.8	40
1892	Diagnosis and management of central nervous system SjÃ¶gren's syndrome. , 2020, , 189-209.		0
1893	The differential expression of natural killer cells in NMOSD and MS. Journal of Clinical Neuroscience, 2020, 71, 9-14.	0.8	15
1894	Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 39, 101920.	0.9	35
1895	MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity â€“ No. Multiple Sclerosis Journal, 2020, 26, 274-276.	1.4	6
1896	A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Multiple Sclerosis and Related Disorders, 2020, 38, 101506.	0.9	36
1897	Detection of autoantibodies in central nervous system inflammatory disorders: Clinical application of cell-based assays. Multiple Sclerosis and Related Disorders, 2020, 38, 101858.	0.9	8
1898	IRAK1 polymorphisms are associated with susceptibility to neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 37, 101438.	0.9	4
1899	Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study. Journal of Neuroimmunology, 2020, 339, 577126.	1.1	31
1900	MIF -173G/C polymorphism is associated with NMO disease severity. Journal of Neuroimmunology, 2020, 339, 577120.	1.1	2
1901	NLRP3 level in cerebrospinal fluid of patients with neuromyelitis optica spectrum disorders: Increased levels and association with disease severity. Multiple Sclerosis and Related Disorders, 2020, 39, 101888.	0.9	10
1902	Comparison of prevalence rates of restless legs syndrome, self-assessed risks of obstructive sleep apnea, and daytime sleepiness among patients with multiple sclerosis (MS), clinically isolated syndrome (CIS) and Neuromyelitis Optica Spectrum Disorder (NMOSD). Sleep Medicine, 2020, 70, 97-105.	0.8	12
1903	Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Current Opinion in Neurology, 2020, 33, 47-54.	1.8	80
1904	Reduced sarcolemmal aquaporin 4 expression can support the differential diagnosis of neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2020, 339, 577121.	1.1	3
1905	Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders. European Radiology, 2020, 30, 1470-1479.	2.3	11
1906	Cognitive functions in Egyptian neuromyelitis optica spectrum disorder.. Clinical Neurology and Neurosurgery, 2020, 189, 105621.	0.6	8

#	Article	IF	Citations
1907	Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody. Multiple Sclerosis and Related Disorders, 2020, 39, 101907.	0.9	9
1908	Neuropsychiatric SLE: From Immune Mechanisms to Clinical Management. , 2020, , .		1
1909	Genetic factors for susceptibility to and manifestations of neuromyelitis optica. Annals of Clinical and Translational Neurology, 2020, 7, 2082-2093.	1.7	20
1910	Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience. Multiple Sclerosis and Related Disorders, 2020, 46, 102542.	0.9	24
1911	Experimental mouse model of NMOSD produced by facilitated brain delivery of NMO-IgG by microbubble-enhanced low-frequency ultrasound in experimental allergic encephalomyelitis mice. Multiple Sclerosis and Related Disorders, 2020, 46, 102473.	0.9	4
1912	Neuromyelitis optica. Nature Reviews Disease Primers, 2020, 6, 85.	18.1	232
1913	A CD33 frameshift variant is associated with neuromyelitis optica spectrum disorders. Biomedical Journal, 2021, 44, S93-S100.	1.4	3
1914	NMOSD acute attack: Understanding, treatment and innovative treatment prospect. Journal of Neuroimmunology, 2020, 348, 577387.	1.1	22
1915	Acute optic nerve lesions in first-ever NMOSD-related optic neuritis using conventional brain MRI: A Latin American multicenter study. Multiple Sclerosis and Related Disorders, 2020, 46, 102558.	0.9	5
1916	Research and progress on biomarkers of neuromyelitis optica spectrum disorders. Journal of Receptor and Signal Transduction Research, 2020, 41, 1-8.	1.3	5
1917	Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. American Journal of Ophthalmology, 2020, 220, 110-114.	1.7	48
1918	Increased cerebrospinal fluid YKL-40 levels are associated with disease severity of neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 45, 102395.	0.9	4
1919	Different alteration patterns of subâ€macular choroidal thicknesses in aquaporinâ€4 immunoglobulin G antibodies seroâ€positive neuromyelitis optica spectrum diseases and isolated optic neuritis. Acta Ophthalmologica, 2020, 98, 808-815.	0.6	2
1920	Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder. Clinical and Experimental Immunology, 2020, 202, 239-248.	1.1	6
1921	Higher Disease and Pain Severity and Fatigue and Lower Balance Skills Are Associated with Higher Prevalence of Falling among Individuals with the Inflammatory Disease of Neuromyelitis Optica Spectrum Disorder (NMOSD). Journal of Clinical Medicine, 2020, 9, 3604.	1.0	5
1922	Possible coexistence of MOG-IgG-associated disease and anti-Caspr2 antibody-associated autoimmune encephalitis: a first case report. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096946.	1.5	6
1923	Blood Neurofilament Light Chain: The Neurologistâ€™s Troponin?. Biomedicines, 2020, 8, 523.	1.4	50
1924	Clinical predictive factors for diagnosis of MOG-IgG and AQP4-IgG related paediatric optic neuritis: a Chinese cohort study. British Journal of Ophthalmology, 2022, 106, 262-266.	2.1	9

#	Article	IF	Citations
1925	Oligodendroglial connexin 47 regulates neuroinflammation upon autoimmune demyelination in a novel mouse model of multiple sclerosis. Clinical and Experimental Neuroimmunology, 2020, 11, 205-206.	0.5	0
1926	Pregnancy and Neuromyelitis Optica Spectrum Disorder â€“ Reciprocal Effects and Practical Recommendations: A Systematic Review. Frontiers in Neurology, 2020, 11, 544434.	1.1	16
1927	Biomarkers in Rare Demyelinating Disease of the Central Nervous System. International Journal of Molecular Sciences, 2020, 21, 8409.	1.8	6
1928	Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2020, 11, 585471.	1.1	6
1929	E.U. paediatric MOG consortium consensus: Part 1 â€“ Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 2-13.	0.7	87
1930	Application of the 2015 neuromyelitis optica spectrum disorders diagnostic criteria in a cohort of Chinese patients. Multiple Sclerosis and Related Disorders, 2020, 46, 102459.	0.9	2
1931	Effect of NMO-IgG on the interleukin-6 cascade in astrocytes via activation of the JAK/STAT3 signaling pathway. Life Sciences, 2020, 258, 118217.	2.0	18
1932	High-throughput investigation of molecular and cellular biomarkers in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	20
1933	Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy, 2020, 12, 1053-1066.	1.0	7
1934	Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Multiple Sclerosis and Related Disorders, 2020, 45, 102428.	0.9	42
1935	Emerging drugs for the treatment of neuromyelitis optica. Expert Opinion on Emerging Drugs, 2020, 25, 285-297.	1.0	14
1936	Treatment and outcome of aquaporin-4 antibodyâ€“positive NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	37
1937	Differential Effects of MS Therapeutics on B Cellsâ€”Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. International Journal of Molecular Sciences, 2020, 21, 5021.	1.8	20
1938	Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders. Journal of Neuroinflammation, 2020, 17, 236.	3.1	19
1939	Native American ancestry significantly contributes to neuromyelitis optica susceptibility in the admixed Mexican population. Scientific Reports, 2020, 10, 13706.	1.6	18
1940	Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Frontiers in Pediatrics, 2020, 8, 339.	0.9	44
1941	Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. Pharmaceuticals, 2020, 13, 341.	1.7	15
1942	Lupus and NMOSD: The Blending of Humoral Autoimmunity. Case Reports in Rheumatology, 2020, 2020, 1-7.	0.2	3

#	Article	IF	Citations
1943	Regulatory B Cells and Its Role in Central Nervous System Inflammatory Demyelinating Diseases. Frontiers in Immunology, 2020, 11, 1884.	2.2	40
1944	Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery. Metabolites, 2020, 10, 374.	1.3	7
1945	Paroxysmal Symptoms in Multiple Sclerosisâ€"A Review of the Literature. Journal of Clinical Medicine, 2020, 9, 3100.	1.0	17
1946	Brain MRI characteristics in neuromyelitis optica spectrum disorders: A large multi-center retrospective study in China. Multiple Sclerosis and Related Disorders, 2020, 46, 102475.	0.9	13
1947	Unraveling B lymphocytes in CNS inflammatory diseases. Neurology, 2020, 95, 733-744.	1.5	10
1948	Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD. Frontiers in Neurology, 2020, 11, 932.	1.1	29
1949	Transverse myelitis associated with primary biliary cirrhosis: clinical, laboratory, and neuroradiological features. International Journal of Neuroscience, 2020, , 1-8.	0.8	3
1950	Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642094797.	1.5	8
1951	Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG). Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642094980.	1.5	23
1952	Autoantibodies against central nervous system antigens in a subset of B cellâ€"dominant multiple sclerosis patients. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21512-21518.	3.3	36
1953	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	112
1954	Deep Learning-Based Method to Differentiate Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 599042.	1.1	22
1955	Insights into Cell Surface Expression, Supramolecular Organization, and Functions of Aquaporin 4 Isoforms in Astrocytes. Cells, 2020, 9, 2622.	1.8	25
1956	Antibody Testing in Atypical Optic Neuritis. Seminars in Ophthalmology, 2020, 35, 287-295.	0.8	4
1957	Toxic effects on astrocytes of extracellular vesicles from CSF of multiple sclerosis patients: a pilot in vitro study. Polish Journal of Pathology, 2020, 71, 270-276.	0.1	1
1958	Moving beyond anti-aquaporin-4 antibodies: emerging biomarkers in the spectrum of neuromyelitis optica. Expert Review of Neurotherapeutics, 2020, 20, 601-618.	1.4	7
1959	Serum albumin level is associated with the severity of neurological dysfunction of NMOSD patients. Multiple Sclerosis and Related Disorders, 2020, 43, 102130.	0.9	7
1960	Overlapping syndrome of MOG-IgG-associated disease and autoimmune GFAP astrocytopathy. Journal of Neurology, 2020, 267, 2589-2593.	1.8	25

#	Article	IF	Citations
1961	Perivenous demyelination: Association with antiâ€myelin oligodendrocyte glycoprotein antibody. Clinical and Experimental Neuroimmunology, 2020, 11, 22-27.	0.5	1
1962	Myelin oligodendrocyte glycoprotein immunoglobulinÂGâ€associated disease. Clinical and Experimental Neuroimmunology, 2020, 11, 28-33.	0.5	2
1963	Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Multiple Sclerosis and Related Disorders, 2020, 43, 102175.	0.9	7
1964	Experimental Models of Neuroimmunological Disorders: A Review. Frontiers in Neurology, 2020, 11, 389.	1.1	11
1965	The Potential Immunoregulatory Roles of Vitamin D in Neuromyelitis Optica Spectrum Disorder. Multiple Sclerosis and Related Disorders, 2020, 43, 102156.	0.9	10
1966	Proteomic profiles of major serum proteins in seropositive NMO patients alter after Rituximab treatment. Journal of Proteins and Proteomics, 2020, 11, 93-103.	1.0	2
1967	BÂcells in autoimmune diseases of the central nervous system. Clinical and Experimental Neuroimmunology, 2020, 11, 163-170.	0.5	1
1968	Spinal Cord Involvement in MS and Other Demyelinating Diseases. Biomedicines, 2020, 8, 130.	1.4	9
1969	Radiological characteristics of neuromyelitis optica spectrum disorder in Kuwait. Clinical Neurology and Neurosurgery, 2020, 196, 106047.	0.6	2
1970	Characteristic of gut microbiota in southeastern Chinese patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 44, 102217.	0.9	8
1971	Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2020, 44, 102249.	0.9	20
1972	The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study. Multiple Sclerosis and Related Disorders, 2020, 44, 102265.	0.9	2
1973	A comparative evaluation of different neuromyelitis optica spectrum disorder sets of criteria. European Journal of Neurology, 2020, 27, 2250-2256.	1.7	1
1974	The CSF Levels of Neutrophilâ€Related Chemokines in Patients with Neuromyelitis Optica. Annals of Clinical and Translational Neurology, 2020, 7, 1245-1251.	1.7	11
1975	Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis. BioMed Research International, 2020, 2020, 1-6.	0.9	13
1976	Epidemiology of Pediatric NMOSD in Germany and Austria. Frontiers in Neurology, 2020, 11, 415.	1.1	10
1977	Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside. Neuroscience Bulletin, 2020, 36, 1213-1224.	1.5	7
1978	Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. Journal of Translational Medicine, 2020, 18, 131.	1.8	43

#	Article	IF	Citations
1979	Imaging of Neuromyelitis Optica Spectrum Disorders. Seminars in Ultrasound, CT and MRI, 2020, 41, 319-331.	0.7	2
1980	Indirect Role of AQP4b and AQP4d Isoforms in Dynamics of Astrocyte Volume and Orthogonal Arrays of Particles. Cells, 2020, 9, 735.	1.8	12
1982	Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population. Multiple Sclerosis and Related Disorders, 2020, 42, 102049.	0.9	4
1983	Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis.		

#	Article	IF	Citations
1999	Update on Pediatric Optic Neuritis. Current Neurology and Neuroscience Reports, 2020, 20, 4.	2.0	17
2000	Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Bloodâ€“brain barrier breakdown and peripheral plasmablasts. Multiple Sclerosis and Related Disorders, 2020, 41, 102005.	0.9	19
2001	Differentiate aquaporin-4 antibody negative neuromyelitis optica spectrum disorders from multiple sclerosis by multimodal advanced MRI techniques. Multiple Sclerosis and Related Disorders, 2020, 41, 102035.	0.9	4
2002	Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis. PLoS ONE, 2020, 15, e0229028.	1.1	6
2004	Autoimmune encephalitis management: MS centers and beyond. Multiple Sclerosis Journal, 2020, 26, 1618-1626.	1.4	5
2005	Diseases of the Brain, Head and Neck, Spine 2020â€“2023. IDKD Springer Series, 2020, , .	0.8	17
2006	Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population. Journal of Neurology, 2020, 267, 1197-1205.	1.8	15
2007	Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. Acta Neuropathologica, 2020, 139, 547-564.	3.9	11
2008	Role of Diffusional Kurtosis Imaging in Differentiating Neuromyelitis Opticaâ€“Related and Multiple Sclerosisâ€“Related Acute Optic Neuritis: Comparison With Diffusion-Weighted Imaging. Journal of Computer Assisted Tomography, 2020, 44, 47-52.	0.5	6
2009	Associations between HLA and autoimmune neurological diseases with autoantibodies. Autoimmunity Highlights, 2020, 11, 2.	3.9	63
2010	Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. Frontiers in Neurology, 2019, 10, 1385.	1.1	26
2011	Hyponatremia Associated with Prophylactic Low-Dose Trimethoprim during Systemic Corticosteroid Therapy for AQP4-Positive Optic Neuritis in a Diabetic Patient. Antibiotics, 2020, 9, 201.	1.5	5
2012	Longitudinal ultra-high field MRI of brain lesions in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 42, 102066.	0.9	4
2013	Possible clinical role of MOG antibody testing in children presenting with acute neurological symptoms. Neurological Sciences, 2020, 41, 2553-2559.	0.9	2
2014	Risk factors of attacks in neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2020, 343, 577236.	1.1	24
2015	Astrocytes Are Required for Oligodendrocyte Survival and Maintenance of Myelin Compaction and Integrity. Frontiers in Cellular Neuroscience, 2020, 14, 74.	1.8	37
2016	Diagnostic and therapeutic issues of inflammatory diseases of the elderly. Revue Neurologique, 2020, 176, 739-749.	0.6	3
2017	Different clinical characteristics of longitudinally extensive transverse myelitis with and without connective tissue disorders: a single-center retrospective study. Neurological Sciences, 2020, 41, 2859-2866.	0.9	1

#	Article	IF	Citations
2018	Linking autoantigen properties to mechanisms of immunity. Advanced Drug Delivery Reviews, 2020, 165-166, 105-116.	6.6	4
2019	HLA association in MOG-IgGâ€“ and AQP4-IgGâ€“related disorders of the CNS in the Dutch population. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	41
2020	Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?. Multiple Sclerosis and Related Disorders, 2020, 42, 102082.	0.9	8
2021	Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurology, The, 2020, 19, 391-401.	4.9	183
2022	Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options. Expert Review of Neurotherapeutics, 2020, 20, 509-516.	1.4	12
2023	Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes. Acta Neuropathologica Communications, 2020, 8, 49.	2.4	5
2024	Cortical topological network changes following optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e687.	3.1	8
2025	Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis. PLoS ONE, 2020, 15, e0224419.	1.1	11
2026	So You Want to Image Myelin Using MRI: An Overview and Practical Guide for Myelin Water Imaging. Journal of Magnetic Resonance Imaging, 2021, 53, 360-373.	1.9	60
2027	New therapies for neuromyelitis optica spectrum disorder. Lancet Neurology, The, 2021, 20, 60-67.	4.9	86
2028	Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan. Journal of the Formosan Medical Association, 2021, 120, 542-550.	0.8	7
2029	An update on epidemiology, diagnosis & management of NMO-SD in the tertiary neurology department of Marrakech (Morocco). Revue Neurologique, 2021, 177, 80-84.	0.6	4
2030	Single-cell approaches to investigate B cells and antibodies in autoimmune neurological disorders. Cellular and Molecular Immunology, 2021, 18, 294-306.	4.8	10
2031	Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach. Multiple Sclerosis Journal, 2021, 27, 841-854.	1.4	20
2032	Differential patterns of interhemispheric functional connectivity between AQP4-optic neuritis and MOG-optic neuritis: a resting-state functional MRI study. Acta Radiologica, 2021, 62, 776-783.	0.5	5
2033	Area postrema syndrome as initial manifestation in neuromyelitis optica spectrum disorder patients: A retrospective study. Revue Neurologique, 2021, 177, 400-406.	0.6	10
2034	Acute and subacute myelopathy. Revue Neurologique, 2021, 177, 557-566.	0.6	2
2035	Could Galectin-3 be a key player in the etiology of neuromyelitis optica spectrum disorder?. Medical Hypotheses, 2021, 146, 110450.	0.8	3

#	Article	IF	Citations
2036	Optical Coherence Tomography in Neuromyelitis Optica spectrum disorder and Multiple Sclerosis: A population-based study. Multiple Sclerosis and Related Disorders, 2021, 47, 102625.	0.9	11
2037	CD8 + T cell subpopulations and proâ€inflammatory cytokines in neuromyelitis optica spectrum disorder. Annals of Clinical and Translational Neurology, 2021, 8, 43-53.	1.7	15
2038	Cerebrospinal fluid lactate level in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders: a hint on differential diagnosis and possible immunopathogenesis. Multiple Sclerosis and Related Disorders, 2021, 47, 102629.	0.9	0
2039	Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	26
2040	Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders. BioDrugs, 2021, 35, 7-17.	2.2	11
2041	Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis â€“ A prospective study from Northwest India. Journal of Neuroimmunology, 2021, 351, 577456.	1.1	2
2042	Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study. Multiple Sclerosis and Related Disorders, 2021, 47, 102652.	0.9	7
2043	Frequency of comorbidities in Neuromyelitis Optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2021, 48, 102685.	0.9	10
2044	B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nature Reviews Drug Discovery, 2021, 20, 179-199.	21.5	296
2045	Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye, 2021, 35, 753-768.	1.1	35
2046	A bright spinal cord. Revue Neurologique, 2021, 177, 154-156.	0.6	0
2048	Use of therapeutic plasma exchange for pediatric neurological diseases. Journal of Clinical Apheresis, 2021, 36, 161-176.	0.7	2
2049	Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. Journal of Neurology, 2021, 268, 1643-1664.	1.8	18
2050	COVID-19 and Autoimmune Demyelinating Diseases. , 2021, , 87-107.		0
2052	Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study. BMC Neurology, 2021, 21, 35.	0.8	4
2053	Neuromyelitis optica spectrum disorder in Asia: Epidemiology and risk factors. Neurology and Clinical Neuroscience, 2021, 9, 274-281.	0.2	5
2056	Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial. Neurotherapeutics, 2021, 18, 868-877.	2.1	6
2057	Spinal Cord Compression and Myelopathies. , 2021, , 251-278.		0

#	Article	IF	Citations
2059	Reflections from a NMOSD case with serum AQP4-Ab negativity but CSF positivity: narrative review of how to interpret AQP4-Ab test results. Annals of Translational Medicine, 2021, .	0.7	0
2060	Management of pediatric post-infectious neurological syndromes. Italian Journal of Pediatrics, 2021, 47, 17.	1.0	8
2061	Atypical optic neuritis: An overview. Indian Journal of Ophthalmology, 2021, 69, 27.	0.5	10
2062	Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein <scp>IgG</scp> associated disorder: A comprehensive neuroâ€ophthalmic review. Clinical and Experimental Ophthalmology, 2021, 49, 186-202.	1.3	9
2063	Strategies to Aid Identification of Apheresis PowerFlow Ports: A Case Report. Journal of Emergency Nursing, 2021, 47, 21-27.	0.5	4
2065	Neuromyelitis optica spectrum disorder: What it is and how it relates to Zika virus. , 2021, , 255-265.		0
2066	Impact of comorbid SjÃ¶gren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. Journal of Neurology, 2021, 268, 1938-1944.	1.8	24
2067	Approach to optic neuritis: An update. Indian Journal of Ophthalmology, 2021, 69, 2266.	0.5	14
2068	B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders. Pharmaceuticals, 2021, 14, 37.	1.7	6
2070	Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singaporeâ€"Epidemiology and evolution of an emerging subspecialty. Neurology and Clinical Neuroscience, 2021, 9, 259-265.	0.2	7
2071	Neuromyelitis optica with rapid respiratory failure: a case report. Acute Medicine & Surgery, 2021, 8, e655.	0.5	3
2072	Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibodyâ€associated disease. Clinical and Translational Immunology, 2021, 10, e1316.	1.7	31
2073	The changing landscape of optic neuritis: a narrative review. Journal of Neurology, 2022, 269, 111-124.	1.8	28
2074	Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurological Sciences, 2021, 42, 3857-3863.	0.9	10
2075	The Emerging Role of Microglia in Neuromyelitis Optica. Frontiers in Immunology, 2021, 12, 616301.	2.2	13
2076	Optic neuritis after ocular trauma in antiâ€aquaporinâ€4 antibodyâ€positive neuromyelitis optica spectrum disorder. Brain and Behavior, 2021, 11, e02083.	1.0	2
2077	Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2021, 48, 102707.	0.9	5
2078	Early Treatment Initiation With Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4â€"Positive Neuromyelitis optica Spectrum Disorder. Frontiers in Neurology, 2021, 12, 608149.	1.1	2

#	Article	IF	Citations
2079	The Role of the IL-33/ST2 Immune Pathway in Autoimmunity: New Insights and Perspectives. Immunological Investigations, 2022, 51, 1060-1086.	1.0	8
2080	Behaviorally consequential astrocytic regulation of neural circuits. Neuron, 2021, 109, 576-596.	3.8	150
2081	Clinical and Prognostic Analysis of Autoantibody-Associated CNS Demyelinating Disorders in Children in Southwest China. Frontiers in Neurology, 2021, 12, 642664.	1.1	6
2082	Serum Biomarkers in Neuro-Ophthalmology: When to Test. Seminars in Ophthalmology, 2021, 36, 322-328.	0.8	1
2083	Foveal changes in aquaporinâ€4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive. European Journal of Neurology, 2021, 28, 2280-2293.	1.7	14
2084	Myelin oligodendrocyte glycoprotein antibody-associated disorders: clinical spectrum, diagnostic evaluation, and treatment options. Clinical and Experimental Pediatrics, 2021, 64, 103-110.	0.9	2
2085	Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Frontiers in Immunology, 2021, 12, 647618.	2.2	32
2088	Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments. Current Pharmaceutical Design, 2022, 28, 272-279.	0.9	3
2089	Neuromyelitis Optica Spectrum Disorder Treatmentâ€"Current and Future Prospects. International Journal of Molecular Sciences, 2021, 22, 2801.	1.8	13
2090	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Annals of Neurology, 2021, 89, 895-910.	2.8	72
2091	The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica. Basic and Clinical Neuroscience, 2021, 12, 199-204.	0.3	1
2093	Investigation of serum biomarkers for neuropathic pain in neuromyelitis optica spectrum disorder: a preliminary study. Annals of Clinical Neurophysiology, 2021, 23, 46-52.	0.1	1
2094	Myelin Oligodendrocyte Glycoprotein Antibodyâ€"Associated Optic Neuritisâ€"A Review. Journal of Neuro-Ophthalmology, 2021, Publish Ahead of Print, e786-e795.	0.4	0
2095	Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders. Journal of Neuroimmunology, 2021, 353, 577494.	1.1	8
2096	Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Multiple Sclerosis and Related Disorders, 2021, 49, 102750.	0.9	20
2097	Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist. Current Rheumatology Reports, 2021, 23, 33.	2.1	16
2098	Comparison of Optic Neuritis with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody and Seropositive Neuromyelitis Optica Antibody. Journal of Korean Ophthalmological Society, 2021, 62, 538-544.	0.0	3
2099	Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder. Frontiers in Immunology, 2021, 12, 660382.	2.2	7

#	Article	IF	Citations
2101	What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM). Multiple Sclerosis and Related Disorders, 2021, 49, 102742.	0.9	15
2102	Effect of inosine monophosphate dehydrogenase-1 gene polymorphisms on mycophenolate mofetil effectiveness in neuromyelitis optica spectrum disorder patients. Multiple Sclerosis and Related Disorders, 2021, 49, 102779.	0.9	0
2103	Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics. Neurotherapeutics, 2021, 18, 1623-1636.	2.1	2
2104	The possible role of Interleukin-6 as a regulator of insulin sensitivity in patients with neuromyelitis optica spectrum disorder. BMC Neurology, 2021, 21, 167.	0.8	7
2105	Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis. Journal of Neurology, 2022, 269, 269-279.	1.8	3
2106	Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis. Frontiers in Neurology, 2021, 12, 637932.	1.1	3
2107	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neuroinflammation, 2021, 18, 105.	3.1	44
2108	Very late onset neuromyelitis optica spectrum disorders. European Journal of Neurology, 2021, 28, 2574-2581.	1.7	8
2109	Current understanding of the epidemiologic and clinical characteristics of optic neuritis. Japanese Journal of Ophthalmology, 2021, 65, 439-447.	0.9	5
2110	Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. Acta Neurologica Belgica, 2022, 122, 135-144.	0.5	11
2111	The prevalence of antiâ€neurofascinâ€155 antibodies in patients with neuromyelitis optica spectrum disorders. Clinical and Experimental Immunology, 2021, 206, 1-11.	1.1	5
2113	Comparison of the retinal vascular network and structure in patients with optic neuritis associated with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies: an optical coherence tomography angiography study. Journal of Neurology, 2021, 268, 4874-4881.	1.8	4
2114	Clinical failure of natalizumab in multiple sclerosis: Specific causes and strategy. Revue Neurologique, 2021, 177, 1241-1249.	0.6	2
2115	Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS). Multiple Sclerosis International, 2021, 2021, 1-7.	0.4	1
2116	Rehabilitation and pharmacotherapy of neuromyelitis optica spectrum disorder: A case report. World Journal of Clinical Cases, 2021, 9, 3951-3959.	0.3	1
2117	Impaired Meningeal Lymphatic Flow in NMOSD Patients With Acute Attack. Frontiers in Immunology, 2021, 12, 692051.	2.2	6
2118	Analysis of site-specific glycan profiles of serum proteins in patients with multiple sclerosis or neuromyelitis optica spectrum disorderâ€"a pilot study. Glycobiology, 2021, 31, 1230-1238.	1.3	2
2119	An Experimental Model of Neuromyelitis Optica Spectrum Disorderâ€"Optic Neuritis: Insights Into Disease Mechanisms. Frontiers in Neurology, 2021, 12, 703249.	1.1	6

#	Article	IF	Citations
2120	Serum neurofilament light chain and glial fibrillary acidic protein in AQP4â€IgGâ€seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. Journal of Neurochemistry, 2021, 159, 913-922.	2.1	11
2121	Cladribine suppresses disease activity in neuromyelitis optica spectrum disorder: a 2â€year followâ€up study. European Journal of Neurology, 2021, 28, 3167-3172.	1.7	1
2122	Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD. International Journal of Molecular Sciences, 2021, 22, 7925.	1.8	4
2123	Role of microbiota-derived short-chain fatty acids in nervous system disorders. Biomedicine and Pharmacotherapy, 2021, 139, 111661.	2.5	106
2124	Comparison of Visual Evoked Potentials in Patients Affected by Optic Neuritis From Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder. Journal of Neuro-Ophthalmology, 2021, Publish Ahead of Print, .	0.4	1
2125	Epstein-Barr virus infection in a woman with aquaporin-4 seropositive neuromyelitis optica. Journal of Neuroimmunology, 2021, 356, 577581.	1.1	2
2126	Serum Peptide Immunoglobulin G Autoantibody Response in Patients with Different Central Nervous System Inflammatory Demyelinating Disorders. Diagnostics, 2021, 11, 1339.	1.3	4
2127	NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. Journal of Neurology, 2022, 269, 836-845.	1.8	5
2128	Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases. European Journal of Human Genetics, 2021, 29, 1485-1490.	1.4	42
2129	Neuromyelitis optica spectrum disorder in Africa: What is the current state of knowledge?. Clinical Neurology and Neurosurgery, 2021, 206, 106709.	0.6	0
2130	Magnetic resonance imaging in neuromyelitis optica spectrum disorder. Clinical and Experimental Immunology, 2021, 206, 251-265.	1.1	14
2131	Aquaporin-4 Removal from the Plasma Membrane of Human MÃ¼ller Cells by AQP4-IgG from Patients with Neuromyelitis Optica Induces Changes in Cell Volume Homeostasis: the First Step of Retinal Injury?. Molecular Neurobiology, 2021, 58, 5178-5193.	1.9	8
2132	Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 20552173211032334.	0.5	4
2133	Bruch Membrane Opening Minimum Rim Width in Neuromyelitis Optica. Journal of Neuro-Ophthalmology, 2021, Publish Ahead of Print, .	0.4	1
2134	Visual outcome of aquaporin-4 antibody-positive optic neuritis with maintenance therapy. Japanese Journal of Ophthalmology, 2021, 65, 699-703.	0.9	0
2135	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology, 2021, 97, e1097-e1109.	1.5	77
2136	Bilateral optic neuritis in a 15-month-old girl from neuromyelitis optica spectrum disorder: The youngest reported case in the literature. Multiple Sclerosis and Related Disorders, 2021, 52, 102961.	0.9	1
2137	The Glymphatic System (En)during Inflammation. International Journal of Molecular Sciences, 2021, 22, 7491.	1.8	70

#	Article	IF	Citations
2138	Optic neuritis classification in 2021. European Journal of Ophthalmology, 2022, 32, 754-766.	0.7	7
2139	Variation in Evolving Optic Neuritis. Journal of Neuro-Ophthalmology, 2021, Publish Ahead of Print, 476-479.	0.4	1
2140	Elderly onset neuromyelitis optica spectrum disorder: a case report. Journal of Neurology, 2021, 268, 4897-4898.	1.8	2
2141	Sleep Quality in Neuromyelitis Optica Spectrum Disorder: A Systematic Review. International Journal of MS Care, 2022, 24, 124-131.	0.4	1
2142	Th17-Related Cytokines as Potential Discriminatory Markers between Neuromyelitis Optica (Devicâ€™s) Tj ETQq0 0 0 rgBT /Overlock 10	1.8	16
2143	Associations of IRAK1 Gene Polymorphisms and mRNA Expression With NMOSD Risk in the Northern Chinese Han Population. Frontiers in Neurology, 2021, 12, 661791.	1.1	1
2144	Treatment of Neuromyelitis Optica Spectrum Disorders. International Journal of Molecular Sciences, 2021, 22, 8638.	1.8	29
2145	Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges. Autoimmunity Reviews, 2022, 21, 102921.	2.5	7
2146	Antiâ€aquaporinâ€4 positiveâ€toâ€negative seroconversion in Latin American patients with neuromyelitis optica spectrum disorder treated with rituximab. Clinical and Experimental Neuroimmunology, 2021, 12, 248-252.	0.5	0
2147	Relapsing neuromyelitis optica in an adolescent girl. BMJ Case Reports, 2021, 14, e242402.	0.2	0
2148	Type I interferon detection in autoimmune diseases: challenges and clinical applications. Expert Review of Clinical Immunology, 2021, 17, 883-903.	1.3	6
2149	Evaluation of Thiol Homeostasis in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology, 2021, 12, 716195.	1.1	7
2150	Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2021, 54, 103118.	0.9	5
2151	Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Current Pharmaceutical Design, 2022, 28, 428-436.	0.9	10
2152	Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 101-111.	0.9	16
2153	Physical, Emotional, Medical, and Socioeconomic Status of Patients With NMOSD: A Cross-Sectional Survey of 123 Cases From a Single Center in North China. Frontiers in Neurology, 2021, 12, 737564.	1.1	3
2155	AQP4â€IgG positive paraneoplastic NMOSD: A case report and review. Brain and Behavior, 2021, 11, e2282.	1.0	9
2156	A preliminary study of association of cigarette smoking with risk of neuromyelitis optica spectrum disorder. Medicine (United States), 2021, 100, e27234.	0.4	2

#	Article	IF	Citations
2157	Chronic Relapsing Inflammatory Optic Neuropathy (CRION). Current Opinion in Ophthalmology, 2021, Publish Ahead of Print, 521-526.	1.3	4
2158	Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. Journal of Neuroinflammation, 2021, 18, 208.	3.1	105
2159	Simultaneous new onset of neuromyelitis optica spectrum disorder in identical twins. BMJ Neurology Open, 2021, 3, e000174.	0.7	1
2160	Excess weight, central adiposity and pro-inflammatory diet consumption in patients with neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2021, 54, 103110.	0.9	7
2161	Superficial Macula Capillary Complexity Changes Are Associated With Disability in Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology, 2021, 12, 724946.	1.1	8
2162	Association of Circulating T Follicular Helper Cells With Idiopathic Optic Neuritis and Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology, 2021, 12, 638473.	1.1	2
2163	Aquaporin-4 Autoantibody Detection by ELISA: A Retrospective Characterization of a Commonly Used Assay. Multiple Sclerosis International, 2021, 2021, 1-6.	0.4	5
2164	Regulatory T cells protect against brain damage by alleviating inflammatory response in neuromyelitis optica spectrum disorder. Journal of Neuroinflammation, 2021, 18, 201.	3.1	19
2165	Psychiatric symptoms as initial manifestation in neuromyelitis optica spectrum disorder without cortical lesions: A report of two cases. Journal of Neuroimmunology, 2021, 359, 577693.	1.1	2
2166	Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis. Multiple Sclerosis and Related Disorders, 2021, 55, 103181.	0.9	15
2167	Are Zika virus cross-reactive antibodies against aquaporin-4 associated to Neuromyelitis Optica Spectrum Disorder?. Journal of Neuroimmunology, 2021, 360, 577697.	1.1	1
2168	Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay. Journal of Neuroimmunology, 2021, 360, 577706.	1.1	7
2169	The role of AQP4 in the pathogenesis of depression, and possible related mechanisms. Brain, Behavior, and Immunity, 2021, 98, 366-377.	2.0	6
2170	Optic neuritis in Asian type opticospinal multiple sclerosis (OSMS-ON) in a non-Asian population: A functional-structural paradox. Multiple Sclerosis and Related Disorders, 2021, 56, 103260.	0.9	2
2171	Pathogenic antibodies to AQP4: Neuromyelitis optica spectrum disorder (NMOSD). Biochimica Et Biophysica Acta - Biomembranes, 2021, 1863, 183772.	1.4	6
2172	Pruritus as an initial symptom of neuromyelitis optica spectrum disorder. A peruvian case report. Neuroimmunology Reports, 2021, 1, 100021.	0.2	0
2175	Neuromyelitis optica, aquaporin-4 antibodies, and neuroendocrine disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 181, 173-186.	1.0	4
2176	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study. NeuroImage: Clinical, 2021, 30, 102608.	1.4	9

#	Article	IF	Citations
2177	Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis. Scientific Reports, 2021, 11, 152.	1.6	18
2178	The Genetics of Multiple Sclerosis. Results and Problems in Cell Differentiation, 2009, 51, 1-19.	0.2	4
2179	Acute, Chronic, and Nonclassical Neuroinflammation: Definitions in a Changing Scientific Environment. Advances in Neurobiology, 2013, , 1-20.	1.3	1
2180	Neuroinflammation in Neurological Disorders. Advances in Neurobiology, 2013, , 21-48.	1.3	2
2181	Demyelinating Diseases of the CNS (Brain and Spine). IDKD Springer Series, 2020, , 165-176.	0.8	7
2182	Topological Aspects of the Bloodâ€“Brain and Bloodâ€“Cerebrospinal Fluid Barriers and Their Relevance in Inflammation. , 2017, , 23-48.		11
2183	Neuromyelitis Optica: Clinical Syndrome and the NMO-IgG Autoantibody Marker. Current Topics in Microbiology and Immunology, 2008, 318, 343-356.	0.7	38
2184	Pathological Heterogeneity of Idiopathic Central Nervous System Inflammatory Demyelinating Disorders. Current Topics in Microbiology and Immunology, 2008, 318, 19-43.	0.7	15
2185	Remyelination-Promoting Human IgMs: Developing a Therapeutic Reagent for Demyelinating Disease. Current Topics in Microbiology and Immunology, 2008, 318, 213-239.	0.7	15
2186	EntzÃ¼ndliche Erkrankungen. , 2019, , 51-98.		2
2187	Urea Transport Mediated by Aquaporin Water Channel Proteins. Sub-Cellular Biochemistry, 2014, 73, 227-265.	1.0	18
2188	A patient with neuromyelitis optica with positive anti-Ro (SS-A) antibody presenting with intractable hiccup and nausea. Modern Rheumatology, 2011, 21, 561-562.	0.9	3
2189	Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. Modern Rheumatology, 2012, 22, 676-684.	0.9	7
2190	Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Modern Rheumatology, 2013, 23, 827-831.	0.9	64
2192	Anatomy, Imaging, and Pathology of the Visual Pathways. , 2011, , 855-924.		1
2194	Visual loss. , 2010, , 103-198.		11
2195	Clinically Isolated Syndromes. Blue Books of Neurology, 2010, , 206-218.	0.1	1
2196	The HLA DRB1*03:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro. Journal of Neuroimmunology, 2017, 310, 1-7.	1.1	22

#	Article	IF	Citations
2197	Maladie deÂDevic. Presse Medicale, 2006, 35, 1701-1704.	0.8	1
2198	Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 42, 102109.	0.9	8
2199	Autoantibody-mediated diseases of the CNS: Structure, dysfunction and therapy. Neuropharmacology, 2018, 132, 71-82.	2.0	48
2200	Devic's disease and autoantibodies. Lancet Neurology, The, 2005, 4, 136-137.	4.9	11
2202	Revised diagnostic criteria for neuromyelitis opticaâ€"incorporation of NMO-IgG status. Nature Clinical Practice Neurology, 2007, 3, E1-E1.	2.7	15
2203	Alterations in the Retinal Vascular Network and Structure in MOG Antibody-Associated Disease: An Optical Coherence Tomography Angiography Study. Journal of Neuro-Ophthalmology, 2021, 41, e424-e432.	0.4	8
2204	Syndrome of inappropriate antidiuretic hormone accompanied by bilateral hypothalamic and anterior thalamic lesions with serum antiaquaporin 4 antibody. BMJ Case Reports, 2017, 2017, bcr-2017-219721.	0.2	8
2205	Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. Journal of Clinical Investigation, 2020, 130, 4025-4038.	3.9	66
2206	Microglia complement astrocytes in neuromyelitis optica. Journal of Clinical Investigation, 2020, 130, 3961-3964.	3.9	7
2207	Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. Journal of Clinical Investigation, 2006, 116, 2385-2392.	3.9	283
2208	Myelin oligodendrocyte glycoproteinâ€"specific T and B cells cooperate to induce a Devic-like disease in mice. Journal of Clinical Investigation, 2006, 116, 2393-2402.	3.9	282
2209	Viruses and Multiple Sclerosis. Neuroscientist, 2011, 17, 659-676.	2.6	53
2210	Lack of astrocytes hinders parenchymal oligodendrocyte precursor cells from reaching a myelinating state in osmolyte-induced demyelination. Acta Neuropathologica Communications, 2020, 8, 224.	2.4	14
2211	Demyelinating diseases. , 2008, , 1513-1608.		9
2212	Neuromyelitis Optica Spectrum Disorder and Other Nonâ€"Multiple Sclerosis Central Nervous System Inflammatory Diseases. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 815-844.	0.4	40
2213	Alteration of Circadian Rhythms in 2D2 Transgenic Mice. Medical Science Monitor, 2018, 24, 8272-8278.	0.5	2
2214	Distribution of Aquaporins 1 and 4 in the Central Nervous System. Current Health Sciences Journal, 2019, 45, 218-226.	0.2	5
2215	Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica. PLoS Medicine, 2007, 4, e133.	3.9	187

#	Article	IF	Citations
2216	Patterns of Antibody Binding to Aquaporin-4 Isoforms in Neuromyelitis Optica. PLoS ONE, 2010, 5, e10455.	1.1	137
2217	Immunodominant T Cell Determinants of Aquaporin-4, the Autoantigen Associated with Neuromyelitis Optica. PLoS ONE, 2010, 5, e15050.	1.1	42
2218	White Matter Atrophy and Cognitive Dysfunctions in Neuromyelitis Optica. PLoS ONE, 2012, 7, e33878.	1.1	85
2219	Autoantibodies Produced at the Site of Tissue Damage Provide Evidence of Humoral Autoimmunity in Inclusion Body Myositis. PLoS ONE, 2012, 7, e46709.	1.1	23
2220	Genetic and Infectious Profiles of Japanese Multiple Sclerosis Patients. PLoS ONE, 2012, 7, e48592.	1.1	65
2221	Retinal Glycoprotein Enrichment by Concanavalin A Enabled Identification of Novel Membrane Autoantigen Synaptotagmin-1 in Equine Recurrent Uveitis. PLoS ONE, 2012, 7, e50929.	1.1	12
2222	Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients. PLoS ONE, 2013, 8, e55843.	1.1	83
2223	Brain Tissue Volumes and Perfusion Change with the Number of Optic Neuritis Attacks in Relapsing Neuromyelitis Optica: A Voxel-Based Correlation Study. PLoS ONE, 2013, 8, e66271.	1.1	20
2224	Connexin 43 Astrocytopathy Linked to Rapidly Progressive Multiple Sclerosis and Neuromyelitis Optica. PLoS ONE, 2013, 8, e72919.	1.1	89
2225	Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis. PLoS ONE, 2015, 10, e0137715.	1.1	47
2226	Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord. PLoS ONE, 2016, 11, e0151244.	1.1	15
2227	A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCR. PLoS ONE, 2016, 11, e0152720.	1.1	7
2228	Structural Alterations of Segmented Macular Inner Layers in Aquaporin4-Antibody-Positive Optic Neuritis Patients in a Chinese Population. PLoS ONE, 2016, 11, e0157645.	1.1	16
2229	Accuracy of the Fluorescence-Activated Cell Sorting Assay for the Aquaporin-4 Antibody (AQP4-Ab): Comparison with the Commercial AQP4-Ab Assay Kit. PLoS ONE, 2016, 11, e0162900.	1.1	12
2230	Disease Type- and Status-Specific Alteration of CSF Metabolome Coordinated with Clinical Parameters in Inflammatory Demyelinating Diseases of CNS. PLoS ONE, 2016, 11, e0166277.	1.1	24
2231	Impact of the anti-aquaporin-4 autoantibody on inner retinal structure, function and structure-function associations in Japanese patients with optic neuritis. PLoS ONE, 2017, 12, e0171880.	1.1	8
2232	Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance. PLoS ONE, 2017, 12, e0181758.	1.1	50
2233	Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach. Arquivos De Neuro-Psiquiatria, 2020, 78, 430-439.	0.3	7

#	Article	IF	Citations
2238	â€œA rose by any other nameâ€¦ does defining extreme phenotypes add to the management of multiple sclerosis?. Annals of Translational Medicine, 2018, 6, 396-396.	0.7	1
2239	Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy. Current Neuropharmacology, 2020, 19, 220-232.	1.4	24
2240	Acute demyelinating optic neuritis: a review. Frontiers in Bioscience - Landmark, 2008, 13, 2376.	3.0	13
2241	Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. Autoimmunity, 2015, 48, 453-9.	1.2	6
2242	Autoimmune thyroiditis associated with neuromyelitis optica (NMO). GMS German Medical Science, 2015, 13, Doc22.	2.7	2
2243	Brain Lipid Binding Protein (FABP7) as Modulator of Astrocyte Function. Physiological Research, 2011, 60, S49-S60.	0.4	31
2246	Autoimmune channelopathies: new antibody-mediated disorders of the central nervous system. F1000 Biology Reports, 2009, 1, 61.	4.0	10
2247	Identification of geraldol as an inhibitor of aquaporinâ€‘4 binding by NMOâ€‘IgG. Molecular Medicine Reports, 2020, 22, 1111-1118.	1.1	4
2248	Optical Coherence Tomography in the Diagnosis and Management of Optic Neuritis and Multiple Sclerosis. Ophthalmic Surgery Lasers and Imaging Retina, 2011, 42, S28-40.	0.4	24
2249	A Case of Systemic Lupus Erythematous Associated with Neuromyelitis Optica (Devic's Syndrome). The Journal of the Korean Rheumatism Association, 2007, 14, 263.	0.1	3
2250	Multiple sclerosis in India: An overview. Annals of Indian Academy of Neurology, 2015, 18, 2.	0.2	15
2251	Neuromyelitis optica spectrum disorders: An update. Annals of Indian Academy of Neurology, 2015, 18, 11.	0.2	20
2252	Therapy of NMO spectrum disorders. Annals of Indian Academy of Neurology, 2015, 18, 16.	0.2	11
2253	Multisystem involvement in neuromyelitis optica. Annals of Indian Academy of Neurology, 2015, 18, 56.	0.2	10
2254	Serological markers associated with neuromyelitis optica spectrum disorders in South India. Annals of Indian Academy of Neurology, 2016, 19, 505.	0.2	24
2255	Differential diagnosis of white matter diseases in the tropics: An overview. Annals of Indian Academy of Neurology, 2009, 12, 12-21.	0.2	17
2256	Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy. Neural Regeneration Research, 2015, 10, 1507.	1.6	41
2257	Association of GTF2IRD1â€“GTF2I polymorphisms with neuromyelitis optica spectrum disorders in Han Chinese patients. Neural Regeneration Research, 2019, 14, 346.	1.6	6

#	Article	IF	Citations
2258	Diagnostic modalities in multiple sclerosis: Perspectives in children. Biomedical Journal, 2014, 37, 50.	1.4	11
2259	Human leukocyte antigens-immunogenetics of neuromyelitis optica or Devicâ€²s disease and the impact on the immunopathogenesis, diagnosis and treatment: a critical review. Neuroimmunology and Neuroinflammation, 2014, 1, 44.	1.4	6
2260	Evolving landscape of multiple sclerosis in India: Challenges in the management. Annals of Indian Academy of Neurology, 2018, 21, 107.	0.2	4
2261	Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica. Asian Journal of Transfusion Science, 2017, 11, 102.	0.1	12
2262	Association between sun exposure, Vitamin D intake, serum Vitamin D level, and immunoglobulin G level in patients with neuromyelitis optica spectrum disorder. International Journal of Preventive Medicine, 2018, 9, 68.	0.2	8
2263	Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico. , 2018, 9, 242.		16
2264	Seropositive Neuromyelitis Optica imitating an Intramedullary Cervical Spinal Cord Tumor: Case Report and Brief Review of the Literature. Asian Spine Journal, 2014, 8, 684.	0.8	5
2265	NÃ¶ro-BehÃ§et HastalarÄ±nÄ±n SerumlarÄ±nda Beyin Dokusu ve Beyin DamarlarÄ±na KarÅŸÄ± Otoantikor VarlÄ±ÄŸÄ±. Noropsikiyatri Arsivi, 2014, 51, 141-147.	0.7	2
2266	Neuritis Ã³ptica inflamatoria. Anales Del Sistema Sanitario De Navarra, 2009, 32, .	0.2	7
2267	Perspectives on cytokine-directed therapies in multiple sclerosis. Swiss Medical Weekly, 2015, 145, w14199.	0.8	10
2268	Specificity of Lower Urinary Tract Symptoms in Neuromyelitis Optica in Comparison With Multiple Sclerosis Patients. International Neurourology Journal, 2018, 22, 185-191.	0.5	5
2269	Rituximab in neuromyelitis optica: A review of literature. World Journal of Neurology, 2015, 5, 39.	0.6	9
2270	Development of Paraneoplastic Neuromyelitis Optica after Lung Resection in a Patient with Squamous Cell Carcinoma. Annals of Thoracic and Cardiovascular Surgery, 2023, 29, 49-52.	0.3	2
2271	Utility of Live Cell-Based Assays for Autoimmune Neurology Diagnostics. journal of applied laboratory medicine, The, 2022, 7, 391-393.	0.6	4
2272	Identification of the clinical and neuroimaging characteristics in children with neuromyelitis optica spectrum disorders: a case series. Translational Pediatrics, 2021, 10, 2459-2466.	0.5	5
2273	Dynamics of AQP4 upon exposure to seropositive patient serum before and after Rituximab therapy in Neuromyelitis Optica: A cell-based study. Journal of Neuroimmunology, 2021, 361, 577752.	1.1	1
2274	Next Generation Sequencing of Cerebrospinal Fluid B Cell Repertoires in Multiple Sclerosis and Other Neuro-Inflammatory Diseasesâ€”A Comprehensive Review. Diagnostics, 2021, 11, 1871.	1.3	2
2276	Consensus of expert advices on routing, diagnosis, and management of patients with neuromyelitis optica spectrum disorders. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2021, 13, 140-147.	0.2	1

#	Article	IF	Citations
2277	Group 2 innate lymphoid cells suppress the pathology of neuromyelitis optica spectrum disorder. FASEB Journal, 2021, 35, e21856.	0.2	3
2278	Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan. Frontiers in Neurology, 2021, 12, 749406.	1.1	2
2279	Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies. Multiple Sclerosis and Related Disorders, 2022, 57, 103332.	0.9	7
2280	Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Multiple Sclerosis and Related Disorders, 2022, 57, 103352.	0.9	19
2281	Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice. Frontiers in Immunology, 2021, 12, 727750.	2.2	1
2282	An uncommon cause of vertigo: Neuromyelitis optica spectrum disorder. Ear, Nose and Throat Journal, 2021, , 014556132110533.	0.4	0
2283	Monocyte to High-Density Lipoprotein Ratio: A Novel Predictive Marker of Disease Severity and Prognosis in Patients With Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology, 2021, 12, 763793.	1.1	3
2284	Uncommon inflammatory/immune-related myelopathies. Journal of Neuroimmunology, 2021, 361, 577750.	1.1	4
2286	Multiple Sklerose und verwandte Krankheitsbilder. , 2005, , 449-464.		1
2287	ZNS und Nervensystem. , 2005, , 277-302.		0
2288	Cameos. , 2006, , 995-1008.		0
2290	Neuromyelitis Optica IgG Predicts Relapse after Longitudinally Extensive Transverse Myelitis. Yearbook of Neurology and Neurosurgery, 2007, 2007, 89-91.	0.0	0
2292	PRIMARY MYELOPATHIES (DEGENERATIVE, INFECTIVE, METABOLIC). , 2007, , 507-510.		0
2293	Neuromylelitis Optica (Devic Syndrome). , 2008, , 433-434.		0
2295	Neuroimmunology. , 2008, , 807-829.		1
2296	PARAINFECTIOUS AND POSTINFECTIOUS DISORDERS OF THE NERVOUS SYSTEM. , 2009, , 519-547.		0
2298	ZNS und Nervensystem. , 2009, , 321-349.		0
2299	Aquaporins in the Brain. , 2009, , 391-404.		0

#	Article	IF	Citations
2301	Optic magnetic resonance imaging findings in 41 patients with neuromyelitis optica. Academic Journal of Second Military Medical University, 2009, 29, 921-925.	0.0	1
2302	Acute Disseminated Encephalomyelitis. Blue Books of Neurology, 2010, 35, 219-236.	0.1	0
2305	Knowledge of Neuromyelitis Optica for Spinal Surgeon. Spinal Surgery, 2011, 25, 114-118.	0.0	0
2307	Future Perspectives of Neuroimmunological Disease Research. Trends in the Sciences, 2011, 16, 66-72.	0.0	0
2308	Secondary Narcolepsy. , 2011, , 321-339.		0
2309	Immunoabsorption plasma pheresis (IAPP) therapy for neuromyelitis optica (NMO) spectrum disorders in two cases. Nihon Toseki Igakkai Zasshi, 2011, 44, 969-975.	0.2	0
2311	Relevance of Autoantibodies for the Classification and Pathogenesis of Neurological Diseases. , 0, , .		0
2312	Multiple Sklerose und verwandte Erkrankungen. , 2012, , 353-363.		0
2315	Parainfectious and Autoimmune Disorders. , 2012, , 3543-3554.		0
2316	Neuroimmunology. , 2012, , 735-755.		0
2317	Therapeutic apheresis for neuromyelitis optica and neuromyelitis optica spectrum disorders. Nihon Toseki Igakkai Zasshi, 2012, 45, 413-419.	0.2	2
2320	Sudden death of neuromyelitis optica: A case report of clinical missed diagnosis. Romanian Journal of Legal Medicine, 2012, 20, 247-250.	0.3	1
2324	Mechanisms of Disease Progression. , 2013, , 71-92.		0
2325	Neuromyelitis optica: a challenging diagnosis at secondary hospital. Autopsy and Case Reports, 2013, 3, 53-61.	0.2	0
2326	Mitochondrial Genome Profile in Demyelinating Diseases. Journal of Neurology & Neurophysiology, 2013, 05, .	0.1	0
2328	Other optic neuropathies in childhood. , 2013, , 571-578.		0
2330	Magnetic Resonance Imaging Features of Neuromyelitis Optica. Journal of the Korean Society of Radiology, 2013, 68, 375.	0.1	0
2331	A Patient with NMO and Ulcerative Colitis: Is it only Autoimmunity?. Journal of Clinical Case Reports, 2013, 03, .	0.0	0

#	Article	IF	Citations
2332	NÃ–RO-BEHÃ‡ET HASTALARININ SERUMLARINDA BEYÄ°N DOKUSU VE BEYÄ°N DAMARLARINA KARÅžI OTOANTÄ°KOR VARLIÄžI. Noropsikiyatri Arsivi, 0, , .	0.7	0
2333	Therapeutical Apheresis in Central Nervous System Diseases. Giornale De Techniche Nefrologiche & Dialitiche, 2013, 25, 13-16.	0.1	0
2334	A Chinese Lady with Combine Neuromyelitis Optica and SjÃ¶gren's Syndrome: A Case Report. Journal of Neurophysiology and Neurological Disorders, 2013, , .	0.0	0
2336	Neuromyelitis Optica Spectrum Disorder as a Para-neoplastic Disorder in a Patient with Metastatic Breast Cancer. SOJ Neurology, 2014, 1, .	0.1	1
2337	Immune System, Adaptive; Overview. , 2014, , 669-674.		0
2339	Efficacy of Plasma Exchange Therapy for Steroid-Unresponsive Neuromyelitis Optica. Journal of Korean Ophthalmological Society, 2014, 55, 465.	0.0	1
2340	The Physiological Functions of Aquaporins. Biophysics, 2014, 02, 19-32.	0.2	1
2342	Aquaporin in Optic Neuropathies. , 2014, , 161-173.		0
2343	Experimental Models of Superantigen-Mediated Neuropathology. , 0, , 169-182.		1
2345	Longitudinal Ekstensif Transvers Miyelit: Olgu Sunumu. Sisli Etfal Hastanesi Tip Bulteni, 2014, , 146-9.	0.1	0
2346	Neuromyelitis optica spectrum disorder and SjÃ¶gren syndrome are overlapping disorders and participate in the same autoimmunity context?. Arquivos De Neuro-Psiquiatria, 2014, 72, 577-579.	0.3	2
2347	Autoimmunerkrankungen. , 2015, , 577-607.		0
2348	Pathologie und Pathophysiologie. , 2015, , 31-37.		0
2349	Demyelinating Diseases. , 2015, , 103-111.		0
2350	Immunohistochemistry. , 2015, , 143-158.		1
2351	A Case of Neuromyelitis Optica Spectrum Disorder Aggravated after Varicella Zoster Infection. Journal of the Korean Child Neurology Society, 2015, 23, 67-70.	0.0	0
2352	First Experience and the Effectiveness of Immunomodulating Treatment in Inflammatory Demyelinating CNS Diseases: Analysis of Nine Patients / ImÅ«nmodulÄ“joÅ¡Ä« Terapijas EfektivitÄte CentrÄlÄs Nervu SistÄ“mas IekaisÄ«gu SaslimÅ¡anu GadÄ«jumos: DeviÅ†u Pacientu AnalÄ«ze. Proceedings of the Latvian Academy of Sciences, 2015, 69, 269-273.	0.0	0
2353	Clinical Outcomes of Neuromyelitis Optica with Brain Magnetic Resonance Imaging Abnormalities. Journal of Neurology Neurological Science and Disorders, 2015, 1, 010-014.	1.2	0

#	Article	IF	Citations
2354	The Swollen Optic Disc in Children. , 2016, , 121-198.		2
2356	Demyelinating Diseases and Neuroinflammation. , 2016, , 139-170.		0
2357	Glia in Neuroimmunology. , 2016, , 21-31.		0
2358	Neuromyelitis Optica: Diagnosis and Treatment. , 2016, , 135-152.		0
2359	Demyelinating Diseases: Multiple Sclerosis and Neuromyelitis Optica. , 2016, , 443-446.		0
2360	Neuromyelitis optica (Devic's disease) - a rare demyelinating disease. MedicÃna Pro Praxi, 2016, 13, 43-46.	0.0	0
2361	Neuromyelitis Optica Spectrum Disorder Presented with Acute Memory Loss. Journal of the Korean Neurological Association, 2016, 34, 213-216.	0.0	0
2362	Differential Diagnosis between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Journal of the Korean Neurological Association, 2016, 34, 290-296.	0.0	4
2364	Successful treatment of neuromyelitis optica spectrum disorder combined with bilateral optic neuritis via plasma exchange. Nihon Toseki Igakkai Zasshi, 2017, 50, 555-559.	0.2	1
2365	Presentation of Neuromyelitis Optica with Recurrent Severe Myelitis and Acute Respiratory Failure in an Old Woman. Zahedan Journal of Researches in Medical Sciences, 2017, 19, .	0.1	0
2366	Mechanisms of Disease Progression. , 2018, , 71-92.		0
2367	AutoantikÃ¶rper gegen Aquaporin 4. , 2018, , 1-2.		0
2368	Tapering Oral Steroid Treatment After IV Methylprednisolone Pulse Therapy in Demyelinating Optic Neuritis. Caspian Journal of Neurological Sciences, 2018, 4, 1-5.	0.1	0
2369	Chronic relapsing inflammatory optic neuropathy. Sisli Etfal Hastanesi Tip Bulteni, 2018, 53, 437-440.	0.1	2
2370	Anti MOG Antibody Seropositive Neuromyelitis Optica: A Rare Pediatric Case. Noropsikiyatri Arsivi, 2018, 57, 257-260.	0.2	0
2371	Successful treatment of steroid-resistant anti-aquaporin 4 antibody-positive optic neuritis with double-filtration plasmapheresis: a case report. Nihon Toseki Igakkai Zasshi, 2018, 51, 379-385.	0.2	0
2375	DÃ©ficit moteur et douleur pluriradiculaire faisant dÃ©couvrir une maladie de Devic. Annales Francaises De Medecine D'Urgence, 2018, 8, 239-240.	0.0	0
2376	RevisiÃ³n de la literatura: relaciÃ³n e importancia de los canales de potasio en esclerosis mÃºltiple. Revista Colombiana De EnfermerÃa, 0, 8, 112-122.	0.1	0

#	Article	IF	Citations
2377	NEUROMYELITIS OPTICA SPECTRUM DISORDERS: DIAGNOSIS AND TREATMENT, THE EXPERIENCE OF CLINICAL OBSERVATIONS. UÄenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2018, 25, 7-13.	0.0	2
2378	Inflammatory and Autoimmune Disorders of the Spinal Cord. , 2019, , 201-213.		0
2379	Neuromyelitis Optica Spectrum Disorder. Contemporary Clinical Neuroscience, 2019, , 523-541.	0.3	1
2380	Autoimmune Astrocytopathy. Contemporary Clinical Neuroscience, 2019, , 329-355.	0.3	0
2381	Neuromyelitis optica spectrum disorder with vertical gaze palsy and hypersomnolence. Annals of Indian Academy of Neurology, 2019, 22, 530.	0.2	1
2382	Biomarkers for Multiple Sclerosis. RSC Drug Discovery Series, 2019, , 55-75.	0.2	0
2383	Anatomie pathologique de la sclÃ©rose en plaques et des maladies apparentÃ©es. , 2019, , 139-150.		0
2384	Inflammatory, Demyelinating, and Autoimmune Diseases in Infants and Children. , 2019, , 1-48.		0
2385	AutoantikÃ¶rper gegen Aquaporin 4. Springer Reference Medizin, 2019, , 247-248.	0.0	0
2386	Glucose-Regulated Protein 78 Autoantibody Associates with Blood-brain Barrier Disruption in Neuromyelitis Optica. Yamaguchi Medical Journal, 2019, 68, 23-29.	0.1	0
2387	Anticuerpos asociados al lupus neuropsiquiÃ¡trico: rol fisiopatolÃ³gico, prevalencia y utilidad diagnÃ³stica. Revista Colombiana De ReumatologÃa, 2019, 26, 111-117.	0.0	2
2388	Vomiting in Neuromyelitis Optica: An Atypical Presentation. Cureus, 2019, 11, e5225.	0.2	2
2389	Neuromyelitis Optica Spectrum Disorder: A Rare Case of Isolated Brainstem Syndrome. Cureus, 2019, 11, e5644.	0.2	3
2390	Clinical Updates and Recent Developments in Neuro-Ophthalmology. , 2020, , 201-249.		0
2391	Systemic lupus erythematosus with the development of neuromyelitis optica (Devic's syndrome) is a rare combination of autoimmune diseases. Sovremennaya Revmatologiya, 2019, 13, 89-95.	0.1	1
2392	Emerging Trends in Optic Neuritis and Associated Demyelinating Diseases. Current Practices in Ophthalmology, 2020, , 1-15.	0.1	0
2394	Neuromyelitis Optica Spectrum Disorders. Current Clinical Neurology, 2020, , 227-234.	0.1	0
2395	Aspiration Pneumonia Caused by Neuromyelitis Optica in a Patient with Suspected COVID-19. Advanced Ultrasound in Diagnosis and Therapy, 2020, 4, 138.	0.1	1

#	Article	IF	Citations
2396	Neuromyelitis Optica Spectrum Disorders. , 2020, , 67-94.		0
2397	Overview of the Current Situation and Challenges about Neuromyelitis Optica Spectrum Disorders in the Republic of Macedonia. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 40-46.	0.1	0
2398	Neuromyelitis optica in patients with myasthenia gravis: Two case-reports. Multiple Sclerosis and Related Disorders, 2020, 43, 102173.	0.9	4
2400	Hope for patients with neuromyelitis optica spectrum disorders â€" from mechanisms to trials. Nature Reviews Neurology, 2021, 17, 759-773.	4.9	57
2401	Spectrum of sublytic astrocytopathy in neuromyelitis optica. Brain, 2022, 145, 1379-1390.	3.7	18
2402	COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2022, 57, 103359.	0.9	18
2403	Neuromyelitis optica spectrum disorder: an overview. Acta Neurobiologiae Experimentalis, 2020, 80, 256-272.	0.4	4
2404	Inner Retinal Layer Disease: Multiple Sclerosis. Beyoglu Eye Journal, 2020, 5, 93-101.	0.1	1
2405	Spine MRI: A Review of Commonly Encountered Emergent Conditions. Topics in Magnetic Resonance Imaging, 2020, 29, 291-320.	0.7	1
2406	Sleep Related Disorders and Inflammatory Diseases of the Central Nervous System. Journal of Sleep Medicine, 2020, 17, 108-112.	0.4	0
2407	An Autopsy Confirmed Neuromyelitis Optica Spectrum Disorder with Extensive Brain White Matter Lesion and Optic Neuritis but Intact Spinal Cord, Clinically Mimicking a Secondary Progressive Multiple Sclerosis-like Course. Internal Medicine, 2022, 61, 1415-1422.	0.3	1
2409	Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110549.	1.5	15
2410	Immunmediierte Erkrankungen des Nervensystems. , 2020, , 37-87.		0
2411	Neuromyelitis optica spectrum disorders in the Arabian Gulf: challenges and growing experience. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521731985019.	0.5	1
2412	Tuberculous Myelopathy Associated with Longitudinally Extensive Lesion: A Clinicoradiological		

#	Article	IF	Citations
2417	Neuromyelitis Optica Spectrum Disorders in Migrants. Sustainable Development Goals Series, 2022, , 201-212.	0.2	0
2418	New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	40
2419	Serum Aquaporin 4-Immunoglobulin G Titer and Neuromyelitis Optica Spectrum Disorder Activity and Severity: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2021, 12, 746959.	1.1	10
2420	Pruritus in neuromyelitis optica spectrum disorders and multiple sclerosis. Journal of Clinical Neuroscience, 2020, 79, 108-112.	0.8	3
2421	Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases. Caspian Journal of Internal Medicine, 2020, 11, 155-162.	0.1	4
2422	Clinical approach to optic neuropathies. Clinical Ophthalmology, 2007, 1, 233-46.	0.9	79
2423	Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. Molecular Vision, 2009, 15, 1638-48.	1.1	24
2424	Anti-aquaporin-4 IgG in Patients Presenting with Unilateral Optic Neuritis: A Cohort Study. International Journal of Preventive Medicine, 2012, 3, 612-5.	0.2	7
2425	Detection of anti-aquaporin-4 autoantibodies in the sera of Chinese neuromyelitis optica patients. Neural Regeneration Research, 2013, 8, 708-13.	1.6	3
2426	A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iranian Journal of Neurology, 2015, 14, 204-10.	0.5	17
2427	Devic's syndrome in aquaporin-4 antibody negative patient. What we need to know â€¦. GMS Ophthalmology Cases, 2014, 4, Doc09.	0.1	0
2428	Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience. Annals of Indian Academy of Neurology, 2017, 20, 229-232.	0.2	5
2429	The pathologic and diagnostic in magnetic resonance imaging of brain and cervical spine of patients with neuromyelitis optica spectrum disorder. Iranian Journal of Neurology, 2018, 17, 58-63.	0.5	1
2430	Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder: A Case Series from Iran. Iranian Journal of Child Neurology, 2019, 13, 99-104.	0.2	1
2431	Identification of Novel Serum Proteins Associated with Myelination and Cholesterol Transport in Neuromyelitis Optica Spectrum Disorders by Mass Spectrometry. Indian Journal of Clinical Biochemistry, 0, , 1.	0.9	0
2432	Comprehensive Analysis of N6-Methyladenosine (m6A) Methylation in Neuromyelitis Optica Spectrum Disorders. Frontiers in Genetics, 2021, 12, 735454.	1.1	3
2433	Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate. Neurology and Therapy, 2022, 11, 137-149.	1.4	8
2434	Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder. Journal of the Formosan Medical Association, 2022, 121, 1647-1656.	0.8	8

#	Article	IF	Citations
2435	Factors influencing intravenous methylprednisolone pulse therapy in Chinese patients with isolated optic neuritis associated with AQP4 antibody-seropositive neuromyelitis optica. Scientific Reports, 2021, 11, 22229.	1.6	4
2436	Approach to Common Visual Complaints Presenting to the Outpatient Neurologist. Seminars in Neurology, 2021, 41, 699-716.	0.5	0
2437	Positive antithyroid antibody predicts severity of neuromyelitis optica spectrum disorder in children. Multiple Sclerosis and Related Disorders, 2021, 57, 103425.	0.9	1
2438	Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder. Neurologist, 2022, 27, 14-20.	0.4	1
2439	Complement as a powerful â€œinfluencerâ€•in the brain during development, adulthood and neurological disorders. Advances in Immunology, 2021, 152, 157-222.	1.1	11
2440	Association of Neuromyelitis Optica Spectrum Disease and Sjogren Syndrome in a Tunisian Patient. Neurology India, 2021, 69, 1065.	0.2	0
2441	Comparative Study of Brain fMRI of Olfactory Stimulation in Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis. Frontiers in Neuroscience, 2021, 15, 813157.	1.4	2
2442	Sparser macula microvasculature in neuromyelitis optica spectrum disorder occurs independently of optic neuritis. Multiple Sclerosis and Related Disorders, 2022, 58, 103470.	0.9	5
2443	Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina. Multiple Sclerosis and Related Disorders, 2022, 58, 103466.	0.9	3
2445	Multidisciplinary Rehabilitation of a Patient With Neuromyelitis Optica. Function and Disability Journal, 2020, 3, 69-76.	0.2	0
2446	Antibodies to Neural Cell Surface Antigens. , 2022, , 135-166.		1
2447	MyÃ©lopathies inflammatoiresÂ: de la SEP Ã la NMO. Pratique Neurologique - FMC, 2022, , .	0.1	0
2448	Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder. Biomedicine Hub, 2022, 7, 11-16.	0.4	2
2449	Social participation and quality of life among patients with neuromyelitis optica spectrum disorders: The mediating effects of depression. Multiple Sclerosis and Related Disorders, 2022, 57, 103445.	0.9	8
2450	High cell surface expression and peptide binding affinity of HLA-DQA1*05:03, a susceptible allele of neuromyelitis optica spectrum disorders (NMOSD). Scientific Reports, 2022, 12, 106.	1.6	3
2451	Pathogenetic mechanism and construction of neuromyelitis optica model by immunization activation. Asian Journal of Surgery, 2022, 45, 883-885.	0.2	0
2452	Neuromyelitis Optica Spectrum Disorders and Glial Fibrillary Acidic Protein Autoimmunity. , 2022, , 315-341.		0
2453	Possibilities of therapy for neuromyelitis optica spectrum disorders. Russkii Zhunal Detskoi Nevrologii, 2022, 16, 49-58.	0.1	0

#	Article	IF	Citations
2454	Serum molecular biomarkers in neuromyelitis optica and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 59, 103527.	0.9	3
2456	Anti-aquaporin-4 immunoglobulin G colorimetric detection by silver nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 41, 102531.	1.7	2
2457	Effective connectivity within the corticothalamic circuit in the neuromyelitis optica patients: A comparative study using resting-state fMRI. Journal of Clinical Neuroscience, 2022, 97, 25-31.	0.8	0
2458	Lower motor neuron involvement in patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2022, 59, 103544.	0.9	0
2459	Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS. Multiple Sclerosis and Related Disorders, 2022, 60, 103664.	0.9	2
2460	Clinical characteristics, sero- prevalence, treatment and outcomes of AQP4 IgG associated neuromyelits optic spectrum disorder (NMOSD) in Sri Lanka. Multiple Sclerosis and Related Disorders, 2022, 59, 103663.	0.9	0
2462	A fatal disease hidden behind a common symptom: Neuromyelitis optica spectrum disorder. Indian Journal of Medical Specialities, 2022, 13, 124.	0.1	0
2463	Immunogenetic mechanism driving neurological and neurodegenerative disorders. , 2022, , 219-244.		0
2464	An Update on Laboratory-Based Diagnostic Biomarkers for Multiple Sclerosis and Beyond. Clinical Chemistry, 2022, 68, 1134-1150.	1.5	10
2466	An Update on the Laboratory Diagnosis of Neuromyelitis Optica Spectrum Disorders. Journal of		

#	Article	IF	Citations
2475	Sexual Dysfunction in Women with Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis. Sexuality and Disability, 0, , 1.	0.4	2
2476	Neuromyelitis Optica Spectrum Disorder in Central America and the Caribbean: A Multinational Clinical Characterization Study. Neurology International, 2022, 14, 284-293.	1.3	5
2477	Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. Frontiers in Neurology, 2022, 13, 866824.	1.1	16
2478	Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil. BMC Neurology, 2022, 22, 95.	0.8	4
2479	Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. Neurotherapeutics, 2022, 19, 808-822.	2.1	14
2480	Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders. International Journal of Molecular Sciences, 2022, 23, 3829.	1.8	7
2481	Neuromyelitis Optica Spectrum Disorders (NMOSD). Current Treatment Options in Neurology, 0, , 1.	0.7	1
2482	Glial Fibrillary Acidic Protein in Blood as a Disease Biomarker of Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology, 2022, 13, 865730.	1.1	9
2483	Multimodal magnetic resonance imaging quantification of gray matter alterations in relapsingâ€remitting multiple sclerosis and neuromyelitis optica spectrum disorder. Journal of Neuroscience Research, 2022, 100, 1395-1412.	1.3	3
2484	Efficacy of Plasma Exchange Treatment for Demyelinating Optic Neuritis Associated with Various Serum Antibodies: A Prospective Cohort Study. Neurology and Therapy, 2022, 11, 797-813.	1.4	3
2485	Adverse Events in NMOSD Therapy. International Journal of Molecular Sciences, 2022, 23, 4154.	1.8	8
2486	Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus. Multiple Sclerosis and Related Disorders, 2022, 62, 103786.	0.9	1
2487	Neuromyelitis optica spectrum disorder in Western Mexico. Multiple Sclerosis and Related Disorders, 2022, 61, 103733.	0.9	3
2488	Microstructural white matter abnormalities in multiple sclerosis and neuromyelitis optica spectrum disorders: Evaluation by advanced diffusion imaging. Journal of the Neurological Sciences, 2022, 436, 120205.	0.3	12
2489	Opticoneuromyelitis associated with melanoma. Case report. Consilium Medicum, 2021, 23, 884-890.	0.1	0
2490	Can Immune Tolerance Be Re-established in Neuromyelitis Optica?. Frontiers in Neurology, 2021, 12, 783304.	1.1	2
2491	Ä‘Æ¡C Ä‘á»‚M Cá»¯NG HÆ¯á»žNG Tá»ª Cá»¦A PHá»” Bá»†NH VIÊM Tá»¦Y THá»Š THáº¦N KINH. Y Hoc Viet Nam, 2021, 507, .0	0.1	0
2492	Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. Life, 2022, 12, 19.	1.1	3

#	Article	IF	Citations
2493	Association Analysis Between HLA-DQA1 Loci and Neuromyelitis Optica Spectrum Disorder in a Han Chinese Population. Neurologist, 2021, Publish Ahead of Print, .	0.4	1
2494	Quantitative Susceptibility Mapping-Derived Radiomic Features in Discriminating Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder. Frontiers in Neuroscience, 2021, 15, 765634.	1.4	3
2496	Internuclear Ophthalmoplegia Characterizes Multiple Sclerosis Rather Than Neuromyelitis Optica Spectrum Disease. Journal of Neuro-Ophthalmology, 2022, Publish Ahead of Print, .	0.4	1
2497	Long-Term Visual Prognosis in Patients With Aquaporin-4-Immunoglobulin Gâ€“Positive Neuromyelitis Optica Spectrum Disorder. Journal of Neuro-Ophthalmology, 2022, Publish Ahead of Print, .	0.4	0
2498	Fractional anisotropy helps to differentiate the optic nerve impairment between neuromyelitis optica spectrum disorders and multiple sclerosis. European Radiology, 2022, , 1.	2.3	3
2499	Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System. Biomolecules, 2022, 12, 591.	1.8	14
2500	The contribution of neuropathology to multiple sclerosis research. European Journal of Neurology, 2022, 29, 2869-2877.	1.7	15
2501	Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD. CNS Neuroscience and Therapeutics, 2022, 28, 981-991.	1.9	15
2502	Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder. European Journal of Neurology, 2022, 29, 2343-2354.	1.7	7
2503	Relatively Early and Late-Onset Neuromyelitis Optica Spectrum Disorder in Central China: Clinical Characteristics and Prognostic Features. Frontiers in Neurology, 2022, 13, 859276.	1.1	2
2504	White Matter. , 0, , 283-310.		0
2509	White Matter Lesions. , 2008, , 1960-1960.		0
2545	Advanced <scp>MRI</scp> quantification of neuroinflammatory disorders. Journal of Neuroscience Research, 2022, 100, 1389-1394.	1.3	1
2546	Herpes zoster preceding neuromyelitis optica spectrum disorder: casual or causal relationship? A systematic literature review. Journal of NeuroVirology, 2022, 28, 201-207.	1.0	2
2547	Neuromyelitis Optica Spectrum Disorders in Africa. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	8
2549	Rituximab in neuromyelitis optica spectrum disorders: Our experience. Annals of Indian Academy of Neurology, 2017, 20, 229.	0.2	10
2550	Immunopathogenesis of acute disseminated encephalomyelitis. , 2022, , 249-263.		0
2551	Pulmonary manifestations of autoimmune diseases. , 2022, , 265-294.		0

#	Article	IF	Citations
2554	Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore. Asia-Pacific Journal of Ophthalmology, 2022, 11, 184-195.	1.3	4
2555	Associations and Diseaseâ€“Disease Interactions of COVID-19 with Congenital and Genetic Disorders: A Comprehensive Review. Viruses, 2022, 14, 910.	1.5	6
2556	Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUCâ€“MSCâ€“NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial. Frontiers in Neurology, 2022, 13, 860083.	1.1	4
2557	Factors Influencing Social Participation Among Persons With Neuromyelitis Optica Spectrum Disorders: A Cross-Sectional Study. Frontiers in Neurology, 2022, 13, .	1.1	2
2558	Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics, 2022, 19, 711-728.	2.1	4
2559	Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2022, 13, .	1.1	0
2560	Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. Journal of Personalized Medicine, 2022, 12, 743.	1.1	6
2561	Seronegative neuromyelitis optica spectrum disorder with longitudinally extending transverse myelitis and optic neuritis: A case report. Annals of Medicine and Surgery, 2022, , 103757.	0.5	0
2562	Clinical and Radiological Features of Myelin Oligodendrocyte Glycoprotein-Associated Myelitis in		

#	Article	IF	Citations
2576	Protocol for the treatment of patients with a spectrum of opiomyelitis-associated diseases using bone marrow stromal cells in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine". Ukrains Kyi Visnyk Psykhonevrolohii, 2022, , 75-79.	0.0	0
2577	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Frontiers in Neurology, 0, 13, .	1.1	84
2578	Cross-syndrome: myasthenia gravis and the demyelinating diseases of the central nervous system combination. Systematic literature review and case reports. Acta Neurologica Belgica, 2023, 123, 367-374.	0.5	1
2579	Disease Course and Outcomes in Patients With the Limited Form of Neuromyelitis Optica Spectrum Disorders and Negative AQP4-IgG Serology at Disease Onset: A Prospective Cohort Study. Journal of		

#	Article	IF	Citations
2594	The prevalence, incidence, and clinical assessment of neuromyelitis optica spectrum disorder in patients with demyelinating diseases. NeurologÃa (English Edition), 2022, , .	0.2	0
2595	Clinical, Radiological and Etiological Spectrum of Acute Transverse Myelitis Cases: A Single Center Experience and Review of the Literature. Akdeniz Medical Journal, 0, , 306-312.	0.0	0
2596	II. Neuromyelitis Optica Spectrum Disorder. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 1568-1574.	0.0	0
2597	Optimal validation of accuracy in antibody assays and reasonable definition of antibody positive/negative subgroups in neuroimmune diseases: a narrative review. Annals of Translational Medicine, 2022, .	0.7	0
2598	Update on glial antibody-mediated optic neuritis. Japanese Journal of Ophthalmology, 2022, 66, 405-412.	0.9	2
2599	Association between infections, the microbiome, vaccination, and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 0, , 135245852211132.	1.4	1
2600	Comparative analysis of clinical and imaging data of first-attack neuromyelitis optica spectrum disorders with and without connective tissue disease. Frontiers in Neurology, 0, 13, .	1.1	4
2601	The role of the complement system in Multiple Sclerosis: A review. Frontiers in Immunology, 0, 13, .	2.2	11
2602	Neuromyelitis Optica Spectrum Disorder. New England Journal of Medicine, 2022, 387, 631-639.	13.9	40
2603	Pathogenic autoantibodies in multiple sclerosis â€" from a simple idea to a complex concept. Nature Reviews Neurology, 2022, 18, 681-688.	4.9	13
2604	Comparing evolvement of visual field defect in neuromyelitis optica spectrum disorder-optic neuritis and idiopathic optic neuritis: a prospective study. BMC Ophthalmology, 2022, 22, .	0.6	1
2605	Neuromyelitis Optica Spectrum Disorders. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 1131-1170.	0.4	6
2606	Clinical features of organizing pneumonia in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. Respiratory Investigation, 2022, 60, 684-693.	0.9	1
2607	First-line immunotherapy of neuronal surface antibody-mediated autoimmune encephalitis: Assessment of therapeutic effectiveness and cost-efficiency. Multiple Sclerosis and Related Disorders, 2022, 66, 104071.	0.9	1
2608	Axon degeneration: new actor in an old play. Neural Regeneration Research, 2023, 18, 547.	1.6	2
2610	Prevalence of multiple sclerosis in Guangzhou, China: A population-based case-finding prospective study. Multiple Sclerosis and Related Disorders, 2022, 68, 104151.	0.9	0
2611	Association of HLA DRB1-DQB1 Haplotypes with the Risk for Neuromyelitis Optica among South Indians. Neurology India, 2022, 70, 1481.	0.2	0
2612	Diversified Treatment Options of Adult Stem Cells for Optic Neuropathies. Cell Transplantation, 2022, 31, 096368972211235.	1.2	6

#	Article	IF	Citations
2613	Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD). International Review of Neurobiology, 2022, , 129-178.	0.9	2
2614	Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer. Frontiers in Pharmacology, 0, 13, .	1.6	7
2615	New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum Disorder. Transfusion Medicine Reviews, 2022, , .	0.9	1
2617	Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis. International Journal of Molecular Sciences, 2022, 23, 9769.	1.8	8
2618	Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome. Current Neurology and Neuroscience Reports, 2022, 22, 589-600.	2.0	3
2619	Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients. Frontiers in Immunology, 0, 13, .	2.2	8
2620	Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurology, The, 2023, 22, 89-100.	4.9	53
2621	Association of cerebrospinal inflammatory profile with radiological features in newly diagnosed treatment-naÃ¯ve patients with multiple sclerosis. Frontiers in Neurology, 0, 13, .	1.1	0
2622	A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder. Journal of Neurology, 2023, 270, 348-356.	1.8	4
2623	CXCL7 aggravates the pathological manifestations of neuromyelitis optica spectrum disorder by enhancing the inflammatory infiltration of neutrophils, macrophages and microglia. Clinical Immunology, 2022, 245, 109139.	1.4	3
2624	Different visual evoked potentials in neuromyelitis optica spectrum disorder-related optic neuritis and idiopathic demyelinating optic neuritis: a prospective longitudinal analysis. BMC Ophthalmology, 2022, 22, .	0.6	1
2625	Pain in neuromyelitis optic spectrum disorder. Multiple Sclerosis and Related Disorders, 2022, 68, 104192.	0.9	0
2626	Neuromyelitis optica spectrum disorder in Western China impacts employment and increases financial burden in women. Frontiers in Neurology, 0, 13, .	1.1	3
2627	Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina. Neurological Sciences, 2023, 44, 281-286.	0.9	1
2628	Rare variants and HLA haplotypes associated in patients with neuromyelitis optica spectrum disorders. Frontiers in Immunology, 0, 13, .	2.2	2
2629	AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review. Multiple Sclerosis and Related Disorders, 2022, 68, 104212.	0.9	3
2630	Incidence and Prevalence of Neuromyelitis Optica Spectrum Disorders in the Background of International Consensus Diagnostic Criteria â€“ A Systematic Review. Neurology India, 2022, 70, 1771.	0.2	1
2631	Pediatric Neuromyelitis Optica is clinically distinct from ADEM: Case report of a 9year old girl. Neuroimmunology Reports, 2022, 2, 100144.	0.2	0

#	Article	IF	Citations
2632	Neuromyelitis optica imitating astrocytoma. Neurologie Pro Praxi, 2022, 23, 336-338.	0.0	0
2633	Cuprizone feeding induces swollen astrocyte endfeet. Pflugers Archiv European Journal of Physiology, 2022, 474, 1275-1283.	1.3	2
2635	Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders. Brain and Behavior, 2022, 12, .	1.0	2
2636	Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, e200037.	3.1	0
2637	Longitudinal Extensive Transverse Myelitis Secondary to Lyme Disease. BezmiÃ¢lem Science, 2022, 10, 652-654.	0.1	0
2638	Predictors of overlapping autoimmune disease in Neuromyelitis Optica Spectrum disorder (NMOSD): A retrospective analysis in two inner-city hospitals.. Journal of the Neurological Sciences, 2022, 443, 120460.	0.3	3
2639	MOG antibody prevalence in adult optic neuritis and clinical predictive factors for diagnosis: A Chinese cohort study. Multiple Sclerosis and Related Disorders, 2022, 68, 104248.	0.9	0
2640	Paraneoplastic Neuromyelitis Optica Spectrum Disorder Related to Glucose-regulated Protein 78 (GRP78) Autoantibodies in a Patient with Lynch Syndrome-associated Colorectal Cancer. Internal Medicine, 2023, , .	0.3	0
2641	Neuromyelitisoptica Spectrum Disease with Brown-SÃ©quard Syndrome as the Initial Presentation: A Case Report and Literature Review. Advances in Clinical Medicine, 2022, 12, 10052-10058.	0.0	1
2643	Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Expert Review of Clinical Immunology, 2023, 19, 71-91.	1.3	6
2644	Transitioning immunotherapy in neuromyelitis optica spectrum disorder â€“ when and how to switch. Expert Opinion on Biological Therapy, 2022, 22, 1393-1404.	1.4	0
2645	Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Frontiers in Immunology, 0, 13, .	2.2	8
2648	Non-immune system comorbidity in neuromyelitis optica spectrum disorders. Journal of Clinical Neuroscience, 2023, 107, 16-22.	0.8	1
2649	Microglial heterogeneity in amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology, 2023, 82, 140-149.	0.9	6
2650	Ependyma: a new target for autoantibodies in neuromyelitis optica?. Brain Communications, 2022, 4, .	1.5	2
2651	The relationship between a previous infectious disease caused by influenza, herpes simplex, or Epstein-Barr viruses as the biological threatening agents with recurrent episodes of multiple sclerosis. , 2022, 125, 662-667.		0
2652	Extracellular Vesicles in Chronic Demyelinating Diseases: Prospects in Treatment and Diagnosis of Autoimmune Neurological Disorders. Life, 2022, 12, 1943.	1.1	1
2653	Behandlung der Neuromyelitis-optica-Spektrum-Erkrankung: RÃ¼ckblick auf das Komplementsystem und andere Aspekte der Pathogenese. Wiener Medizinische Wochenschrift, 2024, 174, 4-15.	0.5	1

#	Article	IF	Citations
2654	Upregulated complement receptors correlate with Fc gamma receptor 3A-positive natural killer and natural killer-T cells in neuromyelitis optica spectrum disorder. Journal of Neuroinflammation, 2022, 19, .	3.1	3
2655	Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?. Frontiers in Neurology, 0, 13, .	1.1	1
2658	Enlarged choroid plexus related to cortical atrophy in multiple sclerosis. European Radiology, 2023, 33, 2916-2926.	2.3	9
2659	A tyrosineâ€based <scp>YXXÎ¦</scp> motif regulates the degradation of aquaporinâ€4 via both lysosomal and proteasomal pathways and is functionally inhibited by a 10â€aminoâ€acid sequence within its Câ€terminus. FEBS Journal, 2023, 290, 2616-2635.	2.2	1
2660	Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases. Neurological Sciences, 2023, 44, 1731-1737.	0.9	2
2661	Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder. Frontiers in Immunology, 0, 13, .	2.2	2
2662	The Characteristics of Cognitive Proficiency in Patients with Acute Neuromyelitis Optica Spectrum Disease and its Correlation with Serum Aquaporin-4 Antibody Titer. Brain Sciences, 2023, 13, 90.	1.1	0
2663	CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series. Vaccine, 2023, 41, 1003-1008.	1.7	1
2664	Clinical characteristics of late-onset neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2023, 70, 104517.	0.9	1
2665	Therapeutic strategies in NMOSD and MOGAD patients: A multicenter cohort study in Latin America. Multiple Sclerosis and Related Disorders, 2023, 71, 104508.	0.9	0
2666	T follicular helper cells contribute to pathophysiology in a model of neuromyelitis optica spectrum disorders. JCI Insight, 2023, 8, .	2.3	4
2667	B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study. Multiple Sclerosis and Related Disorders, 2023, 70, 104524.	0.9	2
2668	Effects of physical therapy intervention in the management of neuromyelitis optica: a case report. Bulletin of Faculty of Physical Therapy, 2023, 28, .	0.2	0
2669	Secreted aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) is a promising predictor for the severity of acute AQP4-IgG positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2023, 70, 104504.	0.9	1
2670	Assessment of intelligence quotient in patients with neuromyelitis optica spectrum disease and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 70, 104492.	0.9	0
2671	Optic neuritis: current challenges in diagnosis and management. Current Opinion in Neurology, 2023, 36, 10-18.	1.8	4
2672	Neuromyelitis Optica Spectrum Disorder: Case Description and Information for Speech-Language Pathologists. Communication Disorders Quarterly, 2024, 45, 131-134.	0.5	0
2673	Analysis of LAP+ and GARP+ Treg subsets in peripheral blood of patients with neuromyelitis optica spectrum disorders. Neurological Sciences, 2023, 44, 1739-1747.	0.9	2

#	Article	IF	Citations
2674	Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD. Scientific Reports, 2023, 13, .	1.6	0
2675	Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort. Multiple Sclerosis and Related Disorders, 2023, 74, 104656.	0.9	0
2676	Accuracy of International Classification of Diseases Codes for Identifying Acute Optic Neuritis. Journal of Neuro-Ophthalmology, 2023, Publish Ahead of Print, .	0.4	0
2677	Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa. International Immunopharmacology, 2023, 116, 109761.	1.7	1
2678	The role of the gut microbiota and fecal microbiota transplantation in neuroimmune diseases. Frontiers in Neurology, 0, 14, .	1.1	5
2679	Relapsing neuromyelitis optica spectrum disorder due to noncompliance to oral corticosteroid therapy. Medicine, Case Reports and Study Protocols, 2022, 3, e0264.	0.0	0
2680	Assessment of sexual life and social life in people with multiple sclerosis. Health Promotion & Physical Activity, 2023, 21, 38-45.	0.2	0
2681	A comparison of the efficacy of tocilizumab versus azathioprine for neuromyelitis optica spectrum disorder: A study protocol for systematic review and meta-analysis. Medicine (United States), 2023, 102, e32748.	0.4	0
2682	Postinfectious aquaporin-4-positive neuromyelitis optica syndrome disorder and nephrotic syndrome. APIK Journal of Internal Medicine, 2023, .	0.1	0
2683	Imaging of Central Nervous System Demyelinating Disorders. CONTINUUM Lifelong Learning in Neurology, 2023, 29, 292-323.	0.4	0
2684	Comments on the article â€œConsensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapyâ€. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2023, 15, 119-122.	0.2	1
2685	Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks. American Journal of Ophthalmology, 2023, 252, 213-224.	1.7	7
2686	Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews. Neurology and Therapy, 2023, 12, 619-633.	1.4	3
2687	Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews. Neurology and Therapy, 2023, 12, 635-650.	1.4	3
2688	The Pathological Activation of Microglia Is Modulated by Sexually Dimorphic Pathways. International Journal of Molecular Sciences, 2023, 24, 4739.	1.8	2
2689	B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. Frontiers in Immunology, 0, 14, .	2.2	7
2690	The neuro-ophthalmological manifestations of NMOSD and MOGADâ€”a comprehensive review. Eye, 2023, 37, 2391-2398.	1.1	3
2691	Multiple Sclerosis and Other Idiopathic Inflammatory-Demyelinating Diseases. , 2013, , 909-943.		0

#	Article	IF	Citations
2692	Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study. Therapeutic Advances in Neurological Disorders, 2023, 16, 175628642311624.	1.5	0
2693	Demyelinating, inflammatory, infectious, and infiltrative optic neuropathies. , 2017, , 599-605.		0
2694	Other demyelinating diseases. , 2013, , 443-450.		0
2695	Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis. Frontiers in Neurology, 0, 14, .	1.1	0
2696	Artificial intelligence in healthcare: a mastery. Biotechnology and Genetic Engineering Reviews, 0, , 1-50.	2.4	3
2697	THE ROLE OF MRI IN DIFFERENTIATING DEMYELINATING AND INFLAMMATORY (NOT INFECTIOUS) MYELOPATHIES. Seminars in Ultrasound, CT and MRI, 2023, , .	0.7	0
2698	Therapeutic response to rituximab in seropositive neuromyelitis optica: Experience from a tertiary care center in South India. Journal of Neurosciences in Rural Practice, 0, .	0.3	0
2699	Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)Ââ€“ revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal of Neurology, 2023, 270, 3341-3368.	1.8	23
2700	Predictive role of blood-based indicators in neuromyelitis optica spectrum disorders. Frontiers in Neuroscience, 0, 17, .	1.4	3
2701	Myelin Oligodendrocyte Glycoprotein as an Autoantigen in Inflammatory Demyelinating Diseases of the Central Nervous System. Biochemistry (Moscow), 2023, 88, 551-563.	0.7	1
2702	Plasma exchange in inflammatory demyelinating disorders of the central nervous system: reasonable use in the clinical practice. Arquivos De Neuro-Psiquiatria, 2023, 81, 296-307.	0.3	3
2703	Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Multiple Sclerosis and Related Disorders, 2023, 74, 104718.	0.9	0
2704	Neuromyelitis Optica Spectrum Disorders: Clinical Perspectives, Molecular Mechanisms, and Treatments. Applied Sciences (Switzerland), 2023, 13, 5029.	1.3	1
2705	Symptomatic trigeminal autonomic cephalalgias in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2023, 74, 104722.	0.9	0
2706	Painful tonic spasms in a patient with neuromyelitis optica spectrum disorder: A case report. SAGE Open Medical Case Reports, 2023, 11, 2050313X2311679.	0.2	2
2709	Chronisch entzÃ¼ndliche ZNS-Erkrankungen. , 2023, , 125-136.		0
2725	Rare autoimmune and autoinflammatory neurologic disorders. , 2023, , 189-219.		0
2737	The temporal relationship of paraneoplastic aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and breast cancer: a systematic review and meta-analysis. Neurological Sciences, 0, , .	0.9	0

#	Article	IF	Citations
2757	Commentary: Targeting chemoattractant chemokine (Câ€“C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders. Frontiers in Immunology, 0, 14, .	2.2	0
2760	Targeting NLRP3 inflammasome for neurodegenerative disorders. Molecular Psychiatry, 2023, 28, 4512-4527.	4.1	1
2763	Case report: Granzyme-B expression by T- and B- cells during severe AQP4-positive Neuromyelitis Optica spectrum disorder with fatal venous thromboembolism outcome. Frontiers in Neurology, 0, 14, .	1.1	1
2767	Multiple sclerosis: Motor dysfunction. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 119-147.	1.0	2
2779	Methyl-CpG-Binding Protein 2 Emerges as a Central Player in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Cellular and Molecular Neurobiology, 2023, 43, 4071-4101.	1.7	0
2780	Neuromyelitis Optica Spectrum Disorders. , 2023, , .		0
2785	Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome. Journal of Neurology, 0, , .	1.8	1
2813	An overview of neuromyelitis optica spectrum disorders. , 2024, , 35-66.		0
2820	Demyelinating Diseases of the CNS (Brain and Spine). IDKD Springer Series, 2024, , 189-202.	0.8	0
2829	Cell-Based Assay to Detect the Autoantibody Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). Methods in Molecular Biology, 2024, , 121-133.	0.4	0
2830	Optic Neuritisâ€”The Dawn of New Era. , 2024, , .		0
2832	Epidemiology of paraneoplastic neurologic syndromes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 57-77.	1.0	0
2833	Antibodies to neural cell surface and synaptic proteins in paraneoplastic neurologic syndromes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 347-364.	1.0	0
2834	Evolution of methods to detect paraneoplastic antibodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 113-130.	1.0	0
2838	Optimizing the diagnostic performance of neural antibody testing for paraneoplastic and autoimmune encephalitis in clinical practice. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 365-382.	1.0	0